

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3017039 T3**

(12) Oversættelse af
europæisk patentskrift

-
- (51) Int.Cl.: **C 12 N 7/01 (2006.01)** **A 61 P 1/00 (2006.01)** **C 12 N 15/70 (2006.01)**
C 12 N 15/74 (2006.01)
- (45) Oversættelsen bekendtgjort den: **2021-06-07**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2021-03-17**
- (86) Europæisk ansøgning nr.: **14819499.6**
- (86) Europæisk indleveringsdag: **2014-07-01**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-05-11**
- (86) International ansøgning nr.: **US2014045034**
- (87) Internationalt publikationsnr.: **WO2015002939**
- (30) Prioritet: **2013-07-01 US 201361841904 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Massachusetts Institute of Technology, 77 Massachusetts Avenue , Cambridge, MA 02139, USA**
Trustees of Boston University, One Silber Way, Boston, MA 02215, USA
- (72) Opfinder: **COLLINS, James, 118 Glen Avenue, Newton, MA 02459, USA**
LU, Timothy, Kuan-ta, 500 Technology Sq., NE47-221, Cambridge, MA 02139, USA
KROM, Russell-John, 44 Cummington Street, Boston, MA 02215, USA
CITORIK, Robert, James, 70 Central Street #1, Somerville, MA 02143, USA
- (74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**
- (54) Benævnelse: **FUNKTIONALISERING AF ENDOGENE BAKTERIER**
- (56) Fremdragne publikationer:
WO-A1-00/61804
WO-A2-2004/007695
US-A1- 2003 165 877
US-A1- 2013 122 549
HOOGENBOOM H R ET AL: "Multi-subunit proteins on the surface of the filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 19, no. 15, 1 January 1991 (1991-01-01), pages 4133-4137, XP001019229, ISSN: 0305-1048
GUY FROYEN ET AL: "Cloning, Bacterial Expression and Biological Characterization of Recombinant Human Granulocyte Chemotactic Protein-2 and Differential Expression of Granulocyte Chemotactic Protein-2 and Epithelial Cell-Derived Neutrophil Activating Peptide-78 mRNAs", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 243, no. 3, 1 February 1997 (1997-02-01), pages 762-769, XP055335027, GB ISSN: 0014-2956, DOI: 10.1111/j.1432-1033.1997.00762.x
RODNEY D BERG: "The indigenous gastrointestinal microflora", TRENDS IN MICROBIOLOGY, vol. 4, no. 11, 1 November 1996 (1996-11-01), pages 430-435, XP055334847, DOI: 10.1016/0966-842X(96)10057-3

Fortsættes ...

ALEJANDRO REYES ET AL: "Going viral: next-generation sequencing applied to phage populations in the human gut", NATURE REVIEWS. MICROBIOLOGY, vol. 10, no. 9, 6 August 2012 (2012-08-06) , pages 607-617, XP055334375, GB ISSN: 1740-1526, DOI: 10.1038/nrmicro2853

WESTWATER CAROLINE ET AL: "Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 47, no. 4, 1 April 2003 (2003-04-01), pages 1301-1307, XP002483598, ISSN: 0066-4804, DOI: 10.1128/AAC.47.4.1301-1307.2003

LU ET AL.: 'Advancing bacteriophage-based microbial diagnostics with synthetic biology' TRENDS IN BIOTECHNOLOGY vol. 31, no. 6, 19 April 2013, pages 325 - 7, XP028550369

CITORIK ET AL.: 'Bacteriophage-based synthetic biology for the study of infectious diseases' CURRENT OPINION IN MICROBIOLOGY vol. 19, 03 July 2014, pages 59 - 69, XP055256177

HAMADY Z Z R: "Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium.", ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND MAY 2013, vol. 95, no. 4, 1 May 2013 (2013-05-01), pages 235-240, XP055386750, ISSN: 1478-7083

DESCRIPTION

FEDERALLY SPONSORED RESEARCH

[0001] This present disclosure was made with Government support under Grant Nos. GM008334 and OD008435, awarded by the National Institutes of Health. The Government has certain rights in the present disclosure.

BACKGROUND OF THE INVENTION

[0002] A human microbiome is considered to be the aggregate of microorganisms that reside on the surface and in deep layers of the skin, in the saliva and oral mucosa, in the conjunctive, and in the gastrointestinal tracts. A human microbiome is thought to be composed of at least ten times as many bacterial cells as human cells, and these bacterial communities are known to have major impacts on the systems in which they reside. For example, recent studies have implicated the human microbiome in many human diseases.

[0003] WO 2004/007695 A2 describes lactobacilli expressing biologically active polypeptides and uses thereof. Hoogenboom et al., nucleic acids research, vol. 19, no. 15, 1 January 1991, pages 4133-4137, relates to multi-subunit proteins on the surface of the filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Froyen et al., Eur. J. Biochem., vol. 243, no. 3, 1 February 1997, pages 762-769, concerns cloning, bacterial expression and biological characterization of recombinant human granulocyte chemotactic protein-2 and differential expression of granulocyte chemotactic protein-2 and epithelial cell-derived neutrophil activating peptide-78 mRNAs. Berg et al., Trends in Microbiology, vol. 4, no. 11, 1 November 1996, pages 430-435, discusses the indigenous gastrointestinal microflora. Hamady et al., Annals of the Royal College of Surgeons of England, vol. 95, no. 4, 1 May 2013 (2013-05-01), pages 235-240, concerns novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium. Reyes et al., Nature Reviews Microbiology, vol. 10, no. 9, 6 August 2012 (2012-08-06), pages 607-617, describes next-generation sequencing applied to phage populations in the human gut.

SUMMARY OF THE INVENTION

[0004] The invention is as defined in the claims and relates to a recombinant non-lytic bacteriophage for use in the treatment of gastrointestinal disease, wherein the recombinant bacteriophage is engineered to deliver to nonpathogenic endogenous bacterial cells at least one genetic circuit, wherein the at least one genetic circuit comprises a nucleotide sequence encoding a therapeutic molecule that is not an antimicrobial protein, and wherein the endogenous bacterial cells remain viable and able to stably maintain expression of the genetic

circuit. The present disclosure is based, at least in part, on the surprising discovery that endogenous bacterial cells of a microbiome (e.g., human microbiome) can be "functionalized" *in vivo* with new genetically encoded capabilities to perform a range of useful functions. Thus, the present disclosure provides, *inter alia*, methods and compositions for selectively manipulating bacterial cells that are stably maintained in a microbiome (e.g., endogenous bacterial cells), for example, to deliver therapeutic molecules and/or to serve as "biosensors." The present disclosure is also based on the discovery that recombinant bacteriophages (e.g., non-lytic, or lysogenic bacteriophages) can be engineered to selectively deliver, to endogenous bacterial cells *in vivo*, particular genetic circuits, which when expressed, functionalize the bacterial cells.

[0005] Thus, various aspects of the present disclosure provide methods of functionalizing endogenous bacteria *in vivo*, the methods comprising delivering to endogenous bacterial cells a recombinant bacteriophage that is engineered to contain at least one genetic circuit. Other aspects of the present disclosure contemplate the delivery of recombinant phagemids to endogenous bacterial cells.

[0006] In the invention, the at least one genetic circuit does not express an antimicrobial protein or peptide.

[0007] Various other aspects of the present disclosure provide recombinant bacteriophages that are engineered for *in vivo* delivery to endogenous bacterial cells and to contain at least one genetic circuit, wherein the at least one genetic circuit does not express an antimicrobial protein or peptide. Other aspects of the present disclosure provide recombinant phagemids that are engineered for *in vivo* delivery to endogenous bacterial cells and to contain at least one genetic circuit, wherein the at least one genetic circuit does not express an antimicrobial protein.

[0008] In the invention, the endogenous bacterial cells are nonpathogenic bacterial cells.

[0009] In the invention, the endogenous bacterial cells are stably maintained in a microbiome.

[0010] In some embodiments, the recombinant bacteriophage is a non-lytic recombinant bacteriophage. In some embodiments, non-lytic bacteriophages, or phagemids, are from a family selected from *Myoviridae*, *Siphoviridae*, *Podoviridae*, *Tectiviridae*, *Corticoviridae*, *Lipothrixviridae*, *Plasmaviridae*, *Rudiviridae*, *Fuselloviridae*, *Inoviridae*, *Microviridae*, *Leviviridae* and *Cystoviridae*. In some embodiments, wherein a non-lytic recombinant *Inoviridae* bacteriophage is an M13 or M13-like bacteriophage. In some embodiments, a recombinant phagemid is an M13-derived phagemid.

[0011] In some embodiments, the genetic circuit contains a nucleic acid with a promoter operably linked to a nucleotide sequence encoding a gene product.

[0012] In some embodiments, the nucleic acid is a recombinant nucleic acid. In some

embodiments, the nucleic acid is a synthetic nucleic acid.

[0013] In some embodiments, the promoter is a constitutively active promoter. In some embodiments, the promoter is an inducible promoter.

[0014] In some embodiments, the genetic circuit is a recombinase-based genetic circuit.

[0015] In the invention, the genetic circuit is engineered to express a therapeutic molecule. In some embodiments, the genetic circuit comprises a nucleic acid with a promoter operably linked to a nucleotide sequence that encodes the therapeutic molecule. In some embodiments, the therapeutic molecule is an antibody, antibody-based drug, Fc fusion protein, anticoagulant, blood factor, bone morphogenetic protein, engineered protein scaffold, enzyme, growth factor, hormone, interferon, interleukin or thrombolytic.

[0016] The genetic circuit may be engineered to detect a condition, such as a cancer, an immune disorder or an infection. The genetic circuit may comprise a nucleic acid with an inducible promoter operably linked to a nucleotide sequence that encodes a reporter molecule. The reporter molecule may be a fluorescent protein. The genetic circuit may comprise a nucleic acid with a promoter operably linked to a nucleotide sequence that encodes toluene dioxygenase or styrene monooxygenase.

[0017] Also provided herein are compositions that comprise any one or more of the recombinant bacteriophages and/or phagemids of the present disclosure.

[0018] As used herein, "a" and "an" should be understood to mean "at least one."

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component illustrated in various figures is represented by a like numeral. For purposes of clarity, not every component may be labeled in every drawing.

FIG. 1 shows a graph of indigo concentration over time for the constitutive PLtetO and the inducible Pbad promoter networks used to express toluene dioxygenase. Toluene dioxygenase (and, thus, indigo) is produced in the presence of the Pbad inducer and in the presence of the Ptet inducer.

FIG. 2 shows a graph of indigo concentration over time for the constitutive PLtetO and the inducible Pbad promoter networks used to express styrene monooxygenase. Styrene monooxygenase (and, thus, indigo) is produced in the presence of the Pbad inducer and in the presence of the Ptet inducer.

FIG. 3 depicts a graph of indigo measurements after overnight infection of bacteria with recombinant M13 bacteriophage harboring different plasmids.

FIG. 4 shows images of plates from an overnight spot test of M13-pBAD-029, M13-kan-029 and M13-pTet-030. Image on the left is with a black backdrop; image on the right is with a white backdrop. For each plate, the spots from top to bottom are: M13-gfp, M13-mCherry, M13-pBAD-styAB, M13-kan-pBAD-styAB, and M13-pTet-styAB. Spots represent a 1:10 dilution series from right to left, starting with 7.5 μ L of stock.

FIG. 5 shows a graph of indigo concentration over time produced by bacteria transformed with the inducible Pbad promoter network expressing styrene monooxygenase ("test network") or infected with recombinant M13 bacteriophage harboring the inducible Pbad promoter network expressing styrene monooxygenase ("bacteriophage network") (top). FIG. 5 also shows a graph of indigo concentration over time produced by bacteria transformed with the constitutive PLtetO promoter network expressing styrene monooxygenase ("test network") or infected with recombinant M13 bacteriophage harboring the constitutive PLtetO promoter network expressing styrene monooxygenase ("bacteriophage network") (bottom). Styrene monooxygenase (and, thus, indigo) is produced in the presence of the Pbad inducer for both the test network and the bacteriophage network.

FIG. 6 shows a graph of the fold change of the concentration of indigo produced over time by bacteria transformed with the inducible Pbad test network versus bacteria infected with the inducible Pbad bacteriophage network (top). FIG. 6 also shows a graph of the fold change of the concentration of indigo produced over time by bacteria transformed with the constitutive PLtetO test network versus bacteria infected with the constitutive PLtetO bacteriophage network (bottom).

FIG. 7 shows a graph of indigo concentration as a function of arabinose inducer dosage. EMG2 cells were infected with M13 bacteriophage carrying the inducible Pbad promoter network expressing styrene monooxygenase (M029).

FIG. 8A depicts a schematic of a general *in vivo* model of the present disclosure. FIG. 8B depicts a general *in vivo* Inflammatory Bowel Disease model of the present disclosure.

FIG. 9 depicts an inducible version of toluene dioxygenase on a test plasmid (pRJK025).

FIG. 10 depicts a constitutive version of toluene dioxygenase on a test plasmid (pRJK026).

FIG. 11 depicts an inducible version of styrene monooxygenase on a test plasmid (pRJK029).

FIG. 12 depicts a constitutive version of styrene monooxygenase on a test plasmid (pRJK030).

FIG. 13 depicts an inducible version of styrene monooxygenase on an M13 plasmid (M029).

FIG. 14 depicts a constitutive version of styrene monooxygenase on an M13 plasmid (M030).

FIG. 15A depicts an example of a genetic circuit of the present disclosure, which includes a P_{TRC-2} promoter operably linked to a ribosomal binding site and a nucleotide sequence encoding green fluorescent protein (GFP) with a LAA protein tag. FIG. 15B depicts a graph showing the change in GFP fluorescence over time obtained from (1) ER2738 *Escherichia coli*

(*E. coli*) cells transformed with a bacteriophage engineered to contain the genetic circuit depicted in FIG. 15A (referred to as a M6G bacteriophage), (2) ER2738 *E. coli* cells transformed with a phagemid engineered to contain the genetic circuit depicted in FIG. 15A (referred to as a p6T phagemid), and (3) ER2738 *E. coli* negative control cells (bacteria only).

FIG. 16 depicts a graph showing the percentage of GFP positive cells in gnotobiotic mice colonized with (1) M6G bacteriophages, (2) ER2738 *E. coli* cells transformed with pLT006 plasmids containing the genetic circuit depicted in FIG. 15A (positive control), and (3) ER2738 *E. coli* negative control cells.

DETAILED DESCRIPTION OF THE INVENTION

[0020] Provided herein are efficient and effective strategies for selectively manipulating endogenous bacterial cells of a microbiome to express genetic circuits, for example, to deliver therapeutic molecules to the host organism or to detect changes in the host organism's biological environment. Surprisingly, the present disclosure shows that these endogenous bacterial cells, which are stably maintained in a host organism, can be manipulated *in vivo* through the use of viruses (e.g., bacteriophages), or virus particles (e.g., phagemids), to serve as, *inter alia*, long-term drug delivery devices and biosensors. One traditional way of manipulating a microbiome is to administer antibiotics; however, antibiotics are broad spectrum in nature and target/kill both pathogenic and non-pathogenic "healthy" bacteria. Another traditional way of manipulating a microbiome is to deliver exogenous bacteria in the form of, for example, probiotic pills or yogurt; however, exogenous bacteria are typically only transiently present in the microbiome to which they are delivered because most existing ecological niches are already occupied by endogenous bacteria. Unlike the foregoing traditional strategies, which are indiscriminate and transient in nature, the present disclosure provides, in some instances, selective and stable delivery of new genetic programs to endogenous bacterial cells already established in a microbiome.

[0021] A "microbiome," as used herein, refers to the totality of microbes in a particular environment (e.g., in/on an organism, in a marine environment (e.g., ocean), and/or in a terrestrial environment (e.g., soil)). A microbiome may refer to the totality of microbes that reside, or are stably maintained, for example, on the surface and in deep layers of the skin, in the saliva and oral mucosa, in the conjunctiva, and in the gastrointestinal tracts of an organism. A "host" organism or subject (e.g., animal such as a mammal, e.g., human) refers to the organism in/on which endogenous bacteria reside. Examples of host organisms or subjects in accordance with the present disclosure include, without limitation, animals such as humans, domesticated animals (e.g., cats, dogs, rodents, rabbits, birds), and farm animals (e.g., cows, pigs, goats, chickens, horse, sheep). It is to be understood that the microbes (e.g., endogenous bacteria) of a microbiome are typically non-pathogenic, or "healthy," microbes (e.g., they exist symbiotically, or in a mutually beneficial relationship, in an organism and do not

cause disease unless the microbes grow abnormally). The bacterial cells (e.g., non-pathogenic bacterial cells) that make up a microbiome are referred to herein as "endogenous" bacterial cells. The endogenous bacteria that exist in/on an organism are distinguished from exogenous bacteria, which can be introduced to an organism and, in some instances, may be pathogenic (e.g., may cause disease).

[0022] The present disclosure is directed to methods of functionalizing endogenous bacteria *in vivo* to express genetic circuits that can be used, for example, to deliver therapeutic molecules and/or to act as biosensors of various biological conditions and/or disease states. To achieve this functionalization, the present disclosure contemplates engineering non-lytic, or lysogenic, recombinant bacteriophages and/or phagemids as vehicles to deliver to endogenous bacterial cells a variety of new genetic programs.

Bacteriophages

[0023] A bacteriophage (also referred to as a phage), is a virus that infects and replicates in bacteria. Bacteriophages are composed of proteins that encapsulate a DNA or RNA genome and may have relatively simple or elaborate structures. Their genomes may encode as few as four genes, and as many as hundreds of genes. Bacteriophages replicate within bacteria following the injection of their genome into the cytoplasm and do so using either a lytic cycle, which results in bacterial cell lysis, or a lysogenic (non-lytic) cycle, which leaves the bacterial cell intact. Bacteriophages of the present disclosure are, in some embodiments, non-lytic (also referred to as lysogenic or temperate). Thus, after phage delivery of a genetic circuit to an endogenous bacterial cell, the bacterial cell may remain viable and able to stably maintain expression of the genetic circuit.

[0024] Examples of non-lytic bacteriophage for use in accordance with the present disclosure include, without limitation, *Myoviridae* (PI-like viruses; P2-like viruses; Mu-like viruses; SPO1-like viruses; phiH-like viruses); *Siphoviridae* (λ -like viruses, γ -like viruses, T1-like viruses; T5-like viruses; c2-like viruses; L5-like viruses; .psi.M1-like viruses; phiC31-like viruses; N15-like viruses); *Podoviridae* (phi29-like viruses; P22-like viruses; N4-like viruses); *Tectiviridae* (*Tectivirus*); *Corticoviridae* (*Corticovirus*); *Lipothrixviridae* (*Alphalipothrixvirus*, *Betalipothrixvirus*, *Gammalipothrixvirus*, *Deltalipothrixvirus*); *Plasmaviridae* (*Plasmavirus*); *Rudoviridae* (*Rudovirus*); *Fuselloviridae* (*Fusellovirus*); *Inoviridae* (*Inovirus*, *Plectrovirus*, M13-like viruses, fd-like viruses); *Microviridae* (*Microvirus*, *Spiromicrovirus*, *Bdellovibrio*, *Chlamydia microvirus*); *Leviviridae* (*Levivirus*, *Allolevivirus*) and *Cystoviridae* (*Cystovirus*). Such phages may be naturally occurring or engineered phages. In some embodiments, a bacteriophage is a coliphage (e.g., infects *Escherichia coli*).

[0025] In some embodiments, a bacteriophage of the present disclosure is an M13 bacteriophage. M13 is a filamentous bacteriophage of the family *Inoviridae* and is composed of circular single-stranded DNA. M13 phages are about 900 nm long and 6-7 nm in diameter with 5 proteins. The minor coat protein, P3, attaches to the receptor at the tip of the F pilus of an

Escherichia coli host cell. Thus, in some embodiments, methods of the present disclosure comprise delivering to endogenous bacterial cells a recombinant M13 bacteriophage that is engineered to contain at least one genetic circuit.

[0026] In some embodiments, the bacteriophage of the present disclosure is isolated from (e.g., collected from, obtained from) stool or sewage.

Phagemids

[0027] In some embodiments of the present disclosure, phagemids are engineered to contain at least one genetic circuit. As used herein, "phagemid" refers to a bacteriophage-derived vector containing the replication origin of a plasmid and the packaging site of a bacteriophage. Examples of phagemids that may be used in accordance with the present disclosure include, without limitation, M13-derived phagemids containing the *fl* origin for filamentous bacteriophage packaging such as, for example, pBluescript II SK (+/-) and KS (+/-) phagemids, pBC SK and KS phagemids, pADL and P1-based phagemids (see, e.g., Westwater CA et al., *Microbiology* 148, 943-50 (2002); Kittleson JT et al., *ACS Synthetic Biology* 1, 583-89 (2012); Mead DA et al., *Biotechnology* 10, 85-102 (1988)). Other phagemids may be used in accordance with the present disclosure and, for example, can be made to work with packaging systems from natural, engineered or evolved bacteriophage.

Endogenous Bacterial Cells

[0028] A microbiome may comprise of a variety of endogenous bacterial species, any of which may be targeted in accordance with the present disclosure. In some embodiments, the genus and/or species of target endogenous bacterial cells may depend on the type of bacteriophage and/or phagemid being used. For example, some bacteriophages exhibit tropism for, or preferentially target, specific host species of bacteria. Other bacteriophages do not exhibit such tropism and may be used to target a number of different genus and/or species of endogenous bacterial cells. In some embodiments, the bacteria are considered to be lysogenic bacteria. As used herein, "lysogenic bacteria" are endogenous bacteria that are infected by a non-lytic (also referred to as lysogenic or temperate) bacteriophage. Lysogenic bacteria are typically not lysed by bacteriophage infection. It should be appreciated that, in some instances, infection of an endogenous bacterial cell by a non-lytic or lysogenic bacteriophage may result in cell lysis of, for example, a small proportion (e.g., less than 20%, less than 10%, less than 5%, less than 2%, or less than 1%) of the infected bacterial cells.

[0029] Bacteria are small (typical linear dimensions of around 1 micron), non-compartmentalized, with circular DNA and ribosomes of 70S. As used herein, the term "bacteria" encompasses all variants of endogenous bacteria. "Endogenous" bacteria naturally reside in a closed system. Bacterial cells of the present disclosure include bacterial

subdivisions of *Eubacteria* and *Archaeobacteria*. *Eubacteria* can be further subdivided into gram-positive and gram-negative *Eubacteria*, which depend upon a difference in cell wall structure. Also included herein are those classified based on gross morphology alone (e.g., cocci, bacilli). In some embodiments, the bacterial cells are Gram-negative cells, and in some embodiments, the bacterial cells are Gram-positive cells. Examples of bacterial cells of the present disclosure include, without limitation, cells from *Yersinia* spp., *Escherichia* spp., *Klebsiella* spp., *Bordetella* spp., *Neisseria* spp., *Aeromonas* spp., *Francisella* spp., *Corynebacterium* spp., *Citrobacter* spp., *Chlamydia* spp., *Hemophilus* spp., *Brucella* spp., *Mycobacterium* spp., *Legionella* spp., *Rhodococcus* spp., *Pseudomonas* spp., *Helicobacter* spp., *Salmonella* spp., *Vibrio* spp., *Bacillus* spp., *Erysipelothrix* spp., *Salmonella* spp., *Streptomyces* spp., *Bacteroides* spp., *Prevotella* spp., *Clostridium* spp., *Bifidobacterium* spp., or *Lactobacillus* spp. In some embodiments, the bacterial cells are from *Bacteroides thetaiotaomicron*, *Bacteroides fragilis*, *Bacteroides distasonis*, *Bacteroides vulgatus*, *Clostridium leptum*, *Clostridium coccoides*, *Staphylococcus aureus*, *Bacillus subtilis*, *Clostridium butyricum*, *Brevibacterium lactofermentum*, *Streptococcus agalactiae*, *Lactococcus lactis*, *Leuconostoc lactis*, *Actinobacillus actinobycetemcomitans*, cyanobacteria, *Escherichia coli*, *Helicobacter pylori*, *Selenomonas ruminatum*, *Shigella sonnei*, *Zymomonas mobilis*, *Mycoplasma mycoides*, *Treponema denticola*, *Bacillus thuringiensis*, *Staphylococcus lugdunensis*, *Leuconostoc oenos*, *Corynebacterium xerosis*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus casei*, *Lactobacillus acidophilus*, *Streptococcus Enterococcus faecalis*, *Bacillus coagulans*, *Bacillus ceretus*, *Bacillus popillae*, *Synechocystis* strain PCC6803, *Bacillus liquefaciens*, *Pyrococcus abyssi*, *Selenomonas nominantium*, *Lactobacillus hilgardii*, *Streptococcus ferus*, *Lactobacillus pentosus*, *Bacteroides fragilis*, *Staphylococcus epidermidis*, , *Zymomonas mobilis*, *Streptomyces phaeochromogenes*, or *Streptomyces ghanaensis*. Thus, bacteriophages and/or phagemids of the present disclosure may target (e.g., specifically target) a bacterial cell from any one or more of the foregoing genus and/or species of bacteria.

[0030] In some embodiments, bacterial cells of the present disclosure are anaerobic bacterial cells (e.g., cells that do not require oxygen for growth). Anaerobic bacterial cells include facultative anaerobic cells such as, for example, *Escherichia coli*, *Shewanella oneidensis* and *Listeria*. Anaerobic bacterial cells also include obligate anaerobic cells such as, for example, *Bacteroides* and *Clostridium* species. In humans, for example, anaerobic bacteria are most commonly found in the gastrointestinal tract. Thus, bacteriophages and/or phagemids of the present disclosure may target (e.g., specifically target) anaerobic bacterial cells.

Genetic circuits

[0031] The non-lytic recombinant bacteriophages and/or phagemid of the present disclosure are engineered to deliver to endogenous bacterial cells one or more of a variety of genetic circuits, which may depend on the particular intended application (e.g., delivery of a therapeutic molecule). A "genetic circuit," as used herein, refers to a nucleic acid containing at least one promoter operably linked to at least one nucleic acid sequence that encodes a gene

product of interest (e.g., protein or RNA). In some embodiments, a genetic circuit contains a nucleic acid with a promoter operably linked to a single gene, and in other embodiments, the promoter is operably linked to a cluster of genes (e.g., an operon). In yet other embodiments, a genetic circuit may contain more than one promoter, each linked (e.g., operably linked) to the same gene, the same cluster of genes, or to a different gene or cluster of genes. Herein, a genetic circuit that is "engineered to express" a particular gene product (e.g., a therapeutic molecule) may be a genetic circuit that contains at least the genetic elements required for expression of the particular gene product. For example, a genetic circuit that is engineered to express a monoclonal antibody may contain at least one nucleic acid with at least one promoter operably linked to at least one nucleotide sequence encoding the primary amino acid sequence of the monoclonal antibody. Herein, a genetic circuit that is "engineered to detect" a particular condition (e.g., a disease state) may be a genetic circuit that contains at least the genetic elements required for regulated expression of a reporter molecule or other molecule that can be visualized or quantified. For example, a genetic circuit that is engineered to detect oxidative stress via pOxyS or pSoxS and to respond by expressing a styrene monooxygenase enzyme or an anti-inflammatory gene such as, for example, interleukin 10. Styrene monooxygenase converts indole, present in the gut, to indigo as a visual readout.

[0032] The genetic circuits of the present disclosure may be constitutive or regulated. A "constitutive" genetic circuit, as used herein, is active in all circumstances in the bacterial cell, whereas a "regulated" genetic circuit becomes active, or inactive, in response to specific stimuli. A genetic circuit is considered to be "active" when a promoter, described elsewhere herein, initiates transcription of an operably linked nucleotide sequence (e.g., gene sequence). A genetic circuit is considered to be "inactive" when transcription of an operably linked nucleotide sequence is terminated. A constitutive genetic circuit may contain a nucleic acid with a constitutive promoter operably linked to nucleotide sequence encoding a gene product of interest. By contrast, a regulated genetic circuit may contain a nucleic acid with an inducible promoter that activates gene expression in response to specific stimuli or that inactivates gene expression in response to specific stimuli.

Genetic Elements

[0033] Genetic circuits of the present disclosure contain at least one genetic element that can regulate gene/protein expression. A "genetic element," as used herein, refers to a nucleotide sequence that has a role in gene expression. For example, nucleic acids (e.g., recombinant nucleic acids) encoding proteins, promoters, enhancers and terminators are considered to be genetic elements.

Nucleic Acids

[0034] As used herein, the term "nucleic acid" refers to at least two nucleotides covalently

linked together, and in some instances, may contain phosphodiester bonds (e.g., a phosphodiester "backbone"). In some embodiments, a nucleic acid of the present disclosure may be considered to be a nucleic acid analog, which may contain other backbones comprising, for example, phosphoramidate, phosphorothioate, phosphorodithioate, O-methylphosphoroamidite linkages, and/or peptide nucleic acids. Nucleic acids of the present disclosure may be naturally occurring, recombinant or synthetic. "Recombinant nucleic acids" may refer to molecules that are constructed by joining nucleic acid molecules and, in some embodiments, can replicate in a living cell. "Synthetic nucleic acids" may refer to molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules. Recombinant and synthetic nucleic acids also include those molecules that result from the replication of either of the foregoing.

[0035] The nucleic acids may be single-stranded (ss) or double-stranded (ds), as specified, or may contain portions of both single-stranded and double-stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribonucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, and isoguanine.

Promoters

[0036] The genetic circuits of the present disclosure may contain nucleic acids with promoter sequences, or promoters, operably linked to a nucleotide sequence encoding a gene product of interest. As used herein, a "promoter" refers to a control region of a nucleic acid sequence at which initiation and rate of transcription of the remainder of a nucleic acid sequence are controlled. A promoter may also contain subregions at which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors. Promoters may be constitutive, inducible, activatable, repressible, tissue-specific or any combination thereof.

[0037] A promoter drives expression or drives transcription of the nucleic acid sequence that it regulates. Herein, a promoter is considered to be "operably linked" when it is in a correct functional location and orientation in relation to a nucleic acid sequence it regulates to control ("drive") transcriptional initiation and/or expression of that sequence.

[0038] A promoter may be classified as strong or weak according to its affinity for RNA polymerase (and/or sigma factor); this is related to how closely the promoter sequence resembles the ideal consensus sequence for the polymerase. The strength of a promoter may depend on whether initiation of transcription occurs at that promoter with high or low frequency. Different promoters with different strengths may be used to construct genetic circuits with different levels of gene/protein expression (e.g., the level of expression initiated from a weak promoter is lower than the level of expression initiated from a strong promoter).

[0039] A promoter may be one naturally associated with a gene or sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon of a given gene or sequence. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.

[0040] In some embodiments, a coding nucleic acid segment may be positioned under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with the encoded nucleic acid sequence in its natural environment. A recombinant or heterologous enhancer refers to an enhancer not normally associated with a nucleic acid sequence in its natural environment. Such promoters or enhancers may include promoters or enhancers of other genes; promoters or enhancers isolated from any other prokaryotic cell; and synthetic promoters or enhancers that are not "naturally occurring" such as, for example, those that contain different elements of different transcriptional regulatory regions and/or mutations that alter expression through methods of genetic engineering that are known in the art. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including polymerase chain reaction (PCR) (see U.S. Pat. No. 4,683,202 and U.S. Pat. No. 5,928,906).

Inducible Promoters

[0041] As used herein, an "inducible promoter" is one that is characterized by initiating or enhancing transcriptional activity when in the presence of, influenced by or contacted by an inducer or inducing agent. An "inducer" or "inducing agent" may be endogenous or a normally exogenous condition, compound or protein that contacts a genetic circuit in such a way as to be active in inducing transcriptional activity from the inducible promoter.

[0042] Inducible promoters for use in accordance with the present disclosure function in a bacterial cell. Examples of inducible promoters for use herein include, without limitation, bacteriophage promoters (e.g. P1s Icon, T3, T7, SP6) and bacterial promoters (e.g. Pbad, PmgrB, PLlacO, Ptrc2, PLtetO, Plac/ara, Ptac, Pm). Examples of bacterial promoters for use in accordance with the present disclosure include, without limitation, positively regulated *E. coli* promoters such as positively regulated σ^{70} promoters (e.g., inducible pBad/araC promoter, Lux cassette right promoter, modified lamdba Prm promote, plac Or2-62 (positive), pBad/AraC with extra REN sites, pBad, P(Las) TetO, P(Las) ClO, P(Rhl), Pu, FecA, pRE, cadC, hns, pLas, pLux), σ^S promoters (e.g., Pdps), σ^{32} promoters (e.g., heat shock) and σ^{54} promoters (e.g., glnAp2); negatively regulated *E. coli* promoters such as negatively regulated σ^{70} promoters (e.g., Promoter (PRM+), modified lamdba Prm promoter, TetR - TetR-4C P(Las) TetO, P(Las) ClO, P(Lac) IQ, RecA_DlexO_DLacO1, dapAp, FecA, Pspac-hy, pel, plux-cl, plux-lac, CinR, CinL, glucose controlled, modifed Pr, modifed Prm+, FecA, PcyA, rec A (SOS), Rec A (SOS), EmrR_regulated, Betl_regulated, pLac_lux, pTet_Lac, pLac/Mnt, pTet/Mnt, LsrA/cl, pLux/cl,

LacI, LacIQ, pLacIQ1, pLas/cl, pLas/Lux, pLux/Las, pRecA with LexA binding site, reverse BBa_R0011, pLacI/ara-1, pLacIq, rrnB PI, cadC, hns, Pfhua, pBad/araC, nhaA, OmpF, RcnR), σ^S promoters (e.g., Lutz-Bujard LacO with alternative sigma factor σ^{38}), σ^{32} promoters (e.g., Lutz-Bujard LacO with alternative sigma factor σ^{32}), and σ^{54} promoters (e.g., glnAp2); negatively regulated *B. subtilis* promoters such as repressible *B. subtilis* σ^A promoters (e.g., Gram-positive IPTG-inducible, Xyl, hyper-spank) and σ^B promoters. Other inducible bacterial promoters may be used in accordance with the present disclosure.

[0043] The administration or removal of an inducer results in a switch between activation and inactivation of the transcription of the operably linked nucleic acid sequence (e.g., nucleic acid encoding a gene product of interest). Thus, as used herein, the active state of a promoter operably linked to a nucleic acid sequence refers to the state when the promoter is actively driving transcription of the nucleic acid sequence (i.e., the linked nucleic acid sequence is expressed). Conversely, the inactive state of a promoter operably linked to a nucleic acid sequence refers to the state when the promoter is not actively driving transcription of the nucleic acid sequence (i.e., the linked nucleic acid sequence is not expressed).

[0044] An inducible promoter for use in accordance with the present disclosure may be induced by (or repressed by) one or more physiological condition(s), such as changes in pH, temperature, radiation, osmotic pressure, saline gradients, cell surface binding, and the concentration of one or more extrinsic or intrinsic inducing agent(s). The extrinsic inducer or inducing agent may comprise, without limitation, amino acids and amino acid analogs, saccharides and polysaccharides, nucleic acids, protein transcriptional activators and repressors, cytokines, toxins, petroleum-based compounds, metal containing compounds, salts, ions, enzyme substrate analogs, hormones or combinations thereof.

[0045] Inducible promoters for use in accordance with the present disclosure include any inducible promoter described herein or known to one of ordinary skill in the art. Examples of inducible promoters include, without limitation, chemically/biochemically-regulated and physically-regulated promoters such as alcohol-regulated promoters, tetracycline-regulated promoters (e.g., anhydrotetracycline (aTc)-responsive promoters and other tetracycline-responsive promoter systems, which include a tetracycline repressor protein (tetR), a tetracycline operator sequence (tetO) and a tetracycline transactivator fusion protein (tTA)), steroid-regulated promoters (e.g., promoters based on the rat glucocorticoid receptor, human estrogen receptor, moth ecdysone receptors, and promoters from the steroid/retinoid/thyroid receptor superfamily), metal-regulated promoters (e.g., promoters derived from metallothionein (proteins that bind and sequester metal ions) genes from yeast, mouse and human), pathogenesis-regulated promoters (e.g., induced by salicylic acid, ethylene or benzothiadiazole (BTH)), temperature/heat-inducible promoters (e.g., heat shock promoters), and light-regulated promoters (e.g., light responsive promoters from plant cells).

[0046] In some embodiments, the inducer used in accordance with the present disclosure is an N-acyl homoserine lactone (AHL), which is a class of signaling molecules involved in bacterial

quorum sensing. Quorum sensing is a method of communication between bacteria that enables the coordination of group based behavior based on population density. AHL can diffuse across cell membranes and is stable in growth media over a range of pH values. AHL can bind to transcriptional activators such as LuxR and stimulate transcription from cognate promoters. In some embodiments, the inducer used in accordance with the present disclosure is anhydrotetracycline (aTc), which is a derivative of tetracycline that exhibits no antibiotic activity and is designed for use with tetracycline-controlled gene expression systems, for example, in bacteria.

[0047] Other inducible promoter systems are known in the art and may be used in accordance with the present disclosure.

Enhancers

[0048] In some embodiments of the present disclosure, a promoter may or may not be used in conjunction with an "enhancer," which refers to a cis-acting regulatory sequence involved in the transcriptional activation of a nucleic acid sequence downstream of the promoter. The enhancer may be located at any functional location before or after the promoter.

Terminators

[0049] In some embodiments, a genetic circuit may contain a terminator sequence, or terminator. A "terminator," as used herein, is a nucleic acid sequence that causes transcription to stop. A terminator may be unidirectional or bidirectional. It is comprised of a DNA sequence involved in specific termination of an RNA transcript by an RNA polymerase. A terminator sequence prevents transcriptional activation of downstream nucleic acid sequences by upstream promoters. Thus, in certain embodiments, a terminator that ends the production of an RNA transcript is contemplated. A terminator may be necessary *in vivo* to achieve desirable gene/protein expression levels.

[0050] The most commonly used type of terminator is a forward terminator. When placed downstream of a nucleic acid sequence that is usually transcribed, a forward transcriptional terminator will cause transcription to abort. In some embodiments, bidirectional transcriptional terminators are provided, which usually cause transcription to terminate on both the forward and reverse strand. In some embodiments, reverse transcriptional terminators are provided, which usually terminate transcription on the reverse strand only.

[0051] In prokaryotic systems, terminators usually fall into two categories (1) rho-independent terminators and (2) rho-dependent terminators. Rho-independent terminators are generally composed of palindromic sequence that forms a stem loop rich in G-C base pairs followed by several T bases. Without wishing to be bound by theory, the conventional model of

transcriptional termination is that the stem loop causes RNA polymerase to pause, and transcription of the poly-A tail causes the RNA:DNA duplex to unwind and dissociate from RNA polymerase.

[0052] Terminators for use in accordance with the present disclosure include any terminator of transcription described herein or known to one of ordinary skill in the art. Examples of terminators include, without limitation, the termination sequences of genes such as, for example, the bovine growth hormone terminator, and viral termination sequences such as, for example, the TO terminator, the TE terminator, Lambda T1 and the T1T2 terminator found in bacterial systems. In some embodiments, the termination signal may be a sequence that cannot be transcribed or translated, such as those resulting from a sequence truncation.

[0053] Other genetic elements are known in the art and may be used in accordance with the present disclosure.

Recombinase-Based Genetic Circuits

[0054] In some embodiments of the present disclosure, the endogenous bacterial cells are functionalized with recombinase-based genetic circuits. A "recombinase," as used herein, is a site-specific enzyme that recognizes short DNA sequence(s), which sequence(s) are typically between about 30 base pairs (bp) and 40 bp, and that mediates the recombination between these recombinase recognition sequences, which results in the excision, integration, inversion, or exchange of DNA fragments between the recombinase recognition sequences. For example, in some embodiments, recombinant bacteriophages and/or phagemids of the present disclosure may be engineered to deliver at least two genetic circuits, one containing a nucleic acid with an inducible promoter operably linked to a nucleic acid encoding a recombinase, and the other containing a nucleic acid with a promoter operably linked to a nucleotide sequence encoding a gene product of interest and optionally containing a terminator, wherein at least one of the promoter and terminator is flanked by a forward and a reverse recognition site of the recombinase. In such embodiments, expression of the gene product of interest of one circuit is regulated by recombinase activity, or inactivity, of the other circuit.

[0055] Recombinases can be classified into two distinct families: serine recombinases (e.g., resolvases and invertases) and tyrosine recombinases (e.g., integrases), based on distinct biochemical properties. Serine recombinases and tyrosine recombinases are further divided into bidirectional recombinases and unidirectional recombinases. Examples of bidirectional serine recombinases for use herein include, without limitation, β -six, CinH, ParA and $\gamma\delta$; and examples of unidirectional serine recombinases include, without limitation, Bxb1, ϕ C31, TP901, TG1, ϕ BT1, R4, ϕ RV1, ϕ FC1, MR11, A118, U153 and gp29. Examples of bidirectional tyrosine recombinases for use herein include, without limitation, Cre, FLP, and R; and unidirectional tyrosine recombinases include, without limitation, Lambda, HK101, HK022 and pSAM2. The serine and tyrosine recombinase names stem from the conserved nucleophilic amino acid

residue that the recombinase uses to attack the DNA and which becomes covalently linked to the DNA during strand exchange.

[0056] The outcome of recombination depends, in part, on the location and orientation of two short repeated DNA sequences that are to be recombined, typically less than 30 bp long. Recombinases bind to these repeated sequences, which are specific to each recombinase, and are herein referred to as "recombinase recognition sequences" or "recombinase recognition sites." Thus, as used herein, a recombinase is "specific for" a recombinase recognition site when the recombinase can mediate inversion or excision between the repeat nucleotide sequences. As used herein, a recombinase may also be said to recognize its "cognate recombinase recognition sites," which flank an intervening genetic element (e.g., promoter, terminator, or output nucleic acid sequence). A genetic element is said to be "flanked" by recombinase recognition sites when the element is located between and immediately adjacent to two repeated nucleotide sequences.

[0057] Recombinases can also be classified as irreversible or reversible. As used herein, an "irreversible recombinase" (also referred to as a "unidirectional recombinase") refers to a recombinase that can catalyze recombination between two complementary recombination sites, but cannot catalyze recombination between the hybrid sites that are formed by this recombination without the assistance of an additional factor. Thus, an "irreversible recognition site" refers to a recombinase recognition site that can serve as the first of two nucleotide recognition sequences for an irreversible recombinase and that is modified to a hybrid recognition site following recombination at that site. A "complementary irreversible recognition site" refers to a recombinase recognition site that can serve as the second of two nucleotide recognition sequences for an irreversible recombinase and that is modified to a hybrid recombination site following homologous recombination at that site.

[0058] Irreversible recombinases, and nucleic acids that encode the irreversible recombinases, are described in the art and can be obtained using routine methods. Examples of irreversible recombinases include, without limitation, phiC31 (ϕ C31) recombinase, coliphage P4 recombinase (Ow & Ausubel, J. Bacteriol. 155, 704-713 (1983)), coliphage lambda integrase (Lorbach et al., J. Mol. Biol., 296, 1175-81 (2000)), Listeria A118 phage recombinase (Loessner et al., Mol. Micro. 35, 324-340 (2000)), and actinophage R4 Sre recombinase (Matsuura et al., J Bacteriol. 178, 3374-3376 (1996)), HK101, HK022, pSAM2, Bxb1, TP901, TG1, ϕ BT1, ϕ RV1, ϕ FC1, MR11, U153 and gp29.

[0059] Conversely, a "reversible recombinase" refers to a recombinase that can catalyze recombination between two complementary recombinase recognition sites and, without the assistance of an additional factor, can catalyze recombination between the sites that are formed by the initial recombination event, thereby reversing it. The product-sites generated by recombination are themselves substrates for subsequent recombination. Examples of reversible recombinase systems include, without limitation, the Cre-lox and the Flp-*frt* systems, R, β -six, CinH, ParA and $\gamma\delta$.

[0060] In some embodiments, the recombinase is serine recombinase. Thus, in some embodiments, the recombinase is considered to be irreversible. In some embodiments, the recombinase is a tyrosine recombinase. Thus, in some embodiments, the recombinase is considered to be reversible.

[0061] The recombinases provided herein are not meant to be exclusive examples of recombinases that can be used in embodiments of the present disclosure. The complexity of the genetic circuits of the present disclosure can be expanded by mining databases for new orthogonal recombinases or designing synthetic recombinases with defined DNA specificities (Groth, A. C. & Calos, M. P. J Mol Biol 335, 667-678, (2004); Gordley, R. M., et al. Proc Natl Acad Sci USA 106, 5053-5058 (2009)). Other examples of recombinases that are useful in the genetic circuits described herein are known to those of skill in the art, and any new recombinase that is discovered or generated is expected to be able to be used in the different embodiments of the present disclosure.

Gene Products

[0062] The present disclosure contemplates recombinant bacteriophages and/or phagemids delivery of genetic circuits that encode one or more of a variety of gene products. As used herein, a "gene product" may refer to a protein product or RNA product that may be used, for example, as a therapeutic molecule or as a diagnostic or reporter molecule. Representative gene products for genetic circuits of the present disclosure include, without limitation, therapeutic proteins, reporter proteins, transcriptional repressors, transcriptional activators, enzymes, receptor proteins, ligand proteins, RNAs, riboswitches, RNA interference (e.g., shRNA, siRNA, microRNA) molecules and recombinases.

Therapeutic molecules

[0063] Methods of the present disclosure may comprise delivering to endogenous bacterial cells a recombinant bacteriophage and/or phagemid that is engineered to contain at least one genetic circuit that expresses a therapeutic molecule. Therapeutic molecules include therapeutic proteins. Therapeutic molecules of the present disclosure may be used to, for example, replace a protein that is deficient or abnormal, augment an existing biological pathway, provide a novel function or activity, interfere with a molecule or organism, and/or deliver other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic molecule contemplated by the present disclosure include, without limitation, antibodies, antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. Other examples include those that bind non-covalently to target (e.g., monoclonal antibodies), those that affect covalent bonds (e.g., enzymes), and those that exert activity without specific interactions (e.g., serum albumin).

[0064] Also contemplated herein are therapeutic molecules, e.g., recombinant therapeutic proteins, used to treat, for example, cancers, immune disorders, infections and/or other diseases. Engineered proteins, including bispecific mAbs and multispecific fusion proteins, and proteins with optimized pharmacokinetics are also contemplated by the present disclosure.

[0065] In some embodiments, the therapeutic proteins is Etanercept, Bevacizumab, Rituximab, Adalimumab, Infliximab, Trastuzumab, Insulin glargine, Epoetin alfa, Pegfilgrastim, Ranibizumab, Darbepoetin alfa, Interferon beta- 1a, Interferon beta- 1a. Insulin aspart, Rhu insulin, Octocog alfa, Insulin lispro, Cetuximab, Peginterferon alfa-2a, Interferon beta- 1b, Eptacog alfa, Insulin aspart, OnabotulinumtoxinA, Epoetin beta, Rec antihemophilic factor, Filgrastin, Insulin detemir, Natalizumab, Insulin (humulin) or Palivizumab.

[0066] Examples of antibodies, antibody fragments, and/or Fc fusion proteins that may be encoded by the genetic circuits of the present disclosure include, without limitation, Abagovomab, Abciximab, Actoxumab, Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD, Alemtuzumab, Alirocumab, Altumomab pentetate, Amatuximab, Anatumomab mafenatox, Anifrolumab, Anrukinzumab , Apolizumab, Arcitumomab, Aselizumab, Atinumab, Atlizumab (or tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab, Bezlotoxumab, Biciromab, Bimagrumab, Bivatuzumab mertansine, Blinatumomab, Blosozumab, Brentuximab vedotin, Briakinumab, Brodalumab, Canakinumab, Cantuzumab mertansine, Cantuzumab ravtansine, Caplacizumab, Capromab pendetide, Carlumab, Catumaxomab, Cedelizumab, Certolizumab pegol, Cetuximab, Citatuzumab bogatox, Cixutumumab, Clazakizumab, Clenoliximab, Clivatuzumab tetraxetan, Conatumumab, Concizumab, Crenezumab, Dacetuzumab, Daclizumab, Dalotuzumab, Daratumumab, Demcizumab, Denosumab, Detumomab, Dorlimomab aritox, Drozitumab, Duligotumab, Dupilumab, Dusigitumab, Echromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab, Efungumab, Eldelumab, Elotuzumab, Elsilimomab, Enavatuzumab, Enlimomab pegol, Enokizumab, Enoticumab, Ensituximab, Eritumomab cituxetan, Epratuzumab, Erlizumab, Ertumaxomab, Etaracizumab, Etrolizumab, Evolocumab, Exbivirumab, Fanolesomab, Faralimomab, Farletuzumab, Fasinumab, FBTa, Felvizumab, Fezakinumab, Ficlatuzumab, Figitumumab, Flanvotumab, Fontolizumab, Foralumab, Foravirumab, Fresolimumab, Fulranumab, Futuximab, Galiximab, Ganitumab, Gantenerumab, Gavilimumab, Gemtuzumab ozogamicin, Gevokizumab, Girentuximab, Glembatumumab vedotin, Golimumab, Gomiliximab, Guselkumab, Ibalizumab, Ibiritumomab tiuxetan, Icrucumab, Igovomab, Imciromab, Imgatuzumab, Inclacumab, Indatuximab ravtansine, Infliximab, Intetumumab, Inolimomab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Itolizumab, Ixekizumab, Keliximab, Labetuzumab, Lambrolizumab, Lampalizumab, Lebrikizumab, Lemalesomab, Lerdelimomab, Lexatumumab, Libivirumab, Ligelizumab, Lintuzumab, Lirilumab, Lodelcizumab, Lorvotuzumab mertansine, Lucatumumab, Lumiliximab, Mapatumumab, Margetuximab, Maslimomab, Mavrilimumab, Matuzumab, Mepolizumab, Metelimomab, Milatuzumab, Minretumomab, Mitumomab, Mogamulizumab, Morolimumab, Motavizumab, Moxetumomab pasudotox, Muromonab-CD3, Nacolomab tafenatox, Namilumab, Naptumomab estafenatox, Narnatumab, Natalizumab, Nebacumab,

Necitumumab, Nerelimomab, Nesvacumab, Nimotuzumab, Nivolumab, Nofetumomab merpentan, Ocaratuzumab, Ocrelizumab, Odulimomab, Ofatumumab, Olaratumab, Olokizumab, Omalizumab, Onartuzumab, Oportuzumab monatox, Oregovomab, Orticumab, Otelixizumab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Palivizumab, Panitumumab, Panobacumab, Parsatuzumab, Pascolizumab, Pateclizumab, Patritumab, Pentumomab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab vedotin, Pintumomab, Placulumab, Polatuzumab vedotin, Ponezumab, Priliximab, Pritoxaximab, Pritumumab, PRO, Quilizumab, Racotumomab, Radretumab, Rafivirumab, Ramucirumab, Ranibizumab, Raxibacumab, Regavirumab, Reslizumab, Rilotumumab, Rituximab, Robatumumab, Roledumab, Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Samalizumab, Sarilumab, Satumomab pendetide, Secukinumab, Seribantumab, Setoxaximab, Sevirumab, Sibrotuzumab, Sifalimumab, Siltuximab, Simtuzumab, Siplizumab, Sirukumab, Solanezumab, Solitomab, Sonepcizumab, Sontuzumab, Stamulumab, Sulesomab, Suvizumab, Tabalumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tanezumab, Taplitumomab paptox, Tefibazumab, Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, Teprotumumab, TGN, Ticilimumab (or tremelimumab), Tildrakizumab, Tigatuzumab, TNX-, Tocilizumab (or atlizumab), Toralizumab, Tositumomab, Tovetumab, Tralokinumab, Trastuzumab, TRBS, Tregalizumab, Tremelimumab, Tucotuzumab celmoleukin, Tuvirumab, Ublituximab, Urelumab, Urtoxazumab, Ustekinumab, Vantictumab, Vapaliximab, Vatelizumab, Vedolizumab, Veltuzumab, Vepalimomab, Vesencumab, Visilizumab, Volociximab, Vorsetuzumab mafodotin, Votumumab, Zalutumumab, Zanolimumab, Zatuximab, Ziralimumab and Zolimomab aritox.

[0067] Other examples of Fc fusion proteins that may be encoded by the genetic circuits of the present disclosure include, without limitation, Etanercept, Alefacept, Abatacept, Rilonacept, Romiplostim, Belatacept and Aflibercept.

[0068] Examples of anticoagulants and/or blood factors that may be encoded by the genetic circuits of the present disclosure include, without limitation, Protein C, Protein S, and antithrombin, Factors I-VIII, prothrombinase, prothrombin, thrombin von Willebrand Factor (vWF), fibrinogen, fibrin and fibrinopeptides.

[0069] Examples of bone morphogenetic proteins (BMPs) that may be encoded by the genetic circuits of the present disclosure include, without limitation, BMP1-BMP7, BMP8a, BMP8b, BMP10, and BMP15.

[0070] Examples of enzymes that may be encoded by the genetic circuits of the present disclosure include, without limitation, any of the enzymes assigned an Enzyme Commission Number (EC) number (e.g., EC1-EC6) by the International Union of Biochemistry and Molecular Biology (IUBMB) (Webb, Edwin C. Enzyme nomenclature 1992: recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. San Diego: Published for the International Union of Biochemistry and Molecular Biology by Academic Press. ISBN 0-12-227164-5 (1992). Other examples include: styrene monooxygenase (StyAB), toluene dioxygenase

(TODC1C2AB), luciferase and lactase. In some embodiments, the enzyme is toluene dioxygenase. In some embodiments, the enzyme is styrene monooxygenase.

[0071] Examples of growth factors that may be encoded by the genetic circuits of the present disclosure include, without limitation, Adrenomedullin (AM), Angiopoietin (Ang), Autocrine motility factor, Bone morphogenetic proteins (BMPs), Brain-derived neurotrophic factor (BDNF), Epidermal growth factor (EGF), Erythropoietin (EPO), Fibroblast growth factor (FGF), Glial cell line-derived neurotrophic factor (GDNF), Granulocyte colony-stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Growth differentiation factor-9 (GDF9), Hepatocyte growth factor (HGF), Hepatoma-derived growth factor (HDGF), Insulin-like growth factor (IGF), Migration-stimulating factor, Myostatin (GDF-8), Nerve growth factor (NGF) and other neurotrophins, Platelet-derived growth factor (PDGF), Thrombopoietin (TPO), Transforming growth factor alpha (TGF- α), Transforming growth factor beta (TGF- β), Tumor necrosis factor-alpha (TNF- α), Vascular endothelial growth factor (VEGF), placental growth factor (PlGF), Foetal Bovine Somatotrophin (FBS) and IL-1-IL7.

[0072] Examples of peptide hormones that may be encoded by the genetic circuits of the present disclosure include, without limitation, Amylin (or Islet Amyloid Polypeptide), Antimüllerian hormone (or Müllerian inhibiting factor or hormone), Adiponectin, Adrenocorticotrophic hormone (or corticotropin), Angiotensinogen and angiotensin, Antidiuretic hormone (or vasopressin, arginine vasopressin), Atrial-natriuretic peptide (or atriopeptin), Brain natriuretic peptide, Calcitonin, Cholecystokinin, Corticotropin-releasing hormone, Enkephalin, Endothelin, Erythropoietin, Follicle-stimulating hormone, Galanin, Gastrin, Ghrelin, Glucagon, Gonadotropin-releasing hormone, Growth hormone-releasing hormone, Human chorionic gonadotropin, Human placental lactogen, Growth hormone, Inhibin, Insulin, Insulin-like growth factor (or somatomedin), Leptin, Lipotropin, Luteinizing hormone, Melanocyte stimulating hormone, Motilin, Orexin, Oxytocin, Pancreatic polypeptide, Parathyroid hormone, Prolactin, Prolactin releasing hormone, Relaxin, Renin, Secretin, Somatostatin, Thrombopoietin, Thyroid-stimulating hormone (or thyrotropin), and Thyrotropin-releasing hormone.

[0073] Examples of interferons (IFNs) that may be encoded by the genetic circuits of the present disclosure include, without limitation, IFN- α , IFN- β , IFN- ω and IFN- γ .

[0074] Examples of interleukins that may be encoded by the genetic circuits of the present disclosure include, without limitation, interleukin 1-17. In some embodiments, the interleukin is Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11 or Interleukin-13.

[0075] Other examples of therapeutic proteins that may be encoded by the genetic circuits of the present disclosure include, without limitation, Insulin (blood glucose regulator), Pramlintide acetate (glucose control), Growth hormone GH (growth failure), Pegvisoman (growth hormone receptor antagonist), Mecasermin (IGF1, growth failure), Factor VIII (coagulation factor), Factor IX (coagulation factor, Protein C concentrate (anti-coagulation), α 1-proteinase inhibitor (anti-trypsin inhibitor), Erythropoietin (stimulates erythropoiesis), Filgrastim (granulocyte colony-stimulating factor, G-CSF; stimulates neutrophil proliferation), Sargramostim^{36, 37}

(granulocytemacrophage colony-stimulating factor, GM-CSF), Oprelvekin (interleukin11, IL11), Human follicle-stimulating hormone (FSH), Human chorionic gonadotropin (HCG), Lutropin- α (human luteinizing hormone), Interleukin 2 (IL2), Interleukin-1 Receptor Agonist, Denileukin diftitox (fusion of IL2 and Diphtheria toxin), Interferon alfacon 1 (consensus interferon), Interferon- α 2a (IFN α 2a), Interferon- α 2b (IFN α 2b), Interferon- α 3 (IFN α 3), Interferon- β 1a (rIFN- β), Interferon- β 1b (rIFN- β), Interferon- γ 1b (IFN γ), Salmon calcitonin (32-amino acid linear polypeptide hormone), Teriparatide (part of human parathyroid hormone 1-34 residues), Exenatide (Incretin mimetic with actions similar to glucagon-like peptide 1), Octreotide (octapeptide that mimics natural somatostatin), Dibotermine- α (recombinant human bone morphogenic protein 2), Recombinant human bone morphogenic protein 7, Histrelin acetate (gonadotropin-releasing hormone; GnRH), Palifermin (Keratinocyte growth factor, KGF), Becaplermin (platelet-derived growth factor, PDGF), Nesiritide (recombinant human B-type natriuretic peptide), Lepirudin (recombinant variant of hirudin, another variant is Bivalirudin), Anakinra (interleukin 1 (IL1) receptor antagonist), Enfuvirtide (an HIV-1 gp41-derived peptide), β -Glucocerebrosidase (hydrolyzes to glucose and ceramide), Alglucosidase- α (degrades glycogen), Laronidase (digests glycosaminoglycans within lysosomes), Idursulfase (cleaves O-sulfate preventing GAGs accumulation), Galsulfase (cleave terminal sulphate from GAGs), Agalsidase- β (human α -galactosidase A, hydrolyzes glycosphingolipids), Lactase (digest lactose), Pancreatic enzymes (lipase, amylase, protease; digest food), Adenosine deaminase (metabolizes adenosine), Tissue plasminogen activator (tPA, serine protease involved in the breakdown of blood clots), Factor VIIa (serine protease, causes blood to clot), Drotrecogin- α (serine protease, human activated protein C), Trypsin (serine protease, hydrolyzes proteins), Botulinum toxin type A (protease, inactivates SNAP-25 which is involved in synaptic vesicle fusion), Botulinum toxin type B (protease that inactivates SNAP-25 which is involved in synaptic vesicle fusion), Collagenase (endopeptidase, digest native collagen), Human deoxyribonuclease I (endonuclease, DNase I, cleaves DNA), Hyaluronidase (hydrolyzes hyaluronan), Papain (cysteine protease, hydrolyzes proteins), L-Asparaginase (catalyzes the conversion of L-asparagine to aspartic acid and ammonia), Rasburicase (urate oxidase, catalyzes the conversion of uric acid to allantoin), Streptokinase (Anistreplase is anisoylated plasminogen streptokinase activator complex (APSAC)), and Antithrombin III (serine protease inhibitor).

Reporter Molecules

[0076] In some embodiments, the genetic circuits of the present disclosure may encode a "reporter." As used herein, a reporter refers to a protein that can be used to measure gene expression and generally produce a measurable signal such as fluorescence, luminescence or color. The presence of a reporter in a cell or organism is readily observed. For example, fluorescent proteins (e.g., green fluorescent protein (GFP)) cause a cell to fluoresce when excited with light of a particular wavelength, luciferases cause a cell to catalyze a reaction that produces light, and enzymes such as β -galactosidase convert a substrate to a colored product. Reporters may be used to quantify the strength or activity of the input received by the systems of the present disclosure. In some embodiments, reporters can be fused in-frame to other

protein coding sequences to identify where a protein is located in a cell or organism. Reporters for use in accordance with the present disclosure include any reporter described herein or known to one of ordinary skill in the art.

[0077] There are several different ways to measure or quantify a reporter depending on the particular reporter and what kind of characterization data is desired.

[0078] Microscopy can be a useful technique for obtaining both spatial and temporal information on reporter activity, particularly at the single cell level. Flow cytometers can be used for measuring the distribution in reporter activity across a large population of cells. Plate readers may be used for taking population average measurements of many different samples over time. Instruments that combine such various functions, may be used, such as multiplex plate readers designed for flow cytometers, and combination microscopy and flow cytometric instruments.

[0079] Fluorescent proteins may be used for visualizing or quantifying gene product expression. Fluorescence can be readily quantified using a microscope, plate reader or flow cytometer equipped to excite the fluorescent protein with the appropriate wavelength of light. Several different fluorescent proteins are available, thus multiple gene expression measurements can be made in parallel. Examples of genes encoding fluorescent proteins that may be used in accordance with the present disclosure include, without limitation, those proteins provided in U.S. Patent Application No. 2012/0003630 (see Table 59).

[0080] Luciferases may also be used for visualizing or quantifying gene product expression, particularly for measuring low levels of gene expression, as cells tend to have little to no background luminescence in the absence of a luciferase. Luminescence can be readily quantified using a plate reader or luminescence counter. Examples of genes encoding luciferases for that may be used in accordance with the present disclosure include, without limitation, dmMyD88-linker-Rluc, dmMyD88-linker-Rluc-linker-PEST191, luxAB, NanoLuc, *Renilla reniformis* luciferase, and firefly luciferase (from *Photinus pyralis*).

[0081] Enzymes that produce colored substrates ("colorimetric enzymes") may also be used for visualizing or quantifying gene product expression. Enzymatic products may be quantified using spectrophotometers or other instruments that can take absorbance measurements including plate readers. Like luciferases, enzymes such as β -galactosidase can be used for measuring low levels of gene expression because they tend to amplify low signals. Examples of genes encoding colorimetric enzymes that may be used in accordance with the present disclosure include, without limitation, *lacZ* alpha fragment, *lacZ* (encoding beta-galactosidase, full-length), and *xylE*.

Transcriptional Activators and/or Repressors

[0082] In some embodiments, the genetic circuits of the present disclosure may encode a

transcriptional activator or repressor, the production of which can result in a further change in state of the cell, and provide additional input signals to subsequent or additional genetic circuits. Transcriptional regulators either activate or repress transcription from cognate promoters. Transcriptional activators typically bind nearby to transcriptional promoters and recruit RNA polymerase to directly initiate transcription. Repressors bind to transcriptional promoters and sterically hinder transcriptional initiation by RNA polymerase. Other transcriptional regulators serve as either an activator or a repressor depending on where it binds and cellular conditions. Transcriptional regulators for use in accordance with the present disclosure include any transcriptional regulator described herein or known to one of ordinary skill in the art. Examples of genes encoding transcriptional regulators that may be used in accordance with the present disclosure include, without limitation, those regulators provided in U.S. Patent Application No. 2012/0003630 (see Table 63).

Enzymes

[0083] In some embodiments, the genetic circuits of the present disclosure may encode an enzyme. In some embodiments, an enzyme is used as a response to a particular input. For example, in response to a particular input received by a genetic circuit of the present disclosure, such as a certain range of toxin concentration present in the environment, the system may activate transcription of nucleic acid sequence that encodes an enzyme that can degrade or otherwise destroy the toxin. In some embodiments, enzymes may be "biosynthetic enzymes" that catalyze the conversion of substrates to products. For example, such biosynthetic enzymes can be used in accordance with the present disclosure to assemble pathways that produce or degrade useful chemicals and materials, in response to specific signals. These combinations of enzymes can reconstitute either natural or synthetic biosynthetic pathways. Enzymes for use in accordance with the present disclosure include any enzyme described herein or known to one of ordinary skill in the art. Examples of genes encoding enzymes that may be used in accordance with the present disclosure include, without limitation, those provided in U.S. Patent Application No. 2012/0003630.

Receptors, Ligands, and Lytic Proteins

[0084] In some embodiments, the genetic circuits of the present disclosure may encode a receptor, ligand or lytic protein. Receptors tend to have three domains: an extracellular domain for binding ligands such as proteins, peptides or small molecules, a transmembrane domain and an intracellular or cytoplasmic domain, which frequently can participate in some sort of signal transduction event such as phosphorylation. In some embodiments, transporters, channels or pumps are used as output products. Transporters are membrane proteins responsible for transport of substances across the cell membrane. Channels are made up of proteins that form transmembrane pores through which selected ions can diffuse. Pumps are membrane proteins that can move substances against their gradients in an energy-dependent

process known as active transport. In some embodiments, nucleic acid sequences encoding proteins and protein domains whose primary purpose is to bind other proteins, ions, small molecules, and other ligands may be used in accordance with the present disclosure. Receptors, ligands and lytic proteins for use in accordance with the present disclosure include any receptor, ligand and lytic protein, described herein or known to one of ordinary skill in the art. Examples of genes encoding receptors, ligands and lytic proteins that may be used in accordance with the present disclosure include, without limitation, those provided in U.S. Patent Application No. 2012/0003630 (see Table 73).

Antimicrobial Proteins/Peptides

[0085] In some examples, the at least one genetic circuit may express an antimicrobial protein and/or peptide. However, it is to be understood that such antimicrobial proteins and/or peptides are specifically excluded from the genetic circuits for use in the present invention. Thus, in the invention, the at least one genetic circuit does not express an antimicrobial protein or peptide. Examples of antimicrobial proteins and/or peptides disclosed herein include gene modules that encode instructions for cell death, or bactericidal proteins. Examples of such gene modules include *pemI-pemK* genes of plasmid R100, the *phd-doc* genes of phage PI, the *ccdA-ccdB* genes of plasmid F, *mazE-mazF* (or *chpAI-chpAK*), *sof-gef*, *kicA-kicB*, *relB-relE*, *chpBI-chpBK* and *gef*. Other examples of antimicrobial proteins and/or peptides include, without limitation, bacteriocins, hydramacin-1, cecropins, moricins, papiliocins, poneratoxins, mastoparans, melittins, spinigerins, cupiennins, oxyopinins, magainins, dermaseptins, cathelicidins, defensins and protegrins. Other antimicrobial proteins and/or peptides are also contemplated by the present disclosure.

Engineering Genetic Circuits

[0086] The genetic circuits of the present disclosure may be engineered using, for example, standard molecular cloning methods (see, e.g., Current Protocols in Molecular Biology, Ausubel, F.M., et al., New York: John Wiley & Sons, 2006; Gibson, D.G., et al., Nature Methods 6(5):343-345 (2009).

Uses of Functionalized Bacteria

[0087] A genetic circuit, in accordance with the present disclosure, may be engineered to impart to endogenous bacteria a variety of functions such as, for example, the ability to express therapeutic molecules, to modify cellular functions, to create cellular responses to environmental conditions, and/or influence cellular development. By providing a method of delivering rational, controllable genetic circuits to bacterial cells of a microbiome *in vivo*, the present disclosure permits the use of such cells as engineered systems to perform a vast

range of useful functions that may greatly benefit the host organism.

[0088] The functionalized endogenous bacterial cells of the present disclosure may be used for a variety of applications, including, without limitation, bioremediation, biosensing and biomedical therapeutics. The genetic circuits may be used to build in the endogenous bacterial cells multiplexed cellular switches for gene expression or synthetic differentiation cascades. The genetic circuits may be used to regulate (e.g., activate and/or deactivate) in the same cell, at the same time or sequentially, transcription of various molecules of interest.

[0089] The methods of the present disclosure may be used to deliver molecules that treat, or alleviate the symptoms associated with, a condition such as, for example, cancer (e.g., gastrointestinal cancer), immune disorders, infections and/or other diseases (e.g., gastrointestinal disease). Thus the present disclosure provides methods of delivering to a subject a recombinant bacteriophage (e.g., coliphage) and/or phagemid engineered to contain at least one genetic circuit. In some embodiments, the genetic circuit comprises a nucleic acid with a promoter operably linked to a nucleotide sequence encoding a therapeutic molecule. The therapeutic molecule may be, for example, an antibody, antibody-based drug, Fc fusion protein, anticoagulant, blood factor, bone morphogenetic protein, engineered protein scaffold, enzyme, growth factor, hormone, interferon, interleukin or thrombolytic.

[0090] Examples of gastrointestinal cancers include, without limitation, cancers of the esophagus, gallbladder, liver, pancreas, stomach, small intestine, large intestine (colon) and rectum.

[0091] Examples of immune diseases include, without limitation, Acute Disseminated Encephalomyelitis (ADEM), Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune angioedema, Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Autoimmune urticaria, Axonal & neuronal neuropathies, Balo disease, Behcet's disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, Chronic fatigue syndrome**, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST disease, Essential mixed cryoglobulinemia, Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic encephalomyelitis, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis (GPA) (formerly called Wegener's Granulomatosis), Graves'

disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Interstitial cystitis, Juvenile arthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's), Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Reiter's syndrome, Relapsing polychondritis, Restless legs syndrome, Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia, Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Type 1 diabetes, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo and Wegener's granulomatosis (also referred to as Granulomatosis with Polyangiitis (GPA)).

[0092] The methods of the present disclosure may be used to deliver molecules that treat, or alleviate the symptoms associated with, gastrointestinal diseases. Examples of gastrointestinal diseases include, without limitation, Crohn's disease, ulcerative colitis and colon cancer.

[0093] Crohn's disease is a condition of chronic inflammation potentially involving any location of the gastrointestinal tract, but it frequently affects the end of the small bowel and the beginning of the large bowel. In Crohn's disease, all layers of the intestine may be involved, and there can be normal healthy bowel in between patches of diseased bowel. Symptoms include persistent diarrhea (loose, watery, or frequent bowel movements), cramping abdominal pain, fever, and, at times, rectal bleeding. Loss of appetite and weight loss also may occur. However, the disease is not always limited to the gastrointestinal tract; it can also affect the joints, eyes, skin and liver. Fatigue is another common symptom. In some embodiments, the methods of the present disclosure are used to deliver to endogenous bacterial cells a genetic circuit that expresses gene(s) encoding the monoclonal antibody, infliximab, Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11, Interleukin-13, or Interleukin-1 Receptor Antagonist. In some embodiments, the present disclosure provides methods of delivering to a

subject having Crohn's disease a recombinant bacteriophage (e.g., coliphage) and/or phagemid engineered to contain at least one genetic circuit. In some embodiments, the genetic circuit comprises a nucleic acid with a promoter operably linked to a nucleotide sequence encoding a monoclonal antibody (e.g., infliximab), Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11, Interleukin-13, or Interleukin-1 Receptor Antagonist.

[0094] Ulcerative colitis is a chronic gastrointestinal disorder that is limited to the large bowel (the colon). Ulcerative colitis does not affect all layers of the bowel, but only affects the top layers of the colon in an even and continuous distribution. The first symptom of ulcerative colitis is a progressive loosening of the stool. The stool is generally bloody and may be associated with cramping abdominal pain and severe urgency to have a bowel movement. The diarrhea may begin slowly or quite suddenly. Loss of appetite and subsequent weight loss are common, as is fatigue. In cases of severe bleeding, anemia may also occur. In addition, there may be skin lesions, joint pain, eye inflammation and liver disorders. Children with ulcerative colitis may fail to develop or grow properly. In some embodiments, the methods of the present disclosure are used to deliver to endogenous bacterial cells a genetic circuit that expresses gene(s) encoding Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11, Interleukin-13, or Interleukin-1 Receptor Antagonist. In some embodiments, the present disclosure provides methods of delivering to a subject having ulcerative colitis a recombinant bacteriophage (e.g., coliphage) and/or phagemid engineered to contain at least one genetic circuit. In some embodiments, the genetic circuit comprises a nucleic acid with a promoter operably linked to a nucleotide sequence encoding a monoclonal antibody (e.g., infliximab), Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11, Interleukin-13, or Interleukin-1 Receptor Antagonist.

[0095] In some embodiments, the present disclosure provides methods of delivering to a subject having colon cancer a recombinant bacteriophage (e.g., coliphage) and/or phagemid that is engineered to contain at least one genetic circuit.

EXAMPLES

Example 1. Indigo Networks on Plasmids (for illustration only)

[0096] Two different oxidative enzymes were chosen for the purpose of converting indole, a metabolite of Tryptophan, to indigo, an insoluble dye. The first enzyme, toluene dioxygenase, is found in the organism *Pseudomonas putida* and is responsible for catalyzing the oxygenation of various ethenes, butenes, and propenes (Woo et al. Journal of Microbiological Methods 40, 181-191 (2000)). Toulene dioxygenase (e.g., TODC1C2AB) is a multicomponent enzyme that primarily converts indole to indole diol, which is then dimerized spontaneously to indigo. Styrene monooxygenase is also found in *Pseudomonas putida* and is responsible for degrading various styrene molecules (O'connor et al. Applied and Environmental Microbiology

63,4287-4291 (1997)). Styrene monooxygenase is made up of two components, StyA and StyB. StyA slowly catalyzes the conversion of indole to indole oxide, which can naturally form 2-oxindole before dimerizing to indigo. StyB converts indole oxide to indoxyl, which forms indigo at a much faster pace. Both enzymes are capable of oxidizing indole and subsequently catalyzing its dimerization to form indigo *in vivo*. Once formed, the indigo can diffuse through the cell membrane and into the extracellular fluid, where at high enough concentrations it aggregates (Pinero-Fernandez et al. Journal of Bacteriology 193:1793-1798 (2011)).

[0097] The indole networks were designed to be either constitutive or inducible. The PltetO promoter is constitutive unless inhibited by the tetR protein, which is not expressed in wild type *E. coli*. The Pbad promoter is induced by the small molecule arabinose in a dose-dependent manner. Ribosomal binding sites (RBSs) were optimized for high expression by using a RBS calculator.

Cloning

[0098] Cloning was accomplished through standard methods. The oxidative enzymes were obtained by PCR amplification from published strains, using primers specific for the 5' and 3' ends. The 5' primer included the designed RBS. Promoter and terminator elements were obtained by PCR from published library plasmids described by Litcofsky et al. (Nat Meth 9(11):1077-1080 (2012)). These purified components were then digested and ligated into the multiple cloning site of the pKE2-MCS cloning plasmid also described by Litcofsky *et al.* The ligated plasmid was then transformed into the test strain MgPro, which is designed to overexpress the tetR and lacI cassettes.

Indigo Production

[0099] Indigo networks were grown overnight in lysogeny broth (LB), then diluted 1:1000 in M9 minimal media (e.g., M9 salts, MgSO₄, CaCl₂, carbon source such as, e.g., glycerol, or glucose). At OD -0.2-0.3, 0.5 µM indole and the respective inducer were added to the media, and samples were collected every hour for four hours. The samples were spun down for one minute at 13k rpm, aspirated and brought up in dimethyl sulfoxide (DMSO). After vortexing, the samples were spun again at 13k rpm before being read on a plate reader at 610 nm. Pbad was induced with 0.01% arabinose. PltetO was induced with 0.5 µg/mL aTe.

Results

[0100] As shown in Figures 1A and 1B, indigo was produced using both the constitutive PLtetO and the inducible Pbad promoter systems for the production of toluene dioxygenase, TODC1C2AB. Similarly, as shown in Figures 2A and 2B, indigo was produced using both the

constitutive PLtetO and the inducible Pbad promoter systems for the production of styrene monooxygenase, StyAB. By contrast, as shown in Figure 2C, little indigo was produced using both the constitutive PLtetO and the inducible Pbad promoter systems for the production of StyA.

Example 2. Transducible Expression of *styAB* Using Engineered M13 Phage (for illustration only)

[0101] One important aspect of engineering genetic circuits that has yet to be thoroughly explored is the ability to deliver and introduce functioning circuits into cells under *in situ* or *in vivo* conditions. Embodiments of the present disclosure provide engineered M13 bacteriophage for delivery of such circuits into a target population. The recombinant bacteriophages provided herein are used to deliver genetic circuits *in vivo* by targeting bacteria in the intestines of mice. This technology has broad applications as a platform for circuit delivery in order to apply some of the exciting creations of synthetic biology such as intricate biosensors to real-life animal models.

[0102] M13mpl8 replicative form DNA was acquired from NEB (#N4018S) and used for the genetic manipulations of M13 phage. *E. coli* XLI 0, a cloning strain of bacteria harboring the F plasmid required for M13 infection, was used for cloning and M13 propagation and was grown in LB with 25 µg/mL chloramphenicol. Briefly, the desired genetic circuits were amplified from template plasmid and cloned *in vitro* into the multiple cloning site of M13mp18. The ligation products were transformed and plated in 0.7% LB top agar along with 200 µL of additional bacteria from overnight culture to generate a bacterial lawn with plaques corresponding to M13 infection foci. Plaques were picked into a 1:3 dilution of overnight XL10 culture in fresh LB and grown for 4 hours to overnight at 37 °C. Culture supernatants were sterile-filtered to collect crude phage preparations, and pellets were subjected to alkaline lysis using QIAGEN® Miniprep Kits for sequencing.

[0103] For initial phenotype verification, an overnight culture of *E. coli* EMG2 (F+) was washed once and subsequently resuspended in M9 plus glucose. Cultures of *E. coli* MG1655Pro harboring the template plasmids used for cloning into M13 were prepared as positive controls in the same manner. Washed cell suspensions were diluted four-fold into fresh M9 plus glucose with 10 mM arabinose (ara), 250 ng/µL anhydrotetracycline (aTc), or neither. Phage supernatants as prepared above were added at 1:100, and cultures were incubated at 37 °C with shaking. After 4 hours, indole was supplemented to a final concentration of 0.25 mM, and cultures were returned to incubate overnight. Indigo production was visualized the following day by spinning down cultures and resuspending in DMSO.

[0104] Next, phage spot testing was performed to test for the generation of visibly indole-converting plaques. Briefly, 0.25 mM indole and 10 mM ara or 250 ng/µL aTc (or neither) was added to 3 mL of top agar along with 300 µL of EMG2 cells or XL10 cells overnight culture. After solidification, 7.5 µL of test phage and a 1:10 dilution series were added onto the top

agar. Plates were incubated overnight at 37 °C and imaged/read one day late (Table 1).

Table 1.

	1	2	3	4	5	6	7	8	9	
F	0.041	1.533	1.349	0.494	1.256	0.482	1.292	1.041	0.991	610
	M9	p29 +ara	p30 +aTc	M29	M29 +ara	Mk29	Mk29 +ara	M30	M30 +aTc	

[0105] This experiment revealed inducible expression of the indole-converting circuit for pBAD-styAB and pTetO-styAB constructs carried on the engineered M13 bacteriophages (Figures 5 and 6).

Strains:

[0106] pRJK029 = MG1655Pro harboring a plasmid carrying pBAD-driven styAB;

pRJK030 = MG1655Pro harboring a plasmid carrying pTet-driven styAB;

M029 = EMG2 infected with M13 phage carrying pBAD-driven styAB;

M-k29 = EMG2 infected with M13 phage carrying pBAD-driven styAB and a kanamycin resistance cassette; and

M030 = EMG2 infected with M13 phage carrying pTet-driven styAB.

Inducers:

[0107] +ara = with 10 mM arabinose

+aTc = with 2.5 µg/mL anhydrotetracycline

M13-Indole Overnight Induction Repeat

[0108] The initial infection assay was repeated using XL10 as the recipient strain for M13 infection instead of EMG2.

[0109] The cultures were spun down at 4000 rpm for 15 min, and the pellets were resuspended in 500 µL DMSO. The resuspended pellet was transferred to 1.5 mL tubes and incubated at 60 °C with mixing for 5 min to dissolve the indigo. The dissolved indigo was spun at 10,000 x g for 5 min. 300 µL of the supernatant was collected for an absorbance reading at 610 nm.

[0110] This experiment revealed inducible expression of the indole-converting circuit for both pBAD-styAB constructs carried on the engineered M13 bacteriophages. The XL10 recipient

failed to show indole conversion with the M13-pTet-styAB construct, however. Since only one inducer concentration was tested, this should be optimized for M13-pTet-styAB, which was previously verified as functional using EMG2 as the recipient strain. EMG2 infected with M13-pTet-styAB looked darker than other spots when held against a white background. They looked less dark towards more concentrated phage treatment. Without being bound by theory, it is possible that the growth of bacteria is too slowed to visualize a phenotype at the higher concentrations of phage.

Example 3. Dose-Response Study of Indigo Production in Bacterial Cells Infected with Bacteriophage M029 (for illustration only)

Phage delivery:

[0111]

1. 1. EMG2 or XL10 cells grown to stationary phase overnight.
2. 2. Cultures washed 2x in M9 minimal media.
3. 3. Cultures diluted 1:4 into experimental conditions.
4. 4. Phage preps added 1:100 as well as dilutions of 10% arabinose (no inducer, 1:400, 1:200, 1:100, 1:50, 1:25, 1:12.5).
5. 5. Cultures grown for 4 hrs at 37 °C in shaking incubator.
6. 6. Indole added to a final concentration of 500 µM, grown for 2 hours, then assessed for Indigo production.

Indigo collection:

[0112]

1. 1. Indigo collected from culture by spinning sample at 15k rpm for 2 min.
2. 2. Supernatant removed.
3. 3. DMSO added back to recover original volume amount.
4. 4. Pellet resuspended and mixed.
5. 5. Samples incubated at 70 °C for 10 min to ensure all indigo dissolves into solution.
6. 6. Samples spun down again at 15k for 2 min.
7. 7. 300 µL of sample added to a 96 well plate and read on a plate reader at 610 nm for OD.

[0113] FIG. 7 shows a graph of indigo concentration as a function of the increasing doses of arabinose inducer (e.g., 1:400, 1:200, 1:100, 1:50, 1:25, 1:12.5).

Example 4. Inflammatory Bowel Disease (IBD) In Vivo Model (for illustration only)

[0114] Mice are given 2% DSS solution in place of their regular drinking water for the course of 8 days. The mice receive approximately 5 ml of DSS solution per day and the solution is replaced on days 3 and 5. After 8 days of treatment, the DSS solution is replaced with regular drinking water or drinking water that contains the therapeutic bacteriophage particles for 7 days. This protocol provides a consistent model for the inflammatory reaction of inflammatory bowel disease (Pizarro et al. Trends in Mol Med. 2003; Wirtz et al. Nature Protocols. 2007). An overview of the IBD model is shown in Figure 5.

Example 5. Bacteriophage and Phagemid Networks In Vitro (for illustration only)

[0115] *Escherichia coli* (*E. coli*) ER2738 bacterial cells were diluted 1:100 in media and grown for 90 minutes or until $OD_{600} = 0.2-0.3$. Next, the bacterial cells were transduced with a 1:50 dilution of bacteriophage (designated M6G bacteriophage) or phagemid (designated p6T phagemid) stock. The bacteriophages and phagemids were engineered to comprise a genetic circuit that contains a nucleic acid with a constitutively active P_{TRC-2} promoter operably linked to a nucleotide sequence encoding GFP (FIG. 15A). Bacterial cells without bacteriophages and phagemids served as a negative control. The bacterial cells were then incubated with shaking at 37 °C, with fluorescence measurements being taken every 2 hours by flow cytometry. Results are shown in Figure 15B. Notably, by 6 hours, there was a 700 fold increase in GFP expression in cells transfected with the phagemids, relative to the negative control.

Example 6. Bacteriophage and Phagemid Networks In Vivo (for illustration only)

[0116] Gnotobiotic mice (a negative control group, a positive control group and a test group) were first colonized with ER2738 *E. coli* bacterial cells (e.g., by spreading the bacteria on the fur of the mice and by gavage). The ER2738 *E. coli* bacterial cells of the positive control group contained a pLT006 plasmid carrying the genetic circuit depicted in Figure 15A. The test group was administered 200 μ l of M6G bacteriophage containing carrying the genetic circuit depicted in Figure 15A in SM buffer via gavage one day post-colonization and three days post-colonization. The positive control group and the negative control group were given 200 μ l of SM buffer only (50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM $MgSO_4$) (blank control). The mice were fed water containing tetracycline to select for ER2738 *E. coli* bacterial cells (which are tetracycline resistant) for a total of 5 days. On days 0 to 5, fecal samples were collected from all mice and stored at -80 °C until ready for GFP characterization. Upon GFP characterization, fecal samples were dissolved in 1 ml of phosphate buffered saline (PBS),

spun down for 3 minutes at 3.4k rpm, and analyzed for GFP expression by FACS (1,000,000 events recorded; gate set up to distinguish GFP⁺ from GFP⁻; "GFP Fluorescence geomean" and "% population GFP⁺" values recorded). Percent GFP⁺ data was used to track expression. All data scaled so that the peak GFP expression of the positive control registered as 100. This technique was used to reduce sample background. Figure 16 shows that by day two post-colonization, 50% of the cells in the test group were positive for GFP, demonstrating successful *in vivo* delivery of bacteriophage engineered to contain a genetic circuit and expression of a molecule encoded by that circuit.

Methods

In Vitro Protocols

Phage delivery

[0117]

1. 1. EMG2 or XL10 cells grown to stationary phase overnight.
2. 2. Cultures washed 2x in M9 minimal media.
3. 3. Cultures diluted 1:4 into experimental conditions.
4. 4. Phage preps added 1:100 as well as any required inducers (e.g., 1:100 of 10% arabinose).
5. 5. Cultures grown for 4 hours at 37 °C in shaking incubator.
6. 6. Cultures read as needed on a fluorescence-activated cell sorting (FACS) or plate reader.

Indigo production

[0118]

1. 1. Using the protocol described above.
2. 2. After 4 hours of growth, indole added to a final concentration of 200-1000 µM (normal human physiological range).
3. 3. Indole collected at desired time points as described and the concentration determined.

Indigo collection**[0119]**

1. 1. Indigo collected from culture by spinning sample at 15k rpm for 2 min.
2. 2. Supernatant removed.
3. 3. DMSO added back to recover original volume amount.
4. 4. Pellet resuspended and mixed.
5. 5. Samples incubated at 70 °C for 10 min to ensure all indigo dissolves into solution.
6. 6. Samples spun down again at 15k for 2 min.
7. 7. 300 µL of sample added to a 96 well plate and read on a plate reader at 610 nm for OD.

Cloning Methods

[0120] Standard cloning methods used, as described elsewhere herein.

In Vivo Protocols**Phage Delivery Protocol**

[0121] Both wild-type and gnotobiotic mice colonized with *E. coli* are fed bacteriophage particles carrying synthetic networks in the drinking water. Bicarbonate may be given concordantly in order to ensure phage survival through the stomach. Phage or Test networks are induced by Arabinose or aTc in the drinking water as well. Treatments are administered to mice 6 weeks or older and may be given for up to one year.

[0122] The method mentioned above may be technically challenging as mice must consume the liquid containing the bacteriophages voluntarily. As an alternative method, the bacteriophage particles (and optionally, bicarbonate) are delivered directly to (e.g., inserted directly into) the stomach through gavage. Arabinose or aTc can also be introduced into the stomach by gavage.

[0123] An enema strategy may also be used. 6-9 week old mice are first anesthetized using continuous isoflurane inhalation or intraperitoneal injection of ketamine-zylasine. Using a sterile and lubricated small gavage needle and a 1 mL syringe, 50 µL of bacteriophage particles suspended in LB or M9 minimal media are slowly injected into the colon of anesthetized mice.

Air bubbles are removed from the syringe prior to the procedure. The gavage needle is inserted only deep enough to ensure the liquid remains in the colon, then the needle is withdrawn. This procedure typically takes 2-5 minutes per mouse. The infected animal is then placed back inside its cage and monitored for any signs of distress. This procedure can be done a maximum of twice a week for a maximum of 2 weeks. Any mice showing signs of severe gastrointestinal distress are euthanized.

[0124] Feces and urine (if possible) are collected from the mice and tested for signs of phage infection. Sections of the gut are examined for signs of inflammation at the end of the experiment.

[0125] Mice are monitored at least twice per week for any signs of gastrointestinal or kidney distress from the bacteriophage treatment. Mice showing signs of severe distress (hunched posture, ruffled appearance, decreased activity, etc.) are euthanized by CO₂ inhalation to effect.

[0126] An overview of the general model is shown in Figure 6.

SEQUENCES

[0127]

SEQ ID NO:1 (pRJK025)

gacgtctgtgcaagtactactgttctgcagtcacttgaattcaagaaaccaatagtcctattgcatcagacattgccgtcactgcg
tcttttactggctcttctcgctaaccaaaccggtaaccccgcttattaaaagcattctgtaacaaagcgggaccaaagccatgaca
aaagcgcgtaacaaaagtgtctataatcacggcagaaaagtcacattgattattgcacggcgtcacactttgctatgcatagc
attttatccataagattagcggatcatacctgacgctttttatcgcaactctctactgtttctccatacagctgaaaagcttacgggag
gaacgttatgaatcagaccgacacatcacctatcaggctgcgcaggagctggaacaccagcgagatagaagecgtctttgacg
agcatgccggacgtatcgatccgcgcatttataccgatgaggatctgtaccaactcgaactggagcgtgtcttcgcccgtcctg
gctgctgttggggcatgaaaccagattcgcaagccgggcgattacatcacgacctacatgggtgaagacctgtcgtggtcgt
ccggcagaaagacgccagcattgccgtgttctgaaccagtgcgccaccgtggcatgcgcattctgcgcgcggatgccgg
aaacgcgaagggcgttcaattgcagctaccacgggtgggcttacgacaccgccggcaattctgtcaatgtgccttacgaggccg
aatccttcgcgtgcctgaacaagaaggaatggagcccgctgaaggcccggtagaacctacaaggccctgattttcccaac
tgggatgagaacgctgtagacctcgacacgtatctgggcgaggcgaagtctacatggaccacatgctcgaccgcaccgagg
ccggcaccgaagcgatcccgggcgtgcagaagtgggtcattccctgtaactggaaattcgccgcagagcagttttgcagcgac
atgtaccatgccgggacgacctgcattctgtctggcatcctggcaggcctgccagaagaccttgaaatggccgacctgtctcg
ccgacagttggcaagcagtaccgtgcgtcatggggcggacatggaagtggcttctatgtcggcgaccccaatctgatgcttgc
atcatggggccaaaggtcaccagctactggaccgaaggccccgcgtcgaaaaggcggccgaacgtctgggtagcgtgga
gcgcggctcgaaactcatggtcgagcacatgaccgtcttccccacgtgttcttctcccaggtatcaatacgggtccggacatgg
catccgcgcgggcccgaacgaggtcgaggtatgggcgtttacgggtggtcgatgctgatgctcctgacgatataaggaagatt
ccggcgccagacgctgcgcaccttctctgccgggtggcgtgttcgagcaggacgacggggagaactgggtcgagatccagca

catcctgcgagggccacaaggcgcggagcgcgcctttcaatgccgagatgagcatggaccagaccgtcgacaacgacccggt
 ttaccccgggcggaatcagcaacaacgtctacagcaggaagctgcccgcgggctctatgccattggctgcggatgatgacat
 ccccgactgggacgcgctgaaggcgacacgctgaatccagagacagcttgccacgcagtggcgcggccagaggcc
 gcatttgacttcgacccaggttgatgcggtggacctgtccattttaaactacaaggaacgaccatgattgattcagccaacag
 agccgacgtctttctccgaagccggcaccgtagcgcgggaactgcagcacgaagtcgagcagttctactattgggaggcca
 agcttctcaacgategccgcttcgaggagtggctgcgctgctcgcgggaagacattcactacttcatgccattcgcaccacgcg
 gatcatgcgggactcgcgccttgaatactcaggtctccgagagtacgcgcacttcgatgacgacgccacgatgatgaaggga
 cgcttgcgcaagatcacgtccgacgtgagctggccgagaaccccgcatcgcggaccggcatctcgtgagcaacgtgatga
 tcgtcggcgagaggcagaaggggagtagaaatctcaagcgccttcattgtgtaccgcaatcgtctggagcggcagctcga
 catctttgccggtgagcgtcgcgatacgttgcgcgtaacacgagcagggccgggttcgagatcgtcaatcggaccatcctgat
 cgaccagagcaccatcctggccaataacctcagttcttcttaggtgatgtcatgacttgacatacatattgcggcaggggtga
 cctgccacccgggtgagatgcagcgtacgaaggcggccggaaacctgtgatggctcgtcaacgtcgtatggcgagttcttcgcg
 gtgcaggatacctgcacgcgtggggactgggcgttgcggatgggtacctggacgggtgatattgtcgaatgcacgttgcatttcg
 gcaagttctgcgtgcggaccgggaagggtgaaggcgtgcctgcttgcacacatcaagggtattcccaatcaagggtcgaaggc
 gatgaagtgcacgtcgtatctcgacaacggggagttgaagtgatggctacctatgtggcgatcgcgcaatggcgtgggtggc
 ttacgaccgcgcagggccctacgtgccgagggcttcgaggggagaatctcgtcgtattggggacgaaccgcacccctatga
 ccgaccatcctgtccaaggcgggtctcgcagggcagccttgagcggccgccatactggccgagggcgattggtacggcgag
 gcccgcacgcacatgctgaccggccgggaagtcactgccccttgatgtgcagacaaggacgatcagctctggatgatggacca
 cgctctctcgcggacgccatcgtcgcgcagggcagtcgagcgcggacgatggcggttggccggcagccaactgccgggcg
 tcgtaacgctgcgcacctacgggtgacgtgcaggtattgcgcgatagttgacttccgcgacgcggctgctgattgtgggtggcg
 gattgatcggctgcgaggtcgcgacgacggcgcgcaagctcggcctgtcgggtcacgatcctggaggcaggtgatgaactgct
 ggtccgagtacttggcgggcggtatcgggtgcctggctgcgcggcctgctgacagaacttgggtgaggtcaggttgggaacg
 ggtgtcgtaggtttttctgggtgagggccagctcgaacaagtcattggccagcgatggcgcgagcttcgtagccgatagcgcactc
 atttgcgtcggcgaggcccgccgatcaacttgcgcgtcaagcgggcttggcatgtgaccgcggcgctattgtcgatcactg
 cgggtgcgacgttgccaaaggcgtattcgcgctcgagatgtggccagttggcgctgcgcggcgccggcggttcgctc
 gaaacctatatgaacgcgcagcgcgaagccgcggcggtggctgcggccattctggggaaaaacgtatcggcaccgcaactg
 cccgtgtcctggacggagatcgtgggcacgcagatggcgggcgatacgaaggacctgggtatttcgtctcgcgcgg
 catgcccggtagtggcgtgcctgttgtccgctgcaggagcgaaggattcaggcggtcgtcgcggtegatgcacccggtg
 acttcgcgcttgcaacccgattggtagaagcccgcgcggcaatcgagccagcacggctggcagatcttcaaacagtatgcgc
 gattttgttcgtcgaatgaaggagacctaacgtgaggtacctgagaattggcttgactcctgttgatagatccagtaatacct
 cagaactccatctggattttgtcagaacgctcgggttgcggcggtttttattgggtgagaatccaagcagtagtcaggatcctc
 aagtcggccggcggtccatggatactcgtcgcaccattacgctagccgctctggagctcggactgcttaagtcgctccatatgctc

 gtccccgggactacacaattgtccccggcgccagggttgatctctatgcacctagggaccgtctcgagagaatcaatattaac
 caacgcgtggcatcaataaaaacgaaaggctcagtcgaaagactgggccttctgtttatctgttgttgcgggtgaacgcctcct
 gagtaggacaaatccggcgccctagacttaggcgttcggctgcggcgagcggatcagctcactcaaaggcggtataacgggt
 atccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaaggccagcaaaaaggccaggaaccgtaaaaaggccg
 cgttgcgtggcggttttccataggctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagagggtggcgaaaccga
 caggactataaagataaccaggcggttccccctggaagctccctcgtgcgctcctgttccgacctgccgcttaccggatacct
 gtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctcaa
 actgagctctctcgcgaaccccccttcagccccggcgctccgcttctcagtaactctcttgaactcgaacccgctaa

gctgggctgctgcaagaaacccccgacagccgacgctgctgcttaccggtaacatcgtctgagttcaacccggtaag
 acacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggatgtaggcgggtgctacagagttcttga
 agtgggtggcctaactacggctacactagaaggacagtatttggatatctgcgctctgctgaagccagttaccttcggaaaaagatt
 ggtagctcttgatccggcaaacaccaccgctggtagcgggtggtttttgtttgcaagcagcagattacgcgcagaaaaaag
 gatctcaagaagatccttgatctttctacggggctgacgctcagtggaaacgaaaactcacgttaagggttttggcatggcta
 gtgcttgattctcaccaataaaaaacgcccggcggcaaccgagcgttctgaacaaatccagatggagttctgaggtcattactg
 gatctatcaacaggaggtccaagccaattctcgaaccccagagttcccgtcagaagaactcgtcaagaaggcgatagaaggcg
 atgcgctgcgaalcgggagcggcgataccgtaaagcacgagggaagcggtcagcccatcgcggccaagctcttcagcaatat
 cacgggtagccaacgctatgtcctgatagcgggtccgccacaccagccggccacagtcgatgaatccagaaaaggcgccatt
 ttccacatgatattcggcaagcaggcaacgcccgtgggtcacgacgagatccctgcggcggcgtacgcgcttgagcctgg
 cgaacagttcggctggcgcgagccctgatgctcttcgtccagatcatcctgatcgacaagaccgggttccatccgagtacgtg
 ctgctcgtatgcgatgtttcgttgggtgctgaatgggcaggtagccggatcaagcgtatgcagccggcgattgcatcagcca
 tgatggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccataagcagccagtccttc
 ccgcttcagtacaacgtcgagcacagccgcgcaaggaacgcccgtcgtggccagccacgatagccgcgctgcctcgtcttg
 cagttcattcagggcaccggacaggtcgggttgacaaaaagaaccggcgaccctgcgctgacagccggaacacggcggc
 atcagagcagccgattgtctgttggcccagtcatagccgaatagcctctccaccaagccggcgagaacctgcgtgcaatcc
 atcttgttaatcatcgaaacgatcctcatcctgtctcttgatcagatcttgatccctgcgccatcagatccttggcggcaagaaa
 gccatccagtttactttgcagggttcccaaccttaccagagggcgggccaactggcaatcc

SEQ ID NO:2 (pRJK026)

gacgtctgtgcaagtactactgttctgcagtcacttgaattctccctatcagtgatagagattgacatccctatcagtgatagagata
 ctgagcacatcagcaggacgcactgaccagctgaaaagcttacgggaggaacgttatgaatcagaccgacacatcacctatc
 aggtcgcgcaggagctggaacaccagcgagatagaagcgtctttgacgagcatgccggacgtatcgtccgcgcatttatac
 cgtatgaggatctgtaccaactgaactggagcgtgtcttcgcccggctctggctgctgttggggcatgaaaccagattcgcaa
 gccgggagattacatcacgacctacatgggtgaagaccctgtcgtggtcgtccggcagaaagacgccagcattgccgtgtcc
 tgaaccagtgccgccaccgtggcatgcgcacatgccgcgcggatgccggaaacgcgaaggcgttcacttgcaactaccacg
 ggtgggcttacgacaccgccggcaatcttgcattgtgccttacgaggccgaatccttcgcgtgcctgaacaagaaggaaatgg
 agcccgtggaaggccgggtagaaacctacaagggcctgatttcgccaaactgggatgagaacgctgtagacctcgacacgt
 atctgggcgaggcgaagtctacatggaccacatgctcgaccgcaccgaggccggcaccgaagcgtatccgggcgtgcaga
 agtgggtcattccctgtaactggaaattcgccgcagagcagttttgcagcgacatgtaccatgccgggacgacctgcacatgct
 tggcatcctggcaggcctgccagaagacctgaaatggccgacctgtccggcagattggcaagcagtaccgtgcgtcat
 ggggcggacatggaagtggcttctatgtcggcgaccccaatctgatgcttgccatcatggggccaaaggtcaccagctactgg
 accgaaggccccgcgtcggaaaaggcggccgaacgtctgggtagcgtggagcggcgtcgaactcatgtcgcagcacat
 gaccgtctccccacgtgttcttctctccagggtatcaatacgggtccggacatggcatccgcgcgggcccgaacgaggtcgaggt
 atgggcgtttacgggtggtcgtatgctgatgctcctgacgatatcaaggaagagttccggcgccagacgctgcgcaccttctctgc
 cgttggcgtgttcgagcaggacgacggggagaactgggtcgagatccagcacatcctgcgagggccacaaggcgcggagcc
 gccctttcaatgccgagatgagcatggaccagaccgtcgacaacgacccggtttaccccgggcggtatcagcaacaacgtcta
 cagcgagggaagctgcccgcgggctctatgccattggctgcggatgatgacatccccgactgggacgcgctgaaggcgac
 acgtgaaatccagagacagcttgcgccacgcagtggcgccggccagaggccgcatcttgacttcgacccaggttggtatgcgt
 ggaccttgtccatttgaatctacaaggaacgacctgattgattcagccaacagagccgacgtctttctccgaaagccggcacc

cgtagcgcccgaactgcagcacgaagtcgagcagttctactattgggaggccaagcttctcaacgatcgccgcttcgaggagt
ggctcgcgctgctcgcggaagacattcactacttcatgeccattcgcaccacgcggatcatcggggactcgcgccttgaatactc
aggctcccagagtlacgcgcacttcgatgacgacgccacgatgatgaaggacgcttcgcgaagatcacgtccgacgtgag
ctggtccgagaaccccgcacgcggaccggcatctcgtgagcaacgtgatgacgctggcgagaggcagaaggggagta
cgaaatctcaagegccttcattgtgtaccgcaatcgtctggagcggcagctcgacatctttccgggtgagcgtcgcgatacgttg
cgccgtaacacgagcagggccgggttcgagatcgtcaatcggaccatcctgatcgaccagagcaccatcctggccaataacc
tcagtttcttcttaggtgatgtcatgacttggacatacatattcggcgagggtgacctgccaccgggtgagatgcagcgctacg
aaggcggccccggaacctgtgatggtctgcaacgtcgatggcgagttcttcgcgggtgcaggatacctgcacgcatggggactg
ggcgttgctggatggttacctggacgggtgatattgtcgaatgcacgttgcatttcggcaagttctgcgtgcggaccgggaagggtg
aaggcgtgcctgcttgc aaacctatcaaggatctcccaatcaaggctgaaggcgatgaagtgcacgtcgatctcgacaacgg
ggagttgaagtatggctacctatgtggcgatcatcggcaatggcggtgggttcacgaccgcgagggccctacgtgccg
agggcttcgaggggagaatctcgtgattggggacgaaccgcacatccccctatgaccgaccatccttgtccaaggcgggtctcg
acggcagccttgagcggccgccatactggccgagggccgattgggtacggcgagggccgcacatgctgaccggccccg
gaagtcactgcccttgatgtgcagacaaggacgatcagctctggatgatggcaccacgctctctcgggacgccatcgtcatcgcg
acgggcagtcgagcgcggacgatggcggttggccggcagccaactgccggcgctcgtaacgctcgcgcacctacggtgacgt
gcaggtattgcgcgafatgttgacttccgcgacgcggctgctgattgtgggtggcggttgcggtgcgaggtcgcgacga
cggcgcgcaagctcggcctgtcggtcacgatcctggaggcaggtgatgaactgctggctccgagtaacttggcgggcgtatcgg
tgcttggtgcgcggcctgctgacagaacttgggtgtcaggtcgagttgggaacgggtgtcgtaggttttctgggtgagggcca
gctcgaacaagtcacggccagcgatggcgcgacgttcgtagccgatagcgcactcatttgcgtcggcgcgaggcccgcgat
caacttgcgcgtcaagcgggcttggcatgtgaccgcggcgctcattgtcgateactgcgggtgcgacgcttgccaaaggcgtatc
gccgtcggagatgtggccagttggccgctgcgcgccggcgccggcggttcgctcgaaacctatataaacgcgcagcgccaa
gccgccgcgggtggctgcggccattctggggaaaaacgtatcggcaccgcaactgcccggtgctctggacggagatcgtggg
catcgcatgcagatggcgggcgatataagggacctggtgatttctcgcgcggcatgcccggtagtggcgtgccctgtt
gttccgctgcaggagcgaaggattcaggcggctcgtcgggtcgatgcaccccgtaacttcgcgcttgcaacccgattggtag
aagcccgcgcggaatcgagccagcagcggtggcagatcttcaaacagtatgcgcgattttgttcgtcgaatgaaggagac
ctaactgaggtacccgagaattggcttggactcctgttgatagatccagtaatgacctcagaactccatctggatttgcagaac
gctcgggttgcggccggcggtttttattgggtgagaatccaagcagtagtcaggatcctcaagtcggccgccggttccatggatact
cgtcgaccattacgctagccgtctggagctcggactgcttaagtcgctccatagctcgttcccgggactacacaattgtcccccg
gcgccagggttgatatctatcgccctagggaccgtctcgagagaatcaatattaatccaacgcgtggcatcaataaaacgaaa
ggctcagtcgaaagactgggctttcgtttatctgttgttgctgggtgaacgctctcctgagtaggacaaatccggcccgcttagac
ttaggcgttcggctgcggcgagcgggtatcagctcactcaaaggcggtataacaggttatccacagaatcaggggataacgcagg
aaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcggttttccataggctccgc
ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaaccgacaggactataaagataccaggcggttc
ccccctggaagctccctcgtgcgctctcctgttccgacctgcccgttaccggatacctgtccgccttctcccttcgggaaagcgtg
gcgctttctcatagctcacgctgtaggtatctcagttcgggtgtaggtcgttcgctccaagctgggctgtctgcacgaacccccgtt
cagcccagccgtgcgccttatccggtaactatcgtcttgagccaacccggtaagacacgacttatcgccactggcagcagcc
actggtaacaggattagcagagcaggtatgtaggcgggtgctacagagttcttgaagtgggtggcctaactacggctacactaga
aggacagtatttggatatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaaacaacca
ccgctggtagcgggtggtttttgttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatctttctac

ggggtctgacgtcagtggaacgaaaactcacgttaagggattttggtcatggctagtgttgatttcaccaataaaaaacgc
 ccggcggcaaccgagcgttctgaacaaatccagatggagttctgaggtcattactggatctatcaacaggagtcgaagccaatt
 ctgaaccccagagtcccgtcagaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgata
 ccgtaaagcacgaggaagcggtcagcccattcgccgccaagctcttcagcaataacacgggtagccaacgctatgtcctgata
 gcggtccggcacaccagccggccacagtcgatgaatccagaaaagcggccattttccacatgatattcggcaagcaggcat
 cggcgtgggtcacgacgagatcctcgccgtcgggcatacgcgccttgagcctggcgaacagttcggctggcgcgagccct
 gatgctcttcgtccagatccttgatcgacaagaccggctccatccgagtacgtgctcgtcgcgatgcgatgtttcgttggtgt
 cgaatgggcaggttagccgatcaagcgtatgcagccgccgcattgcacagccatgatggatactttctcggcaggagcaag
 gtgagatgacaggagatcctgccccggcacttcgccaatagcagccagtccttcccgttcagtgcacaacgtcgagcacag
 ccgcgcaagggaacggcgtcgtggccagccacgatagccgcgctgcctcgtcttgagttcattcagggcaccggacaggtc
 ggtcttgacaaaaagaaccgggcgacctgcgctgacagccggaacacggcggcatcagagcagccgattgtctgttggtcc
 cagtcatagccgaatagcctctccaccaagccgccggagaacctgcgtgcaatccatcttgttcaatcatgcgaaacgatcctc
 atcctgtctcttgatcagatcttgatccctgcgccatcagatccttggcggcaagaaagccatccagtttactttgcagggttcc
 caaccttaccagagggcggccaactggcaattec

SEQ ID NO:3 (pRJK029)

gacgtctgtgcaagtactaagaaaccaatagtcataattgcatcagacattgccgtcactgcgtcttttactggctcttctcgtaac
 caaacggtaaccccgttattaaaagcattctgtaacaaagcgggaccaaagccatgacaaaagcgcgtaacaaaagtgtct
 ataatcacggcagaaaagtccacattgattatttgacggcgtcacactttgctatgccatagcattttatccataagattagcga
 tcatacctgacgctttttatcgcaactctctactgtttctccatacagctgaaggattaaggaggtagcatgcatgaaaaagcgtatc
 ggtattgttggtgcaggcactgccggcctccatcttggcctcttctccgagcatgacgtcgacgtcactgtgtacactgatcg
 taagcccgatgagtacagtggactgcggctcctgaataccgttctcacaacgcgggtgacgggtgcagcgggaggttgcctcg
 acgtcaatgagtggcgtctgaggagtttgctatttcggccactactactacgtagggtggcgcagcccatgcgtttctacggt
 gatctcaaggctcccagccgtgcagtggactaccgtctctacctgccgatgctgatgcgtgcactggaagccaggggaggcaa
 gttctgtacgacgccgtgtctgccgaagatctggaagggtgtcggagcagtatgatctgctggtgtgtgactggtaaatac
 gccctcggcaagggtgtcgcgaagcagtcggaaaactcggccttcgagaagccgcaacgggcactgtgcgttggtctctcaa
 gggcatcaagggaagcaccgattcgcgcggtgactatgtccttctcggcagggcatggcgagctgattgagattccaacctgtc
 gttcaatggcatgagcacagcgtggtgtcgcgaaccatattggtagcgcgtctggaagtctcggccacaccaagtatgacga
 tgacccgcgtgcgttctcgtatgatgctggagaagctgcgtaagcatcatccttccgttgccgagcgcacatgatccggctgag
 ttgcacctggccaacagttctctggacatcctccagggcgggtgtgtgcccagtattccgcgacgggtcatgcgacctcaataacg
 gcaaaaccatcatcgggctgggcgacatccaggcaactgtcgatccggcttgggccagggcgcgaacatggcgtcctatgc
 ggcatggattctgggcgaggaaatccttgcgcactctgtctacgacctgcgcttcagcgaacacctggagcgtcggcggcagg
 atcgcgtgctgtgcgccaccgctggaccaacttactctgagcgccttcacggaacttccgccggaattcctcacttctca
 gatcctgagccagagccgtgaaatggctgatgagttcacggacaacttcaactatccggaacttcagtgggatcgttctccagc
 ccggaacgtatcggtcagtgggtgcagccagtacgcacccactattgcggcctgacgctattgctccgctgggtcaaggccagcg
 gagccctaactcctgggtgattcaaatgacgttaaaaaaagatgtggtggtggatcgaactccaccagcttccgccaggcggtt
 gcaactgtcgcgacgggaattgcggttctcagcgcggagactgacgagggcgaagtgcattggcatgacggtgaacagcttca
 cctccatcagttctggacccgccgactgtgatggtgtccctgaagtcgggccgtatgcattgagctgctgactcaaggcggacgt
 tcggcgtcagcctcctgggtgaaagtcagaagatgttatcggcattcttcagcaagcgtgtgatcgcgactcctcctcctgct

ttcacagttcagggcgcctccccactctgcgggacgccatggcctggttcgaatgcgaggtggagagcacgggtgaagtaca
 cgaccacacgctcttcattgcgcgcgttagcgccgtgtggagtgccggaggcgaatgccccccagccgctgctgttctttgccag
 ccgttatcacggcaacccgttgccgctgaattgaaacgttcgagaattggcttggaactcctgttgatagatccagtaatgacctca
 gaactccatctggattgttcagaacgctcgggtgccggcggcggtttttattggtgagaatccaagcagtagtcaaagcttccgc
 aaggtaccactttgccgcggagtattgtacattgaaggatcctcaagtcggccgcccgttccatggatactcgtcgaccattac
 gctagccgtctggagctcggactgcttaagtcgctccatagctcgttcccgggactacacaattgtccccggcgccagggttg
 atatctatcgccctagggaccgtctcgagagaatcaatattaatccaacgcgtggcatcaaataaacgaaaggctcagtcgaa
 agactgggcctttcgttttatctgttgttgcgggtgaacgctctcctgagtaggacaaatccgccgccctagacttaggcgttcgg
 ctgcggcgagcgggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgt
 gagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcggttttccataggctccgccccctgacga
 gcatcacaataacgacgctcaagtcagaggtggcgaaacccgacaggactataaagataaccaggcggttccccctggaagct
 cctcgtgcgctcctgttccgacctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcata
 gctcacgctgtaggtatctcagttcgggtgtaggtcgttcgctccaagctgggctgtctgcacgaacccccgttcagcccgaccg
 ctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatgccactggcagcagccactggtaacag
 gattagcagagcgaggtatgtaggcgggtgctacagagttctgaaagtgggtggcctaactacggctacactagaaggacagtattt
 ggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaacaaaccaccgctggtagc
 ggtgggtttttgtttgcaagcagcagattacgcgcagaaaaaaggatcctaagaagatccttgatctttctacggggtctgac
 gctcagtggaaacgaaaactcacgttaagggttttggatggttagtgcttgattctcaccataaaaaacgcccggcgggcaa
 ccgagcgttctgaacaaatccagatggagttctgaggtcattactggatctatcaacaggagtcgaagccaattctcgaaccca
 gagtcccgtcagaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgataccgtaaagcac
 gaggaagcgggtcageccattcggcgccaagctcttcagcaatatcacgggtagccaacgctatgtcctgatagcgggtccgcca
 caccagcggcgccacagtcgatgaatccagaaaagcggccattttccaccatgatattcggcaagcaggcatcgccgtgggtc
 acgacgagatcctcggcgctgggcatacgcgccttgagcctggcgaacagttcggctggcgagccccctgatgctcttcgtc
 cagatcatcctgatcgacaagaccgggttccatccgagtacgtgctcgtcgtatgcgatgttctgcttggtggtcgaatgggcag
 gtagccggatcaagcgtatgcagccgccgcattgcatcagccatgatggatactttctcggcaggagcaaggtgagatgacag
 gagatcctgccccggcacttcgccaatagcagccagtccttcccgttcaagtacaacgtcgagcacagccgcgcaagga
 acgcccgtcgtggccagccacgatagccgcgtgcctcgttctgcagttcattcagggcaccggacaggtcgggtttgacaaa
 aagaaccgggcgacctgcgctgacagccggaacacggcggcatcagagcagccgattgtctgttgtgcccagtcatagcc
 gaatagcctctccaccaagccgccggagaacctgcgtgcaatccatcttgttcaatcatgcgaaacgatcctcatcctgtctctt
 gatcagatcttgatccccctgcgccatcagatccttggcggcaagaaagccatccagtttactttgcagggttcccaacctacca
 gagggcgggcccaactggcaattcc

SEQ ID NO:4 (pRJK030)

gacgtctgtgcaagtacttcctatcagtgatagagattgacatccctatcagtgatagagatactgagcacatcagcaggacgc
 actgaccagctgaaggattaaggaggtagcatgcatgaaaaagcgtatcggattgttgggtgcaggcactgccggcctccatc
 ttggcctcttctccgccagcatgacgtcgacgtcactgtgtacactgatcgtaagcccgatgagtacagtggactgcggctcct
 gaataccgttgcacaaacgcgggtgacgggtgcagcgggaggttgcctcgcaggtcaatgagtggcgtctgaggagtttggt
 attcggccactactactacgtaggtggggcgcagcccatgcgtttctacgggtgatctcaaggctcccagccgtgcagtggacta
 ccgtctctacctgccgatgctgatgcgtgcactggaagccagggggcggcaagttctgctacgacgccgtgtctgccgaagatct

ggaagggtgtcggagcagtatgatctgctggtgtgtgactggtaaatacgccctcggcaagggtgttcgagaagcagtcg
aaaactcgcccttcgagaagccgcaacgggcactgtgcgttggtctcttaaggccatcaagggaagcaccgattcgcgcggtg
actatgtccttctcggcaggcatggcgagctgattgagattccaacctgtcgttcaatggcatgagcacagcgtggtgctcg
aaaaccatattgtagcgatctggaagtcctcgccacaccaagtatgacgatgacccgcgtgcgttctcgatctgatgctgga
gaagctgcgtaagcatcatccttcggtgccgagcgcacgatccggctgagttcgacctggccaacagttctctggacatcctc
cagggcggtgtgtgccagtatccgcgacggctcatgcgacctcaataacggcaaaaccatcatcgggctgggcgacatcca
ggcaactgtcgatccggcttgggccagggcgcgaacatggcgtcctatgcggcatggattctgggcgaggaaatccttgcgc
actctgtctacgacctgcgcttcagcgaacacctggagcgtcgccgccaggatcgctgctgtgcgccacccgctggaccaac
ttcactctgagcgccttcacggaacttcgccgaattcctcaccttcttcagatcctgagccagagccgtgaaatggctgatga
gttcacggacaacttcaactatccggaacttcagtggtatcgcttctccagcccggaacgtatcggtcagtggtgcagccagtac
gcaccactattcggcctgacgctattgctccgctggtaaggccagcggagccctaactcctgggtgattcaaatgacgttaa
aaaaagatgtggtggtgatctgactccaccagcttccgccaggcgggtgactgttcgcgacgggaattgcggttctcagcg
cggagactgacgagggcgaagtgcattggcatgacgggtgaacagcttcacctcatcagtcggaccgccgactgtgatgt
gtccctgaagtcgggctgatgcatgagctgctgactcaaggcggacgcttcggcgtcagcctcctgggtgaaagtcagaaga
tgttateggcattcttcagcaagcgtgtgatcgatggcactcctcctcctgcttccacagttcaggccggcctccccactctgcggg
acgccatggcctggttcgaatgcgaggtggagagcagcgttgaaatcacgaccacacgctcttcattgcgcgcgttagcgcc
tgtggagtgcgggagggcaatgccccccagccgctgctgttcttccagccgttatcacggcaaccggttgcgctgaattga
aacgttcgagaattggttgactcctgttgatagatccagtaatgacctcagaactccatctggatttgcagaacgctcgttg
ccgccggcggtttttattggtgagaatccaagcagtagtcaaagcttcgcaagggtaccactttgcgcggagtattgtacatt
gaaggatcctcaagtcggcgcccgcttcctgatactcgtcgaccattacgctagccgtctggagctcggactgcttaagtcg
ctccatagctcgttcccggaactacacaattgtccccggcgccagggtgatatactcgcctagggaaccgtctcgagagaa
tcaatattaatccaacgcgtggcatcaaataaaacgaaaggctcagtcgaaagactgggccttctgtttatctgttgttcggtg
aacgctctcctgagtaggacaaatccgccgccctagacttagcggttcggctgcggcgagcgggtatcagctcactcaaaggcg
gtaatacgggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgt
aaaaaggccgcgttgctggcggttttccataggctccgccccctgacgagcatcaaaaatcgacgctcaagtcagaggtg
gcgaaaccgacaggactataaagataccaggcggttccccctggaagctcctcgtgcgctctcctgttccgacctgccgctt
accggatacctgtccgccttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtc
gttcgctccaagctgggtgtctgcacgaacccccgttcagcccagccgctgcgccttatccggtaactatcgtttagtcca
acccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcgggtgctac
agagtcttgaagtgggtgacctaacggctacactagaaggacagatattgggtatctgcgctctgctgaagccagttacctcg
gaaaaagagttggtagctcttgatccggcaaaacaaccaccgctggtagcgggtgtttttgttgcaagcagcagattacgcg
cagaaaaaaaggatctcaagaagatcctttgatctttctacgggggtctgacgctcagtggaacgaaaactcaggttaagggattt
tggtcatggctagtgttggttctaccaataaaaaacgcccggcggaaccgagcgttctgaacaaatccagatggagttctg
aggtcattactggtatcatcaacaggagtccaagccaattctcgaaccccgaggtcccgtcagaagaactcgtcaagaaggc
gatagaaggcgatgcgctgcgaatcgggagcggcgataaccgtaaaacgaggaaggcggtcagccattcggcgccaagc
tcttcagcaatatcagggtagccaacgctatgtctgatagcgggtccgccacaccagccggccacagtcgatgaatccaga
aaagcggccatttccaccatgatattcggcaagcaggcatcgccgtgggtcacgacgagatcctcggcgctgggcatacgcg
ccttgagcctggcgaacagttcggctggcgcgagccctgatgctcttcgtccagatcatcctgatcgacaagaccggcttccat
ccgagtacgtgctcgtcgatgcgatgtttcgttggtgtggaatgggcaggtagccggatcaagcgtatgcagccgccgcat

tgcacagccatgatggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccatagea
gccagtccttcccgttcagtgacaacgtcagcacagccgcgcaagggaacgcccgtcgtggccagccacgatagccgcg
ctgcctcgtcttgagttcattcagggcaccggacaggtcggcttgacaaaaagaaccgggcgaccctgcgctgacagccgg
aacacggcggcatcagagcagccgattgtctgttgcccagtcatagccgaatagcctctccaccaagccgccggagaac
ctgcgtgcaatccatcttgttcaatcatgcgaaacgacccatcctgtctcttgatcagatcttgatccccctgcgccatcagatcctt
ggcggcaagaaagccatccagtttactttgcagggttcccaaccttaccagaggggcgcccaactggcaatcc

SEQ ID NO:5 (M029)

aatgctactactattagtagaattgatgccacctttcagctcgcgccccaaatgaaaatagctaaacaggttattgaccatttgc
gaaatgtatctaattggtcaaaactaaatctactcgttcgcagaattgggaatcaactgttatatggaatgaaacttcagacaccgta
cttagttgcatatttaaacatgttgagctacagcattatattcagcaattaagctetaagccatccgcaaaaatgacctcttatcaa
aaggagcaattaaaggctactcttaactctgacctgttgaggttgcttccggctcgttgccttgaagctcgaattaaacgcgat
atttgaagtcttccgggcttctcttaactcttttgatgcaatccgcttgccttgcactataatagtcagggtaaagacctgattttgatt
tatggtcattctcgtttctgaactgtttaagcatttgagggggattcaatgaatatttatgacgattccgcagtattggacgctatcc
agtctaaacattttactattacccccctctggcaaaactcttttgcaaaaagcctctcgtattttggttttatcgtcgtctggtaaacga
gggttatgatagtgttgctcttactatgcctcgtaatccctttggcggttatgtatctgcattagtgaatgtgggtattcctaaatctcaac
tgatgaatctttctacctgtaataatgttggtccgtagttcgtttattaacgtagattttcttcccaacgtcctgactggataatgagc
cagttcttaaaatcgcaataaggtaattcacaatgattaaagttgaaattaaaccatctcaagcccaatttactactcgttctgggtttc
tcgtcagggcaagccttattcactgaatgagcagccttgttacgttgatttgggtaataatccggttctgtcaagattactcttg
atgaaggtcagccagcctatgcgcctgggtctgtacaccgttcctctgtcctctttcaaaagttgggtcagttcgggtcccttatgattgac
cgtctgcgcctcgttccggctaagtaacatggagcaggtcgcggatttcgacacaatttatcaggcgatgatacaaatctccgttg
tactttgttcgcgcttggataatcgtcgggggtcaaagatgagtggttttagtgattcttttgcctctttcgttttaggttggtgccttc
gtagtggcattacgtattttacccgtttaatggaaacttctcatgaaaaagcttttagtccctcaaagcctctgtagccgttgctaccc
tcgttccgatgctgtctttcgtcgtgaggggtacgatcccgcaaaagcggcctttaactccctgcaagcctcagcgaccgaata
tateggttatgcgtgggcgatgggtgtgtcattgtcggcgcaactatcggtatcaagctgtttaagaaatcacctcgaaagcaag
ctgataaaccgatacaattaaaggctccttttggagccttttttggagattttcaacgtgaaaaaattattattcgaattccttttagtt
gttccctttctattctcactccgctgaaactgttgaaagttgttttagcaaaatcccatacagaaaattcatttactaacgtctggaaaga
cgacaaaacttttagatcggttacgtaactatgagggtgtctgtggaatgctacaggcgtttagttgtactggtgacgaaactca
gtgttacgggtacatgggttctattgggcttgcataccctgaaaatgagggtggtggctctgagggtggcggttctgagggtggc
ggttctgagggtggcggtactaaacctcctgagtacggtgatacacctattccgggtatacttatacaacctctcgacggcac
ttatccgcctggtactgagcaaaaccccgtaactcctaactcttctttagggagctcagcctcttaatactttcatgtttcagaata
ataggttccgaaataggcagggggcattaactgtttatacgggcactgttactcaaggcactgaccccgtaaaacttattaccag
tacactcctgtatcatcaaaagccatgtatgacgcttactggaacggtaaatcagagactgcgctttccattctggctttaatgagg
atttatttgtttgtgaatatcaaggccaatcgtctgacctgcctcaacctcctgtcaatgctggcggcggctctggtggtggttctgg
tggcggctctgagggtggtggtctctgagggtggcggttctgagggtggcggtctgagggaaggcggttccgggtggtggtct
ggttccggtgattttgattatgaaaagatggcaaacgctaataagggggctatgaccgaaaatgccgatgaaaacgcgctacag
tctgacgctaaaggcaaaactgattctgtcgtactgattacgggtgctgtatcgalgtttcattggtgacgtttccggccttgctaa
tggtaatggtgctactggtgattttgctggctctaatcccaatggctcaagtcgggtgacgggtgataattcactttaatgaataatt
tccgtcaatatttaccttccctccctcaatcggtgaatgtcggccttttgccttggcgctggtaaacatataaattttctattgattgt

gacaaaataaaacttattccgtggtgtctttgcgtttctttatatgttgccacctttatgtatgtattttctacgtttgctaacatactgcgta
 ataaggaggtcttaateatgccagttcttttgggtattccgttattattgcgtttcctcggtttcttctggtaactttgttcggctatctgct
 tacttttcttaaaaaagggttcggtaagatagctattgctatttcattgtttcttgccttattattgggcttaactcaattcttggtggttat
 ctctctgatattagcgcctcaattaccctctgactttgttcagggtgttcagtttaattctcccgtctaatagcgcttccctgttttatgttatt
 ctctctgtaaaggctgctattttcattttgacgttaacaaaaaatcgtttcttatttggattgggataaataataggctgtttattttgt
 aactggcaaattaggctctggaaagacgctcgttagcgttggttaagattcaggataaaattgtagctgggtgcaaaatagcaact
 aatcttgatttaaggcttcaaaacctcccgcaagtcgggaggttcgctaaaacgcctcgcgttcttagaataccggataagccttct
 atatctgatttgcttgctattgggcgcggtaatgattectacgatgaaaataaaaaacggcttgcttggtctcgatgagtgcggtactt
 ggttaatacecggttcttggaaatgataaggaaagacagccgattattgattggtttctacatgctcgtaaattaggatgggalattatt
 tttcttggtcaggacttatctattgttgataaacaggcgcgttctgcattagctgaacatgttggtttattgtcgtcgtctggacagaatta
 ctttaccttttgtcgggtactttatattcttattactggctcgaaaatgcctctgcctaaattacatgttggcgttgtaaatatggcgatt
 ctcaattaagccctactgttgagcgttggctttatactggtaagaattgtataacgcataatgatactaaacaggcttttctagtaatta
 tgattccggtgtttattcttatttaacgccttattatcacacggtcggtatttcaaaccattaaatttaggtcagaagatgaaattaacta
 aaatatatttgaaaaagtttctcgcgttctttgtcttgcgattggattgcatcagcattacatagttatataaccaacctaagcc
 ggaggttaaaaaaggtagtctctcagacctatgatttggataaattcactattgactcttctcagcgttctaactaagctatcgctatgtt
 ttaagggttctaagggaataattaatagcgcgatttacagaagcaagggttattcactcacatatattgatttatgtactgtttcc
 attaaaaaaggtaattcaaatgaaattgttaaatgtaattaattttgtttcttgatgtttgtttcatcatcttcttttgtcaggtaattgaaa
 tgaataatcgcctctgcgcgattttgtaacttggatttcaaagcaatcaggcgaatccgttattgtttctcccgatgtaaaagggtact
 gttactgtatattcatctgacgttaaacctgaaaatctacgcaatttctttatttctgtttacgtgcaataattttgataggttaggttct
 aaccttccattattcagaagtataatccaaacaatcaggattatattgatgaattgccatcatctgataatcaggaatatgatgataa
 ttccgctccttctggtggtttctttgttccgcaaaatgataatgttactcaaacttttaaaattaataacgttcgggcaaggatttaata

 cgagttgtcgaattgtttgtaaagtctaatacttctaatacctcaaatgtattatctattgacggctctaatactattagttgttagtgctcct
 aaagatatttttagataaccttctcaattcctttcaactgttgatttgcgaactgaccagatattgattgaggggttgatatttgagggtc
 agcaagggtgatgctttagattttcatttgcgtggtctcagcgtggcactgttgcaggcgggttgaatactgaccgcctcacctc
 tgtttatcttctgctggtggttcgttcggtatttttaatggcgaatgttttagggctatcagttcgcgcattaaagactaatagccattca
 aaaatattgtctgtgccacgtattcttacgctttcagggtcagaagggttctatctctgttggccagaatgtcccttttattactggctgt
 gtgactggtgaatctgccaatgtaataatccattcagacgattgagcgtcaaaatgtagggtatttccatgagcgttttctctgttgc
 aatggctggcggtaattattgttctggatattaccagcaaggccgatagtttgagttcttctactcaggcaagtgtatttactaatc
 aaagaagtattgtacaacgggttaatttgcgtgatggacagactcttttactcgggtggcctcactgattataaaaacacttctcagga
 ttctggcgtaccgttctgtctaaaatccctttaatcggcctcctgttttagctcccgtctgattctaacgaggaaagcacgttatagc
 tgcctgcaaaagcaaccatagtagcgcgcctgtagcggcgcattaaagcgcggcgggtgtggtggttacgcgcagcgtgaccg
 ctacacttgccagcgccttagcgcgccttctcgttttcttcttcttcttctcgcacgttcgcgggttccccgtcaagctcta
 aatcgggggctcccttaggggttcgatttagtgccttacggcacctcgacccaaaaaacttgattgggtgatggttcacgtagt
 gggccatcgccttgatagacggttttcgcctttgacgttggagtcacgttctttaatagtggactcttgttccaaactggaacaa
 cactcaacctatctcgggtattcttttgatttataagggttttgcgatttcggaaccaccatcaaacaggattttgcctgctgg
 ggcaaaccagcgtggaccgcttgctgcaactctctcagggccaggcgggtgaagggaatcagctgttcccgtctcactgggtg
 aaaagaaaaaccacctggcgcctcaatcgaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgaca
 ggtttcccactggaaagcgggcagtgagcgaacgcaattaatgtgagttagctcactcattaggcaccacaggtttacactt
 tatgcttccggctcgtatgttgttgggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgaattcga
 gctctgactactgcttggttctaccaataaaaaaacgcccggcggcaaccgagcgttctgaacaaatccagatggagttctga

ggtcattactggatctatcaacaggaggtccaagccaattctcgaacgtttcaattcagcggcaacgggttgccgtgataacggct
 ggcaaagaacagcagcggctggggggcattcgcctccggcactccacaggcgctaacgcgcgcaatgaagagcgtgtggt
 cgtgtacttcaaccgtgctctccacctgcattcgaaccaggccatggcgtcccgagagtggggaggccggcctgaactgtg
 aaagcaggaggaggagtgccatcgatcacacgcttgctgaagaatgccgataacatcttctgactttcaccaggaggctgac
 gccgaagcgtccgccttgagtcagcagctcatgcatacggcccgaacttcaggacaccatcacagtcggcgggtccagactg
 atggagggtgaagctgttcaccgtcatgccatgcacttgcctcgtcagtcctccgcgtgagaaccgcaattcccgtcgcgaac
 agtgaaccgcctggcgggaagctgggtggagtcgatatccaccaccacatctttttaacgtcatttgaatcaccaggaggttagg
 gctccgctggccttgaccagcggagcaatagcgtcaggccgcaatagtgggtgcgtactgggtgcaccactgaccgatacgtt
 ccgggctggagaagcgatcccactgaagtccggatagttgaagttgtccgtgaactcagccatttcacggctctggctcag
 gatctgaagggaaggtaggaattccggcggaagtccgtgaaggcgctcagagtgaagttgggtccagcgggtggcgcacag
 cacgcgactcctggcggcgacgctccagggtgttcgctgaagcgaggtcgtagacagagtgcgcaaggatttctcggccaga
 atccatccgcgcataggacgccatgttcgcgccctggcccaagaccggatcgacagttgcctggatgtcggccagcccgatgat
 ggttttgccgttattgagggtcgcagtcgacgctgcggaatactggcacaacaccgccctggaggatgtccagagaactgttggc
 caggtcgaactcagccggatcgatgcgctcggcaacggaaggatgatgcttacgcagcttctccagcatcagatcgaggaaac

 gcacgcgggtcagtcatacttggtgtgggcgaggacttcagatcgctaccaatatggttttcgagcaccagcgtgtgtc
 tgccattgaacgacagggttggaatcctaatcagctcgcctatgccttggcgagaaggacatagtcaccgcgcgaatcgggtgtt
 ccttgatgcccttgaagagaccaacgcacagtgccttgcggcttctcgaaggcgagttttcggactgcttctgaacacctt
 gccgagggcgtattaccagtgcacacaaccagcagatcatactgctccgacagcccttcagatcttcggcagacacggcgt
 cgtagcagaacttgcgccccctggcttccagtgcacgcatcagcatcggcaggtagagacggtagtccactgcacggctggg
 agccttgagatcaccgtagaaacgcagtggtgcggcccacctacgtagtagtagtggtccgaaatagccaaactcctcagacg
 gccactcattgacgtcaggggcaacctcccgtgcaccgtcaccgcgttgtagcaacggatttcaggagccgcagtcactg
 tactcatcgggcttacgatcagtgtagacagtgacgtcaggtcatgctggcggagggaaggccaagatggaggccggcag
 tgcctgcaccaacaataccgatacgtttttcatgcagctacctccttaatccttcagctgtatggagaaacagtagagagttgcg
 ataaaaagcgtcagggtatgatccgctaattcttatggataaaaatgctatggcatagcaaagtgtgacgccgtgcaataatcaatg
 tggacttttctgccgtgattatagacactttgttacgcgctttgtcatggctttgtcccgtttgttacagaatgcttttaataagcg
 gggttaccgggtttggttagcgagaagagccagtaaaagacgcagtgacggcaatgtctgatgcaatatggactattggtttcttg
 gtacccggggatcctctagagtcgacctgcaggcatgcaagcttggcactggccgtcgtttfacaacgtcgtgactgggaaaac
 cctggcggttaccacacttaatgccttgacgacatcccccttcgccagctggcgtaatagcgaagaggcccgcaccgatcgc
 ccttcccaacagttgcgcagcctgaatggcgaaatggcgctttgcctgggttccggcaccagaagcgggtgccggaaagctgggt
 ggagtgcgacttcttgaggccgatactgtcgtcgtccctcaaaactggcagatgcacgggttacgatgcgcccactacacca
 cgtgacctatcccattacgggtcaatccgcgtttgttcccacggagaatccgacgggttggtactcgtcacatttaattgtgatgaa
 agctgggtacaggaaggccagacgcgaattattttgatggcggttccatttggttaaaaaatgagctgatttaacaaaaatttaag
 cgaattttaacaaaaatattaacgtttacaatttaaatatttgctatacaatcttctgtttttggggcttttctgattataaccggggtac
 atatgattgacatgctagttttacgattaccgttcacgattctctgtttgtcctcagactctcaggcaatgacctgatagcctttgtag
 atctctcaaaaatagctaccctctccggcattaatttatcagctagaacgggtgaatatcatattgatggtgatttgactgtctccggc
 ctttctacccttttgaatctttacacattactcaggcattgcatttaaaatatagagggttctaaaaatftttatccttgcgttgaa
 ataaaggcttctcccgcaaaagtattacagggtcataatgtttttggtacaaccgatttagctttatgctctgaggctttattgcttaatt
 ttgctaattctttgccttgccgtgatgattattggatgtt

SEQ ID NO:6 (M030)

aatgctactactattagtagaattgatgccaccttttcagctcgcgccccaaatgaaaatatagctaaacagggttattgaccatttgc
gaaatgtatctaattggcactaaatctactcgttcgcagaattgggaatcaactgttatatggaatgaaacttccagacaccgta
ctttagttgcatatttaaacatgttgagctacagcattatattcagcaattaaagctctaagccatccgcaaaaatgacctcttataca
aaggagcaattaaagggtactctctaactctgacctgttggagtttgcctccggctcgttgccttgaagctcgaattaaaacgcgat
atgtgaagtctttcgggcttctcttaattcttttgatgcaatccgctttgcttctgactataatagtcagggtaaagacctgattttgatt
tatggtcattctcgttttctgaactgtttaagcatttgagggggattcaatgaatatattatgacgattccgcagtattggacgctatcc
agtctaaacattttactattacccccctctggcaaaactcttttgcaaaaagcctctcgtctattttggttttatcgtcgtctggtaaacga

gggttatgatagtgttgccttactatgcctcgtaatcccttttggcggttatgtatctgcattagtgatgtgggtattcctaaatctcaac
tgatgaatctttctacctgtaataatgttggtccgttagttcgttttattaacgtagattttcttcccaacgtcctgactgggtataatgagc
cagttcttaaaatcgcataaggtaattcacaatgattaaagtigaaattaaaccatctcaagcccaatttactactcgttctgggtgttc
tcgtcagggcaagcccttattcactgaatgagcagctttgttacgttgatttgggtaatgaatatccgggtcttgcgaagattactcttg
atgaaggtcagccagcctatgcgcctggctgtacaccgttcactgtcctctttcaaaagtggtcagttcgggtcccttatgattgac
cgtctgcgcctcgttccggctaagtaacatggagcaggtcgcggatttcgacacaatttatcaggcgatgatacaaactcgcgttg
tactttgttcgcgcttgggtataatcgctgggggtcaaagatgagtggttttagtgattctttgcctcttctgttttaggttggtgccttc
gtagtggcattacgtattttaccctgttaatggaaacttccctcatgaaaaagtcttttagtcctcaaaagcctctgtagccgttgctacc
tcgttccgatgctgtctttcgtcgtgaggggtgacgatcccgcaaaagcggcctttaactccctgcaagcctcagcgaccgaata
tatcggttatgcgtgggcgatgggtgtgtcattgtcggcgcaactatcgggtatcaagctgtttaagaaattcacctcgaaagcaag
ctgataaaccgatacaattaaaggtccttttggagccttttttggagattttcaacgtgaaaaaattattattcgaattccttttagtt
gttccctttctattctcactccgctgaaactgttgaaagtgttttagcaaaatcccatagaaaaattcatttactaacgtctggaaaga
cgacaaaacttttagatcggttacgtaactatgagggctgtctgtggaatgctacaggcggtgtagtgttactgggtgacgaaactca
gtgttacgggtacatgggttccctattgggcttgcctatccctgaaaatgaggggtgggtggtctgaggggtggcgggttctgaggggtggc
gggttctgaggggtggcgggtactaaacctctgagtacgggtgatacacctattccgggctatacttatataaacctctcgcacggcac
ttatccgcctggtactgagcaaaaccccgctaactcctaactcttctcttgaggagtctcagcctcttaatactttcatgtttcagaata
ataggttccgaaataggcagggggcattaactgtttataggggcaactgttactcaaggcaactgaccccgtaaaacttattaccag
tacactcctgtatcatcaaaaagccatgtatgacgcttactggaacggtaaatcagagactgcgctttccattctggtcttaatgagg
atattattgttttgtaatacaaggccaatcgtctgacctgcctcaacctcctgtcaatgctggcggcggctctgggtgtgtgttctgg
tggcggctctgaggggtgtgtgtctgaggggtggcgggttctgaggggtggcggctctgaggggagggcgggtccgggtgtgtgtct
gggtccgggtgattttgattatgaaaagatggcaaacgctaataagggggctatgaccgaaaatgccgatgaaaacgcgctacag
tctgacgctaaaggcaaacctgattctgtcgtactgattacgggtgtgtatcgtatggttcattgggtgacgtttccggccttgctaa
tggtaatgggtgtactgggtgattttgctggctctaattcccaatggctcaagtcgggtgacgggtgataattcacctttaatgaataatt
tccgtcaatatttaccttccctccctcaatcgggtgaatgtcgccctttgtctttggcgctggtaaaccatatgaattttctattgattgt
gacaaaataaacttattccgtgtgtctttgcgtttcttttatatgttgccacctttatgratgtattttctacgtttgtaacatactgcgta
ataaggagctttaatcatgccagttcttttgggtattccgttattattgcgtttccctcgggttccctctggttaactttgttcgggtatctgct
tacttttcttaaaaagggttcggtaagatagctatttctatttcttcttcttattattgggcttaactcaattcttgtgggttat
ctctctgatattagcgtcattaccctctgactttgttcaggggtgttcaggttaattctcccgtctaattgcgcttccctgtttttatgttatt
ctctctgtaaaggctgctattttcatttttgacgttaaacaaaaaatcgtttcttattttggattgggataaataataggctgtttattttgt
aactggcaaataggctctggaaaagacgctcgttagcgttggttaagattcaggataaaattgtagctgggtgcaaaatagcaact
aatcttgatttaaggcttcaaaacctcccgcgaagtcgggaggttcgctaaaacgcctcgcgttcttagaataccggataagccttct
atatctcatttcttcttctatttggcgcgcgtaaatgattcctacagatgaaaataaaaaacgccttcttcttctcagatgaatccggtactt

gggttaataccccgttcttggaatgataaggaaagacagccgattattgattggtttctacatgctcgtaaattaggatgggatattatt
 ttcttgttcaggacttatctattgttgataaacaggcgcttctgcattagctgaacatgttggtttattgtcgtcgtctggacagaatta
 ctttaccctttgtcggtagctttatattctcttattactggctcgaaaatgcctctgcctaaattacatgttggcggttgtaaataatggcgatt
 ctcaattaaagccctactgttgagcgttggtttatactggtaagaattgtataacgcataatgataactaaacaggccttttctagtaatta
 tgattccgggtgtttattcttatttaacgccttattatcacacggctgggtatttcaaaccattaaatttaggagcagaagatgaaattaacta
 aaatatatttgaaaaagtgttctcgcgttcttgcgttgcgattggatttgcacagcattacatagttatataacccaacctaagcc
 ggagggttaaaaaggtagtctctcagacctatgatttggataaattcactattgactcttctcagcgtttaatctaagctatcgctatgtt
 ttcaaggattctaagggaataattaatagcgacgattacagaagcaagggttactcacatatattgatttatgtactgtttcc
 attaaaaaaggtaattcaaatagaattgttaaatgtaattaattttgtttcttgatgttggttcatctcttctttgtcaggtaattgaaa
 tgaataatcgcctctgcgcgatttggtaacttggatttcaaagcaatcaggcggaatccgttattgtttctccgatgtaaagggtact
 gttactgtatattcatctgacgttaaacctgaaaatctacgcaatttcttatttctgtttacgtgcaataattttgatatggtaggttct
 aaccttccattattcagaagtataatccaaacaatcaggattatattgatgaattgccatcatctgataatcaggaatatgatgataa
 ttccgctccttctggtggtttcttgttccgcaaaatgataatgttactcaaacttttaaaattaataacgttcgggcaaggatttaata
 cgagtgtcgaattgtttgtaaagtctaatacttctaatacctcaaatgtattatctattgacggctctaactctattagttgttagtgctcct
 aaagatatttttagataaccttctcaattcctttcaactgttgatttgcacactgaccagatattgattgaggggttgatatttgagggtc
 agcaagggtgatgcttttagatttttcatgtctgctggtctcagcgtggcactgttgcaggcggtgtaatactgaccgcctcacctc
 tgtttatcttctgctggtggtcgttcggtatttttaattggcgatgttttagggctatcagttcgcgcattaaagactaatagccattca
 aaaatattgtctgtgccacgtattcttaccgtttcaggtcagaagggttctatctctgttggccagaatgtcccttttattactggctgt
 gtgactggtgaatctgccaatgtaaataatccattcagacgattgagcgtcaaaatgtaggatttccatgagcgttttctctgttgc
 aatggctggcggttaatatgttctggatattaccagcaaggccgafagtttgagtcttctactcaggcaagtgtattactaatac
 aaagaagtattgtacaacgggttaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaacacttctcagga
 ttctggcgtagccgttctgtctaaaatccctttaatcggcctcctgttttagctcccgtctgattctaacgaggaaagcaggttatac
 tgctcgtcaaaagcaaccatagtagcgccctgtagcggcgcaataagcgcgcggtgtgtgtgttacgcgagcgtgaccg
 ctacacttgccagcgccctagcgcccgtccttctgctttcttcccttcttctcgtccacgttcgccggctttccccgtcaagctcta
 aatcggggggtcccttaggggttcgatttagtgctttacggcacctcgaccccaaaaacttgatttgggtgatggttcacgtagt
 gggccatcgccctgatagacggttttcgccctttgacgttggagtcacgttctttaatagtggactcttgttccaaactggaacaa
 cactcaacctatctcgggctattcttttgatttataagggttttgcgatttcggaaccacatcaaacaggatttctgcctgtgtg
 ggcaaaccagcgtggaccgcttgtgcaactctctcaggggccaggcggtgaagggaatcagctgttggcgtctcactgggtg
 aaaaagaaaaccacctggcgcccaatcagcaaacgcctctccccgcgcgttggccgattcattaatgcagctggcacgaca
 gggttcccactggaagcgggcagtgagcgcaacgcaattaatgtgagtttagtctactcattaggaacccaggtttacactt
 tatgcttcgggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgaattcga
 gctctgactactgcttgattctaccaataaaaaacgcccggcggaaccgagcgttctgaacaaatccagatggagttctga
 ggtcattactggatctatcaacaggagtgccaagccaattctcgaacgtttcaattcagcggcaacgggttgccgtgataacggct
 ggcaaagaacagcagcggctggggggcattcgcctccggcactccacaggcgctaacgcgcgcaatgaagagcgtgtgtgt
 cgtgtacttcaaccgtgctctccacctcgcattcgaaccaggccatggcgctccgcagagtggggaggccggcctgaactgtg
 aaagcaggaggaggagtggcatcgatcacacgcttgtgtaagaatgccgataacatcttctgactttcaccagagggtgac
 gccgaagcgtccgcttgagtcagcagctcatgcatacggcccgacttcagggaacacatcacagtcggcggttcagactg
 atggagggtgaagctgttaccgtcatgccatgcacttcgcctcgtcagctctccgcgtgagaaccgcaattcccgtcgcgaac
 agtgcacccgcctggcggaagctggtgagtcgatatccaccaccacatcttttttaacgtcatttgaatcacceaggagttagg

gctccgctggccttgaccagcggagcaatagcgtcaggccgcaatagtgggtgcgtactggctgcaccactgaccgatacgtt
 ccgggctggagaagcgcgatcccactgaagtccggatagtgaagttgtccgtgaactcatcagccatttcacggctctggctcag
 gatctgaaggaaaggtaggaattccggcggaagttccgtgaaggcgtcagagtgaagttgggtccagcgggtggcgcacag
 cacgcgatcctggcggcgacgctccagggtgttcgctgaagcgcaggctcgtagacagagtgcgcaaggatttctcggccaga
 atccatgccgcataggacgccatgttcgcgccctggcccaagaccggatcgacagtggcctggatgtcggccagcccgatgat
 ggttttgccgttattgagggtcgcgtgaccgtcgcggaatactggcacaacaccgccctggaggatgtccagagaactgttggc
 caggctgaactcagccggatcgatgcgtcggcaacggaaggatgatgcttacgcagcttctccagcatcagatcgaggaaac
 gcacgcgggtcgtcgtactgtgtgtggcgaggacttccagatcgctaccaatatggttttcgagcaccagcgtgtgtctca
 tgcattgaacgacagggttgaatctcaatcagctcgccatgccctggcgagaaggacatagtcaccgcgcgaatcgggtgctt
 ccttgatgcccttgaagagaccaacgcacagtggccgttgcggcttctcgaaggggcagttttcggactgcttctcgaacacctt
 gccgagggtgtatttaccagtgcacacaaccagcagatcatactgctccgacagcccttccagatcttcggcagacacggcgt
 cgtagcagaacttgccgccctggcttcagtgcacgcgtcagcatcggcaggtagagacggtagtccactgcacggctggg
 agccttgagatcaccgtagaaacgcgtgggtgcggccacctacgtagtagtagtggccgaaatagccaaactcctcagacg
 gccactcattgacgtcgagggaacctcccgtgcaccgtcaccgcgttgtagcaacggatttcaggagccgcagtcactg
 tactcatcgggttacgatcagtgacacagtgacgtcgacgtcatgctggcgagggaagaggccaagatggaggccggcag
 tgctgcaccaacaataccgatacgtttttcatgcatgctacctcttaaccttcagctgggtcagtgctcctgctgatgtgctc
 agtatctctatcactgatagggtgtcaatctctatcactgatagggaggtacctggggtacctctagagtcgacctgcaggcatg
 caagcttggcactggccgtcgtttfacaacgtcgtgactgggaaaacctggcgttacctcaacttaategccttgcagcacatcc
 cctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaaatggc
 gctttgcctggtttccggcaccagaagcgggtgccggaaagctgggtggagtgcgatcttctgaggccgatactgtcgtcgtcc
 cctcaaaactggcagatgcacgggtacgatgcgccatctacaccaacgtgacctatcccattacgggtcaatccgccgtttgttccc
 acgggagaatccgacgggtgttactcgtcacatttaattgtgatgaaagctgggtacaggaaggccagacgcgaattattttga
 tggcggttcctattggttaaaaaatgagctgatttaacaaaaatattaacgtttacaatttaaatatttg
 ctatataaatcttctgtttttggggcttttctgattatcaaccggggtacatatgattgacatgctagttttacgattaccgttcacgat
 tctcttgtttgtccagactctcaggcaatgacctgatagcctttgtagatctctcaaaaatagctacctctccggcattaatttatca
 gctagaacgggtgaatatcatattgatggtgatttgactgtctccggccttctcacccttttgaatctttacctacacattactcaggc
 attgcatttaaaatatatgagggttctaaaaattttatccttgcgttgaaataaaggcttctcccgcaaaagtattacagggtcataat
 gtttttggtacaaccgatttagctttatgctctgagggttattgcttaattttgctaattctttgccttgcctgtatgattattggatgtt

SEQ ID NO:7 (pLT006)

gacgtctgtcaagtactactgttctgcagtcacttgaattcgataccagctgggtggagtgcaccaaggagcatgcgaagga
 aacgtttcgagaagcttcgcaagggtaccactttgccgcggagtatttgatattgaaggatcctcaagtcggccgccgttcc
 atggatactcgtcgaccattacgctagccgtctggagctcggactgcttaagtcgctccatatgctgaaatgagctgttgacaatta
 atcatccggctcgtataatgtgtggaattgtgagcggataacaatttcacaccccgggataaggaggacaattgatgcgtaaagg
 agaagaacttttactggagttgtcccaattcttgtgaattagatgggtgatgttaatgggcacaaattttctgtcagtggagaggggt
 gaagggtgatgaacatacggaaaacttacccttaattttatgtcactactggaaaactacctgttccgtggccaacacttgcact
 actttcggttatggtgtcaatgctttgcgagataccagatcacatgaacagcatgacttttcaagagtccatgcccgaaagg
 tactgtacaggaaagaactatattttcaaaagatgacgggaactacaagacacgtgctgaagtcaagttgaagggtgataccctgt
 taatagaatcgagttaaaagggtattgattttaaagaagatggaaacattcttgacacaaattggaatacaactataactcacacaa
 tgtatacatcatggcagacaaacaaaagaatggaatcaaagtttaacttcaaaattagacacaaactgaagatggaaagcgttcaa

ctacgagaccattatcaacaaaatactccgattggcgatggccctgtcctttaccagacaaccattacctgtccacacaatctgcc
 ctttcgaaagatcccaacgaaaagagagaccacatggtccttctgagtttgtaaccgctgctgggattacacatggcatggatg
 aactatacaaaataaggcgccagggttgatatctatcgccctagggaccgtctcgagagaatcaatattaatccaacgcgtggcat
 caaataaaacgaaaggctcagtcgaaagactgggcctttctgtttatctgttggtgtcgggtgaacgctctcctgagtaggacaaat
 ccggccgacctagacttaggcgttcggctgcggcgagcggfatcagctcactcaaaggcggttaatacgggttalccacagaatea
 ggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcggtt
 ttccataggctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagagggtggcgaaacccgacaggactataaa
 gataccaggcggtttccccctggaaagctccctcgtgcgctctcctgttccgacctgcccgttaccggatacctgtccgcctttctcc
 cttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcgggtgtaggtcgttcgctccaagctgggctgtctg
 cacgaacccccgttcagccgaccgctgcgccttatccggttaactatcgtcttgagtcacaacccggttaagacacgacttatcg
 ccactggcagcagccactggtaacaggattagcagagcgaggatgtaggcgggtgctacagagtcttgaagtgggtggcctaa
 ctacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttgtagctcttgat
 ccggcaaaacaaaccaccgctggtagcgggtggtttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaag
 atcctttgatctttctacggggtctgacgctcagtggaacgaaaactcacgttaagggttttggcatggctagtgtcttgattct
 caccaataaaaaacgcccggcggaaccgagcgttctgaacaaatccagatggagttctgaggtcattactggatctatcaaca
 ggagtcgaagccaattctcgaaccccagagtcctcagagaactcgtcaagaaggcgatagaaggcgatgcgctgcga
 atcgggagcggcgataccgtaaaagcacgaggaagcggtcagccattcggcccaagctcttcagcaatatcacgggtagcc
 aacgctatgtcctgatagcggtcgccacaccagccggccacagtcgatgaatccagaaaagcggccattttccaccatgata
 ttcggcaagcaggeatcgccgtgggtcacgacgagatcctcgccgtcgggcatacgcgccttgagcctggcgaacagttcgg
 ctggcgcgagccccctgatgctcttcgtccagatcactctgatcgacaagaccggcttccatccgagtacgtgctcgtcgtatgag
 atgtttcgttggtggtcgaatgggcaggtagccggatcaagcgtatgcagccggcgattgcatcagccatgatggatactttct
 cggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccataagcagccagtccttcccgttcagtgac
 aacgtcgagcacagccgcgcaagggaacgcccgtcgtggccagccacgatagccgcgctgcctcgtcttgcaagttcattcagg
 gcaccggacaggtcgggtcttgacaaaaagaaccgggcgacctgcgctgacagccggaacacggcggcatcagagcagcc
 gattgtctgttggtgccagtcatagccgaatagcctctccaccaagccggcgagaaacctgcgtgcaatccatcttgttcaatca
 tgcgaaacgatectcctctgtctcttgatcagatcttgatccctgcgcatcagatccttggcggcaagaaagccatccagttta
 ctttgacggggttcccaaccttaccagaggcgggcccaactggcaattcc

SEQ ID NO:8 (pPh006)

gacgtctgtgcaagtactactgttctgcagtcacttgaattcgataccagctgggtggagtgccaccaaggagcatgcgaagga
 aacgtttcgagaagcttccgcaagggtaccactttgccggcggagtatttgatattgaaggatcctcaagtcggccgccggttcc
 atggatactcgtcgaccattacgctagccgtctggagctcggactgcttaagtcgctccatctgctgaaatgagctgttgacaatta
 atcatccggctcgtataatgtgtggaattgtgagcggataacaattcacacccccgggataaggaggacaattgatgcgtaaagg
 agaagaacttttactggagttgtcccaattcttgaattagatgggtgatgtaattgggcacaaatttctgtcagtgagagggt
 gaagggtgatgcaacatacggaaaacttacccttaaattttatgtcactactggaaaactacctgttccgtggccaaacttgcact
 actttcgggttatggtgttcaatgctttgcgagataccagatcacatgaaacagcatgacttttcaagagtgccatgcccgaaggt
 tacgtacaggaaagaactatattttcaagatgacgggaactacaagacacgtgctgaagtcaagtttgaagggtgatacccttgt
 taatagaatcgagttaaaagggtattgattttaaagaagatggaaacattcttgacacaaatttgaatacaactataactcacacaa
 tgtatacatcatggcagacaaacaaaagaatggaatcaaagttaactcaaaattagacacaaacattgaagatggaagcgttcaa
 ctacgagaccattatcaacaaaatactccgattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatctgcc

ctttcgaaagatcccaacgaaaagagagaccacatggctccttcttgagtttgtaaccgctgctgggattacacatggcatggatg
 aactatacaataaggcgccaggggtgatatctatgccctagggaccgtctcgagagcgccctgtagcggcgattaagcgc
 ggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctccttctgcttcttcccttcttct
 cgccacgttcgccggccttccccgtcaagctctaaatcgggggctcccttaggggtccgatttagtgctttacggcacctcgacc
 ccaaaaaacttgattaggggtgatggttcacgtagtgggccatgccctgatagacgggttttcgcccttgacgttgagtcacgt
 tcttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgattataagggattttgccgatttc
 ggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattaaatattaatccaacgcgtggcatcaataaaacgaa
 aggctcagtcgaaagactgggccttctgtttatctgttgttgcgggtgaacgctctcctgagtaggacaaatccggcgccctaga
 cttaggcgttcggctgcggcgagcgggtatcagctcactcaaaggcggtatacgggtatccacagaatcaggggataacgcag
 gaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcggttttccataggctccg
 ccccccgtgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataaccaggcggtt
 cccctggaagctccctcgtgcgtctcctgttccgaccctgccgcttaccggatacctgtccgccttctcccttcgggaagcgt
 ggcgcttctcatagctcagctgtaggtatctcagttcgggtgtaggtcggtcgtccaagctgggctgtctgcacgaacccccg
 ttcagcccgaccgctgcgccttatccgtaactatcgtttgagtcgaacccggtaagacacgacttatcgccactggcagcagc
 cactggtaacaggattagcagagcgaggtatgtaggcgggtctacagagttcttgaagtgggtggcctaactacggctacactag
 aaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaacaaacc
 accgctggtagcgggtggtttttgttgcaagcagcagattacgcgcagaaaaaaggatcgaagaagatccttgatcttttcta
 cggggtctgacgctcagtggaacgaaaactcaggttaagggttttggtcatggctagtgttggttctaccaataaaaaacg
 cccggcggaaccgagcgttctgaacaaatccagatggagttctgaggtcattactggatctatcaacaggagtccaagccaat
 tctcgaaccccagagtcccgtcagaagaactcgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgat
 accgtaaacgacgaggaagcgggtcagccattcggcgccaagctcttcagcaatatcacgggtagccaacgctatgtctgat
 agcgggtccgccacaccagccggccacagtcgatgaatccagaaaagcggccatttccaccatgatattcggcaagcaggc
 atcgccgtgggtcacgacgagatcctcggcgctgggcatacgcgccttgagcctggcgaaacagttcggctggcgagcccc
 tgatgctcttcgtccagatcctctgatcgacaagaccggcttccatccgagtacgtgctcgtcgtatgcgatgtttcgttggtgg
 tgaatgggcaggtagccggatcaagcgtatgcagccgccgcatcagccatgatggatactttctcggcaggagcaag
 gtgagatgacaggagatcctgccccggcacttcgcccataagcagccagtccttcccgttcagtgaacgtcgagcacag
 ccgcgcaaggaacggcgctgtggccagccacgatagccggctgcctcgtcttgagttcattcagggcaccggacaggtc
 ggtcttgacaaaaagaaccggcgaccctgcgctgacagccggaacacggcggtcatcagagcagccgattgtctgttggtcc
 cagtcatagccgaatagcctctccaccaagccggcgagaaacctgcgtgcaatccatcttgttcaatcatcgaaacgatectc
 atcctgtctcttgatcagatcttgatccccctgcgccatcagatccttggcggaagaaagccatccagtttactttgcagggttcc
 caaccttaccagagggcgggccaactggcaattec

SEQ ID NO:9 (M6G bacteriophage)

aatgctactactattagtagaattgatgccaccttttcagctcgcgccccaaatgaaaatatagctaaacaggttattgaccatttgc
 gaaatgtatctaattggtcaactaaatctactcgttcgcagaattgggaatcaactgttatatggaatgaaactccagacaccgta
 cttagtgcataattaaaacatgttgagctacagcattatattcagcaattaaagcttaagccatccgcaaaaatgacctcttataa
 aaggagcaattaaaggctactcttaactctgacctgttgaggtttgcttcgggtctggttcgcttgaagctcgaattaaaacgcgat
 attggaagtcttctgggtctctcttaattcttttgatgcaatccgcttctgactataatagtcagggtaaagacctgattttgatt
 tatggctattctcgtttctgaactgtttaagcatttgagggggattcaatgaatatttatgacgattccgcagtttgacgctatcc

agctaaacattttactattacccccctctggcaaaacttcttttgcaaaagcctctcgcctattttggttttatcgtcgtctggtaaacga
gggttatgatagtgttgctcttactatgcctcgtaatcccttttggcggttatgtatctgcattagtgaatgtgggtattcctaaatctcaac
tgatgaatctttctacctgtaataatgttggtccggttagttcgttttattaacgtagatttttcttcccaacgtcctgactgggtataatgagc
cagttcttaaaatcgcataaggttaattcacaatgattaaagtgaatfaaaccatctcaagcccaatttactactcgttctgggtgttctc
tcgtcagggcaagccttattcactgaatgagcagccttggttacggtgatttgggtaatgaatatccggttctgtcaagattactcttg
atgaagggtcagccagcctatgcgcctgggtctgtacaccgttcacgtctgtcctctttcaaagtgggtcagttcgggtcccttatgattgac
cgtctgcgcctcgttccggctaagtaacatggagcaggtcgcggatttcgacacaatttatcaggcgatgatacaaatctccgttg
tactttgttctgcgcttggtataatcgtgggggtcaaagatgagtgttttagtgattcttttgcctcttctgttttaggttggtgccttc
gtagtggcattacgtattttaccggttaatggaaacttctcatgaaaaagtctttagtctcctcaaagcctctgtagccgttgctaccc
tcgttccgatgctgtctttcgtcgtgaggggtgacgatcccgcaaaagcggcctttaactccctgcaagcctcagcgaccgaata
tatcggttatgcgtgggcgatggtgtgttcattgtcggcgcaactatcggtatcaagctgtttaagaaattcacctcgaaagcaag
ctgataaaccgatacaattaaaggctccttttggagccttttttggagattttcaacgtgaaaaaattattattcgaattccttttagtt
gttcccttctattctcactccgctgaaactgttgaaagtgttagcaaaatcccatagaaaaattcattactaacgtctggaaaga
cgacaaaacttttagatcggttacgctaactatgagggctgtctgtggaatgtacaggcggttagttgtactggtgacgaaactca
gtgttacgggtacatgggttcctattgggctgtatccctgaaaatgaggggtggtggtctgaggggtggcggttctgaggggtggc
ggttctgaggggtggcggtactaaacctcctgagtacgggtgatacacctattccgggtatacttatacaacctctcgacggcac
ttatccgcttggtactgagcaaaaccccgtaactcctaactcttctttagggagctcagcctcttaatactttcatgtttcagaata
ataggttccgaaataggcagggggcattaactgtttatacgggcactgttactcaaggcactgaccccgtaaaacttattaccag
tacactcctgtatcatcaaaagccatgtatgacgcttactggaacggtaaatcagagactgcgctttccattctggctttaatgagg
atttatttgtttgtaatatcaaggccaatcgtctgacctgcctcaacctcctgtcaatgctggcggcggtctgtgtgtgtgtgtgt
tggcggctctgaggggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
ggttccggtgattttgattatgaaaagatggcaaacgctaataagggggctatgaccgaaaatgccgatgaaaacgcgctacag
tctgacgctaaggcaaaccttgattctgtcgtactgattacgggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
tggtaatggtgtactggtgattttgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
tccgtcaatatttaccctccctccctcaatcgggtgaatgtcgccctttgtctttggcgctggtaaacatataatttctattgattgt
gacaaaataaacttattccgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt
ataaggagtcttaatacatgccagttcttttgggtattccgttattattgcgttccctcgggttccctctgttaactttgttcggctatctgt
tactttcttaaaaagggttcggtaagatagctattgtatttattgttcttctgtcttattattgggcttaactcaattcttgggttat
ctctctgatattagcgtcaattaccctctgactttgttcagggtgttcagtttaattctccgtctaatgcgcttccctgtttttatgttatt
ctctctgtaaaggctgtattttcatttttgacgttaaacaaaaaacgtttcttattttggattgggataaataatatggctgtttattttgt
aactggcaaataggctctggaaaagacgctcgttagcgttgtaagattcaggataaaattgtagctgggtgcaaaatagcaact
aatcttgatttaaggcttcaaaacctcccgcaagtgggaggttcgtaaaacgcctcgcgttcttagaataaccggataagccttct
atatctgatttctgtattgggcgcggtaatgattcctacgatgaaaataaaaacggcttctgttctcgtatgagtgcggtactt
ggtttaatacccggttcttggaatgataaggaaagacagccgattattgattggtttctacatgctcgtaaattaggatgggatattatt
tttctgttcaggacttatctattgttgataaacaggcgcgttctgcattagctgaacatgttggttattgtcgtcgtctggacagaatta
ctttaccttttgcggfactttatattcttattactggctcgaaaatgcctctgcctaaattacatgttggcggttgtaaatatggcgatt
ctcaattaaagccctactgttgagcgttggttttatactggtaagaatttgtataacgcataatgatactaaacaggctttttctagtaatta
tgattccggtgtttattcttatttaacgccttatttatacacaggctcggtatttcaaacattaaatttaggtcagaagatgaaattaacta
aaatataattgaaaaagtttctcgcgttctttgtcttgcgattggatttgcacagcatttacatagttatataaccaacctaagcc

ggagggttaaaaaggtagtctcagacctatgatttggataaatcactattgactctctcagcgtcttaatctaagctatcgctatgtt
 ttcaaggattctaagggaataattaatagcgacgatttacagaagcaagggtattcactcacatatattgatttatgtactgtttcc
 attaaaaaggtaattcaaatgaaattgttaaatgtaattaattttgtttcttgatgtttgttcatcatcttcttttgetcaggtaattgaaa
 tgaataatcgcctctgcgcgattttgtaacttggtattcaaagcaatcaggcgaatccgttattgtttctccgatgtaaaagggtact
 gttactgtatattcatctgacgttaaacctgaaaatctacgcaatttctttatttctgttttacgtgcaaataattttgataggttaggttct
 aaccttccattattcagaagtataatccaaacaatcaggattatattgatgaattgccatcatctgataatcaggaatatgatgataa
 ttccgctccttctggtggtttctttgttccgcaaaatgataatgttactcaaacttttaaaattaataacgttcgggcaaaggatttaata
 cgagttgtcgaattgtttgtaaagtctaatacttctaatactcctcaaatgtattatctattgacggctetaatctattagttgttagtgcct
 aaagatatttttagataaccttctcaattcctttcaactgttgatttgccaactgaccagatattgattgaggggttgatatttgagggttc
 agcaagggtgatgcttttagattttcatctgtctggtctcagcgtggcactgttgagggcgtgttaatactgaccgcctcacctc
 tgtttatcttctgctgggtggttcgttggattttaalgcgatgttttagggctatcagttcgcgcattaaagactaatagccattca
 aaaatattgtctgtgccacgtattcttacgctttcaggtcagaagggttctatctctgttgccagaatgtcccttttattactggtcgt
 gtgactggtgaatctgccaatgtaaataatccatttcagacgattgagcgtcaaaatgtaggtatttccatgagcgttttctgttgc
 aatggctggcggtaataattgttctggatattaccagcaaggccgatagtttgagttcttactcaggcaagtgtattactaatac
 aaagaagtattgctacaacggtaatttgcgtgatggacagactctttactcgggtggcctcactgattataaaaacacttctcagga
 ttctggcgtaccgttctgtctaaaatccctttaatcggcctcctgttttagctcccgtctgattctaacgaggaaagcacgttatac
 tgctcgtcaaagcaaccatagtagcgccctgtagcggcgcattaaagcggcgggtgtggtgttacgcgcagcgtgaccg
 ctacacttgccagcgccttagcgcccgtcctttcgttttcttcccttcttctcgtccacgttcgccggttccccgtcaagctcta
 aatcgggggctcccttaggggttcgatttagtgccttacggcacctcgaccccaaaaaacttgattgggtgatggttcacgtagt
 gggccatcgccctgatagacgggttttcgccctttgacgttgaggtccacgttctttaatagtgactcttgttccaaactggaacaa
 cactcaacctatctcgggctattcttttgattataagggttttgcgatttcgggactgcttaagtcgtccatattgctgaaatga
 gctgttgacaattaatcatccggctcgtataatgtgtggaattgtgagcggataacaatttcacaccccgggataaggaggacaat
 tgatgcgtaaaggagaagaacttttactggagttgtcccaattcttgttgaattagatggtgatgttaatgggcacaaattttctgtc
 agtgagagggtgaagggtgatgcaacatacggaaaacttacccttaaatttatttgcactactggaaaactacgttccgtggcc
 aacacttgcactacttccggttatggtgttcaatgctttgcgagataccagatcacatgaaacagcatgacttttcaagagtgc
 atgcccgaagggttacgtacaggaaagaactatattttcaaagatgacgggaactacaagacacgtgctgaagtcaagttgaag
 gtgatacccttgtaatagaatcgagttaaaagggtattgattttaaagaagatggaaacattcttgacacaaattggaatacaacta
 taactcacacaatgtatacatcatggcagacaaaacaaaagaatggaatcaaagttaacttcaaaattagacacaacattgaagat
 ggaagcgttcaactagcagaccattatcaacaaaatactccgattggcgatggccctgtcctttaccagacaaccattacctgtc
 cacacaatctgcccttgcgaaagatcccaacgaaaagagagaccacatggtccttcttgagtttgaaccgtgctgggattacac
 atggcatggatgaactatacaataaggcgccagggttgatatctatcgccctagggaccgtctcgagagaatcaatattaatcc
 aacgcgtggcatcaataaaacgaaaggctcagtcgaaagactgggccttctgtttatctgttgttgcgtgaacgctctctg
 agtaggacaaatccgccgccctagactattggttaaaaaatgagctgatttaacaaaaattaatgcgaattttaacaaaatattaac
 gtttacaatttaaatatttgcctatacaatcttctgttttggggcttttctgattatcaaccgggglacatatgattgacatgctagttt
 acgattaccgttcategattctctgtttgtccagactctcaggcaatgacctgatagccctttagatctctcaaaaatagetaccc
 tctccggcattaatttatcagctagaacggttgaatatcataattgatggtgatttgactgtctccggcctttctcacccttttgaatttta
 cctacacattactcaggcattgcatttaaaatatatgagggttctaaaaattttatccttgcgttgaaataaaggcttctcccgcaa
 agtattacagggtcataatgttttggtaacaaccgatttagctttatgctctgaggetttattgcttaattttgctaattctttgccttgcct
 gtatgatttattgatgtt

[0128] It is to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims, embodiments may be practiced otherwise than as specifically described.

[0129] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents, and/or ordinary meanings of the defined terms.

[0130] The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."

[0131] The phrase "and/or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and/or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and/or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and/or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0132] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and/or" as defined above. For example, when separating items in a list, "or" or "and/or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e. "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0133] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least

one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and/or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

[0134] It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

[0135] In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively.

SEQUENCE LISTING

[0136]

<110> Massachusetts Institute of Technology Trustees of Boston University

<120> FUNCTIONALIZATION OF ENDOGENOUS BACTERIA

<130> M0656.70302WO00

<140> Not Yet Assigned

<141> 2014-07-01

<150> US 61/841,904

<151> 2013-07-01

<160> 9

<170> PatentIn version 3.5

<210> 1

<211> 6249

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 1

gacgtctgtg caagtactac tgttctgcag tcacttgaat tcaagaaacc aatagtccat	60
attgcatcag acattgccgt cactgcgtct tttactggct cttctcgcta accaaaccgg	120
taaccccgtt tattaagaac attctgtaac aaagcgggac caaagccatg acaaaagcgc	180
gtaacaaaag tgtctataat cacggcagaa aagtccacat tgattatttg cacggcgtca	240
cacttttgcta tgccatagca tttttatcca taagattagc ggatcatacc tgacgctttt	300
tatcgcaact ctctactgtt tctccataca gctgaaaagc ttacggggagg aacgttatga	360
atcagaccga cacatcacct atcaggctgc gcaggagctg gaacaccagc gagatagaag	420
cgctctttga cgagcatgcc ggacgtatcg atccgcgcac ttataccgat gaggatctgt	480
accaactcga actggagcgt gtcttcgccc ggtcctggct gctgttgggg catgaaaccc	540
agattcgcaa gccgggggat tacatcacga cctacatggg tgaagaccct gtcgtggctg	600
tccggcagaa agacgccagc attgccgtgt tcttgaacca gtgccgccac cgtggcatgc	660
gcatctgccg cgcggatgcc ggaaacgcga aggcgttcac ttgcagctac cacgggtggg	720
cttacgacac cgcgggcaat cttgtcaatg tgccttacga ggccgaatcc ttgcgtgcc	780
tgaacaagaa ggaatggagc ccgtgaagg cccgggtaga aacctacaag ggctgattt	840
tcgccaaactg ggatgagaac gctgtagacc tcgacacgta tctggggcag gcgaagttct	900
acatggacca catgctcgac cgcaccgagg ccggcaccga agcgatcccg ggcgtgcaga	960
agtgggtcat tccctgtaac tggaaattcg ccgcagagca gttttgcagc gacatgtacc	1020
atgccgggac gacctcgcat ctgtctggca tcttggcagg cctgccagaa gaccttgaaa	1080
tgcccgacct tgcctccgcg acagttggca agcagtaccg tgcgtcatgg ggcggacatg	1140
gaagtggctt ctatgtcggc gaccccaatc tgatgcttgc catcatgggg ccaaaggcca	1200
ccagctactg gaccgaaggc cccgcgtcgg aaaaggcggc cgaacgtctg ggtagcgtgg	1260
agcgcggctc gaaactcatg gtcgagcaca tgaccgtctt cccacgtgt tcttctctcc	1320
caggtatcaa tacgggtccg acatggcatc cgcgcgggac gaacgaggtc gaggtatggg	1380
cgtttacggt ggtcgatgct gatgctcctg acgatataca ggaagagttc cggcgccaga	1440
cgtgcgcac cttctctgcc ggtggcgtgt tcgagcagga cgacggggag aactgggtcg	1500
agatccagca catcctgcga ggccacaagg cgcggagccg ccctttcaat gccgagatga	1560
gcatggacca gaccgtcgac aacgaccggg tttaccccg gcgatcagc aacaacgtct	1620
acagcgagga agctgccgcg gggctctatg ccattggct gcggatgatg acatcccccg	1680
actgggacgc gctgaaggcg acacgctgaa tccagagaca gcttgcgcca cgcagtggcg	1740
ccggccagag gccgcatttg acttcgaccc aggttggatg cgggtggacct tgtccatttg	1800
aaatctacaa ggaacgacca tgattgattc agccaacaga gccgacgtct ttctccgcaa	1860
gccggcaccg gtagcgcccg aactgcagca cgaagtcgag cagttctact attgggaggc	1920
caagcttctc aacgatcgcc gcttcgagga gtggttcgcg ctgctcgcgg aagacattca	1980
ctacttcatg ccatttcgca ccacgcggat catgcgggac tcgcgccttg aatactcagg	2040
ctcccagagag tacgcgcact tcgatgacga cgccacgatg atgaagggac gcttgcgcaa	2100
gatcacgtcc gacgtgagct ggtccgagaa cccgcgatcg cggaccggc atctcgtgag	2160

caacgtgatg atcgtcggcg cagaggcaga aggggagtag gaaatctcaa gcgccttcat 2220
 tgtgtaccgc aatcgtctgg agcggcagct cgacatcttt gccggtgagc gtcgcgatac 2280
 gttgcgccgt aacacgagcg aggcggggtt cgagatcgtc aatcggacca tcctgatcga 2340
 ccagagcacc atcctggcca ataacctcag tttcttcttc taggtgatgt catgacttgg 2400
 acatacatat tgcggcaggg tgacctgcca cccggtgaga tgcagcgcta cgaaggcggc 2460
 ccggaacctg tgatggtctg caacgtcgat ggcgagttct tcgcggtgca ggatacctgc 2520
 acgcatgggg actgggcggt gtcggatggt tacctggacg gtgatattgt cgaatgcacg 2580
 ttgcatttcg gcaagttctg cgtgcggacc gggaaggtag aggcgctgcc tgcttgcaaa 2640
 cctatcaagg tattcccaat caaggtcgaa ggcgatgaag tgcacgtcga tctcgacaac 2700
 ggggagttga agtgatggct acccatgtgg cgatcatcgg caatggcgtg ggtggcttca 2760
 cgaccgcgca ggccctacgt gccgagggct tcgaggggag aatctcgctg attggggacg 2820
 aaccgcattc cccctatgac cgaccatcct tgtccaaggc ggttctcgac ggcagccttg 2880
 agcggccgcc catactggcc gaggccgatt ggtacggcga ggcccgcatc gacatgctga 2940

 ccggccccga agtcactgcc cttgatgtgc agacaaggac gatcagttct gatgatggca 3000
 ccacgctctc tgcggacgcc atcgtcatcg cgacgggcag tcgagcgcgg acgatggcgt 3060
 tgcccggcag ccaactgccg ggcgtcgtaa cgctgcgcac ctacggtgac gtgcaggtat 3120
 tgcgcgatag ttggacttcc gcgacgcggc tgctgattgt gggtagcgga ttgatcggt 3180
 gcgaggtcgc gacgacggcg cgcaagctcg gcctgtcggc cacgatcctg gaggcaggtg 3240
 atgaactgct ggtccgagta cttgggcggc gtatcgggtc ctggctgcgc gccctgctga 3300
 cagaacttgg tgtgcaggtc gagttgggaa cgggtgtcgt aggtttttct ggtgagggcc 3360
 agctcgaaca agtcatggcc agcgatgggc gcagcttcgt agccgatagc gcactcattt 3420
 gcgtcggcgc ggagcccgcg gatcaacttg cgcgtcaagc gggcttggca tgtgaccgcg 3480
 gcgtcattgt cgatcactgc ggtgcgacgc ttgccaaagg cgtattcgcc gtcggagatg 3540
 tggccagttg gccgtgcgc gccggcggcc ggcgttcgct cgaaacctat atgaacgcgc 3600
 agcgccaagc cgccgcgggtg gctgcggcca ttctggggaa aaacgtatcg gcaccgcaac 3660
 tgcccgtgtc ctggacggag atcgttgggc atcgcatgca gatggcgggc gatatcgaag 3720
 gacctggtga tttcgtctcg cgcggcatgc ccggtagtgg cgctgccctg ttgttccgcc 3780
 tgcaggagcg aaggattcag gcggtcgtcg cggtcgatgc acccgtgac ttcgcgcttg 3840
 caaccgatt ggtagaagcc cgcgcggcaa tcgagccagc acggctggca gatctttcaa 3900
 acagtatgcg cgattttgtt cgtgcgaatg aaggagacct aacgtgaggt acccgagaat 3960
 tggcttggac tcctgttgat agatccagta atgacctcag aactccatct ggatttgttc 4020
 agaacgctcg gttgcgcccg ggcgtttttt attggtgaga atccaagcag tagtcaggat 4080
 cctcaagtcg gccgcccgtt ccatggatac tcgtcgacca ttacgctagc cgtctggagc 4140
 tcggactgct taagtcgctc catatgctcg ttcccgggac tacacaattg tccccggcg 4200
 ccagggttga tatctatcgc cctagggacc gtctcgagag aatcaatatt aatccaacgc 4260
 gtggcatcaa ataaaacgaa aggctcagtc gaaagactgg gcctttcggt ttatctgttg 4320
 tttgtcgggtg aacgctctcc tgagtaggac aaatccgccg ccctagactt aggcgttcgg 4380
 ctaccccaac caatataac tcaactcaaa acgaataaac attatccac acaatcaaac 4440

```

-----
gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag 4500
gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca caaaaatcga 4560
cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 4620
ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc 4680
tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg 4740
gtgtaggtcg ttcgctccaa gctgggctgt ctgcacgaac cccccgttca gcccgaccgc 4800
tgcgccttat ccggtaaacta tcgtcttgag tccaaccggg taagacacga cttatcgcca 4860

ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag 4920
ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg tatctgcgct 4980
ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaacc 5040
accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaagga 5100
tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtggaa cgaaaactca 5160
cgtaaggga ttttggtcac ggctagtgtc tggattctca ccaataaaaa acgcccggcg 5220
gcaaccgagc gttctgaaca aatccagatg gagttctgag gtcattactg gatctatcaa 5280
caggagtcca agccaattct cgaaccccag agtcccgcctc agaagaactc gtcaagaagg 5340
cgatagaagg cgatgcgctg cgaatcggga gcggcgatac cgtaaagcac gaggaagcgg 5400
tcagcccatt cgcgcgaag ctcttcagca atatcacggg tagccaacgc tatgtcctga 5460
tagcggctcg ccacaccag ccggccacag tcgatgaatc cagaaaagcg gccattttcc 5520
accatgatat tcggcaagca ggcctcgccg tgggtcacga cgagatcctc gccgtcgggc 5580
atacgcgcct tgagcctggc gaacagttcg gctggcgcca gccctgatg ctcttcgtcc 5640
agatcatcct gatcgacaag accggcttcc atccgagtac gtgctcgctc gatgcgatgt 5700
ttcgcttggg ggtcgaatgg gcaggtagcc ggatcaagcg tatgcagccg ccgcattgca 5760
tcagccatga tggatacttt ctcggcagga gcaagggtgag atgacaggag atcctgcccc 5820
ggcacttcgc ccaatagcag ccagtccttt cccgcttcag tgacaacgct gagcacagcc 5880
gcgcaaggaa cgcctgcgt ggccagccac gatagccgcg ctgcctcgct ttgcagttca 5940
ttcagggcac cggacaggtc ggtcttgaca aaaagaaccg ggcgaccctg cgctgacagc 6000
cggaacacgg cggcatcaga gcagccgatt gtctgttgtg ccagtcata gccgaatagc 6060
ctctccacc aagccgccgg agaacctgcg tgcaatccat cttgttcaat catgcgaaac 6120
gatcctcatc ctgtctcttg atcagatctt gatccctgc gccatcagat ccttggcggc 6180
aagaaagcca tccagtttac tttgcagggc ttcccaacct taccagaggg cggcccaact 6240
ggcaattcc 6249

```

<210> 2

<211> 6037

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 2

gacgtctgtg caagtactac tgttctgcag tcacttgaat tctccctatc agtgatagag	60
attgacatcc ctatcagtga tagagatact gagcacatca gcaggacgca ctgacccagc	120
tgaaaagctt acgggaggaa cgttatgaat cagaccgaca catcacctat caggctgcgc	180
aggagctgga acaccagcga gatagaagcg ctctttgacg agcatgccgg acgtatcgat	240
ccgcgcattt ataccgatga ggatctgtac caactcgaac tggagcgtgt cttcgcccg	300
tcctggctgc tgttggggca tgaaacccag attcgcaagc cgggcgatta catcacgacc	360
tacatgggtg aagaccctgt cgtggtcgtc cggcagaaag acgccagcat tgccgtgttc	420
ctgaaccagt gccgccaccg tggcatgcgc atctgccgcg cggatgccgg aaacgcgaag	480
gcgttcactt gcagctacca cgggtgggct tacgacaccg ccggcaatct tgtcaatgtg	540
ccttacgagg ccgaatcctt cgcgtgcctg aacaagaagg aatggagccc gctgaaggcc	600
cgggtagaaa cctacaaggg cctgattttc gccaaactggg atgagaacgc tgtagacctc	660
gacacgtatc tgggcgaggc gaagttctac atggaccaca tgctcgaccg caccgaggcc	720
ggcaccgaag cgatcccggg cgtgcagaag tgggtcattc cctgtaactg gaaattcgcc	780
gcagagcagt tttgcagcga catgtaccat gccgggacga cctcgcatct gtctggcatc	840
ctggcaggcc tgccagaaga ccttgaaatg gccgacctg ctccgccgac agttggcaag	900
cagtaccgtg cgtcatgggg cggacatgga agtggcttct atgtcggcga cccaatctg	960
atgcttgcca tcatggggcc aaaggtcacc agctactgga ccgaaggccc cgcgtcggaa	1020
aaggcggccg aacgtctggg tagcgtggag cgcggctcga aactcatggt cgagcacatg	1080
accgtcttcc ccacgtgttc ctccctccca ggtatcaata cggtcgggac atggcatccg	1140
cgcgggccga acgaggtcga ggtatgggcg tttacggtgg tcgatgctga tgctcctgac	1200
gatatcaagg aagagttccg gcgccagacg ctgcgcacct tctctgccgg tggcgtgttc	1260
gagcaggacg acggggagaa ctgggtcgag atccagcaca tcctgcgagg ccacaaggcg	1320
cggagccgcc ctttcaatgc cgagatgagc atggaccaga ccgtcgacaa cgacccgggtt	1380
taccccgggc ggatcagcaa caacgtctac agcgaggaag ctgccgcggg gctctatgcc	1440
cattggctgc ggatgatgac atccccgac tgggacgcgc tgaaggcgac acgtgaatc	1500
cagagacagc ttgcgccacg cagtggcgcc ggccagaggc cgcatttgac ttcgacccag	1560
gttggatgcg gtggaccttg tccatttgaa atctacaagg aacgaccatg attgattcag	1620
ccaacagagc cgacgtcttt ctccgcaagc cggcaccogt agcgcocgaa ctgcagcacg	1680
aagtcagaca gttctactat tgggaggcca agcttctcaa cgatcgccgc ttcgaggagt	1740
ggttcgcgt gctcgcggaa gacattcact acttcatgcc cattegcacc acgcggatca	1800
tgccggactc gcgccttgaa tactcaggct cccgagagta cgcgcacttc gatgacgacg	1860
ccacgatgat gaagggacgc ttgcgcaaga tcacgtccga cgtgagctgg tccgagaacc	1920
ccgcatecgc gacccggcat ctcgtgagca acgtgatgat cgtcggcgca gaggcagaag	1980
gggagtaoga aatctcaagc gccttcattg tgtaccgcaa tcgtctggag cggcagctcg	2040
acatctttgc cggtgagcgt cgcgatacgt tgcgccgtaa cacgagcgag gccggggttcg	2100
agatcgtcaa tcggaccatc ctgatcgacc agagcaccat cctggccaat aacctcagtt	2160

tcttcttcta ggtgatgtca tgacttggac atacatattg cggcaggggtg acctgccacc	2220
cggtgagatg cagcgctacg aaggcggccc ggaacctgtg atggtctgca acgtcgatgg	2280
cgagttcttc gcggtgcagg atacctgcac gcatggggac tgggcgttgt cggatggtta	2340
cctggacggt gatattgtcg aatgcacggt gcatttcggc aagttctgcg tgcggaccgg	2400
gaaggtgaag gcgctgcctg cttgcaaacc tatcaaggta ttcccaatca aggtcgaagg	2460
cgatgaagtg cacgtcgatc tcgacaacgg ggagttgaag tgatggctac ccatgtggcg	2520
atcatcggca atggcgtggg tggcttcacg accgcgcagg ccctacgtgc cgagggcttc	2580
gaggggagaa tctcgctgat tggggacgaa ccgcactctc cctatgaccg accatccttg	2640
tccaaggcgg ttctcgacgg cagccttgag cggccgccc a tactggccga ggccgattgg	2700
tacggcgagg cccgcacgca catgctgacc ggcccggagg tcaactgccct tgatgtgcag	2760
acaaggacga tcagtctgga tgatggcacc acgctctctg cggacgccat cgtcatcgcg	2820
acgggcagtc gagcgcggaac gatggcgttg cccggcagcc aactgccggg cgtcgtaacg	2880
ctgcgcacct acggtgacgt gcaggtattg cgcgatagtt ggacttcgcg gacgcggctg	2940
ctgattgtgg gtggcggatt gatcggtgcg gaggtcgcga cgacggcgcg caagctcggc	3000
ctgtcgggtca cgatcctgga ggcaggtgat gaactgctgg tccgagtact tgggcggcgt	3060
atcgggtgcct ggctgcgcgg cctgctgaca gaacttgggtg tgcaggtcga gttgggaacg	3120
ggtgtcgtag gtttttctgg tgagggccag ctgcaacaag tcatggccag cgatgggcgc	3180
agcttcgtag ccgatagcgc actcatttgc gtcggcgcgg agcccgcgga tcaacttgcg	3240
cgtcaagcgg gcttggcatg tgaccgcggc gtcattgtcg atcactgcgg tgcgacgctt	3300
gccaaaggcg tattcgccgt cggagatgtg gccagttggc cgctgcgcgc cggcggccgg	3360
cgttcgctcg aaacctatat gaacgcgcag cgccaagccg ccgcggtggc tgcggccatt	3420
ctggggaaaa acgtatcggc accgcaactg cccgtgtcct ggacggagat cgctgggcat	3480
cgcattgcaga tggcgggcga tatcgaagga cctggtgatt tcgtctcgcg cggcatgccc	3540
ggtagtggcg ctgccctggt gttccgctg caggagcgaa ggattcaggc ggtcgtcgcg	3600
gtcgatgcac cccgtgactt cgcgcttgca acccgattgg tagaagcccg cgcggcaatc	3660
gagccagcac ggctggcaga tctttcaaac agtatgcgcg attttgttcg tgcgaatgaa	3720
ggagacctaa cgtgaggtac ccgagaattg gcttggactc ctgttgatag atccagtaat	3780
gacctcagaa ctccatctgg atttgttcag aacgctcggg tgccgccggg cgttttttat	3840
tggtgagaat ccaagcagta gtcaggatcc tcaagtcggc cgcccgttcc atggatactc	3900
gtcgaccatt acgctagccg tctggagctc ggactgctta agtcgctcca tatgctcgtt	3960
cccgggacta cacaattgtc ccccggcgcg agggttgata tctatcgccc tagggaccgt	4020
ctcgagagaa tcaatattaa tccaacgcgt ggcacaaat aaaacgaaag gctcagtcga	4080
aagactgggc ctttcgtttt atctgttggt tgctcggtgaa cgctctcctg agtaggacaa	4140
atccgccgcg ctagacttag gcgttcggct gcggcgagcg gtatcagctc actcaaaggc	4200
ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg	4260
ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg	4320
ccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg	4380

actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac	4440
cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca	4500
tagctcacgc tgtaggtatc tcagttcggg gtaggtcgtt cgctccaagc tgggctgtct	4560
gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc	4620
caaccgggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag	4680
agcgaggtat gtaggcgggtg ctacagagtt cttgaagtgg tggcctaact acggctacac	4740
tagaaggaca gtatttggtg tctgcgctct gctgaagcca gttaccttcg gaaaaagagt	4800
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaa	4860
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg	4920
gtctgacgct cagtggaaacg aaaactcacg ttaagggatt ttgggtcatgg ctagtgcttg	4980
gattctcacc aataaaaaac gcccggcggc aaccgagcgt tctgaacaaa tccagatgga	5040
gttctgaggt cattactgga tctatcaaca ggagtccaag ccaattctcg aacccagag	5100
tcccgctcag aagaactcgt caagaaggcg atagaaggcg atgcgctgcg aatcgggagc	5160
ggcgataccg taaagcacga ggaagcggtc agcccattcg ccgccaagct cttcagcaat	5220
atcacgggta gccaacgcta tgtcctgata gcggtcgcgc acaccagcc ggccacagtc	5280
gatgaatcca gaaaagcggc cattttccac catgatattc ggcaagcagg catcgccgtg	5340
ggtcacgacg agatcctcgc cgtcgggcat acgcgccttg agcctggcga acagttcggc	5400
tggcgcgagc ccctgatgct cttcgtccag atcatcctga tcgacaagac cggcttccat	5460
ccgagtacgt gctcgtcga tgcgatgttt cgcttggtgg tcgaatgggc aggtagccgg	5520
atcaagcgta tgcagccgcc gcattgcac agccatgatg gatactttct cggcaggagc	5580
aaggtgagat gacaggagat cctgccccgg cacttcgccc aatagcagcc agtcccttcc	5640
cgcttcagtg acaacgtcga gcacagccgc gcaaggaacg cccgtcgtgg ccagccacga	5700
tagccgcgct gcctcgtctt gcagttcatt cagggcaccc gacaggtcgg tcttgacaaa	5760
aagaaccggg cgaccctgcg ctgacagccg gaacacggcg gcacagagc agccgattgt	5820
ctgttggtgcc cagtcatagc cgaatagcct ctccacccaa gccgcgggag aacctgcgtg	5880
caatccatct tgttcaatca tgcgaaacga tcctcatcct gtctcttgat cagatcttga	5940
tcccctgcgc catcagatcc ttggcggcaa gaaagccatc cagtttactt tgcagggctt	6000
cccaacctta ccagagggcg gcccaactgg caattcc	6037

<210> 3

<211> 4497

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 3

gacgtctgtg caagtactaa gaaaccaata gtccatattg catcagacat tgccgtcact	60
gcgtctttta ctggctcttc tcgctaacca aaccggtaac cccgcttatt aaaagcattc	120
tgtaacaaag cgggaccaaa gccatgacaa aagcgcgtaa caaaagtgtc tataatcacg	180

gcagaaaagt ccacattgat tatttgcaag gcgtcacact ttgctatgcc atagcatttt 240
tatccataag attagcggat catacctgac gctttttatc gcaactctct actgtttctc 300
catacagctg aaggattaag gaggtagcat gcatgaaaaa gcgtatcggg attgttggtg 360
caggcactgc cggcctccat cttggcctct tcctccgcca gcatgacgtc gacgtcactg 420
tgtacactga tcgtaagccc gatgagtaca gtggactgcg gctcctgaat accgttgctc 480
acaacgcggg gacgggtgcag cgggaggttg ccctcgacgt caatgagtgg ccgtctgagg 540
agtttggtta tttcggccac tactactacg taggtgggccc gcagcccatg cgtttctacg 600
gtgatctcaa ggctcccagc cgtgcagtgg actaccgtct ctacctgccg atgctgatgc 660
gtgcactgga agccaggggc ggcaagttct gctacgacgc cgtgtctgcc gaagatctgg 720
aagggtctgc ggagcagtat gatctgctgg ttgtgtgcac tggtaaatac gccctcggca 780
aggtgttcga gaagcagtcc gaaaactcgc ccttcgagaa gccgcaacgg gcactgtgcg 840
ttggtctctt caagggcatc aaggaagcac cgattcgcgc ggtgactatg tccttctcgc 900
cagggcatgg cgagctgatt gagattccaa ccctgtcgtt caatggcatg agcacagcgc 960
tggtgctcga aaacatatt ggtagcgtc tggaaagtct cggccacacc aagtatgacg 1020
atgaccgcgc tgcgttcctc gatctgatgc tggagaagct gcgtaagcat catccttcgc 1080
ttgccgagcg catcgatccg gctgagttcg acctggccaa cagttctctg gacatcctcc 1140
agggcgggtg tgtgccagta ttccgcgacg gtcatgcgac cctcaataac ggcaaaacca 1200
tcatcgggct gggcgacatc caggcaactg tcgatccggg cttggggccag ggcgcgaaca 1260
tggcgtccta tgcggcatgg attctgggcg aggaaatcct tgcgcactct gtctacgacc 1320

tgcgcttcag cgaacacctg gagcgtcgcc gccaggatcg cgtgctgtgc gccaccgct 1380
ggaccaactt cactctgagc gccttcacgg aacttcgcgc ggaattcctc accttccttc 1440
agatcctgag ccagagccgt gaaatggctg atgagttcac ggacaacttc aactatccgg 1500
aacttcagtg ggatcgcttc tccagcccg gacgtatcgg tcagtgggtc agccagtacg 1560
caccactat tgcggcctga cgctattgct ccgctgggtca aggccagcgg agccctaact 1620
cctgggtgat tcaaatgacg ttaaaaaaag atgtggtggt ggatatcgac tccaccagct 1680
tccgccaggc ggttgcaactg ttccgcgacg gaattgcggg tctcagcgcg gagactgacg 1740
agggcgaagt gcatggcatg acggtgaaca gttcacctc catcagttct gaccgcgga 1800
ctgtgatggg gtccctgaag tcgggcccga tgcattgagct gctgactcaa ggcggacgct 1860
tcggcgtcag cctcctgggt gaaagtcaga agatgttatc ggcatctctc agcaagcgtg 1920
tgatcgatgg cactcctcct cctgctttca cagttcaggg cggcctcccc actctgcggg 1980
acgccatggc ctggttcgaa tgcgaggtgg agagcacggg tgaagtacac gaccacacgc 2040
tcttcattgc gcgcgttagc gcctgtggag tgccggaggc gaatgcccc cagccgctgc 2100
tgttctttgc cagccgttat cacggcaacc cgttgccgct gaattgaaac gttcgagaat 2160
tggcttgga cctgttgat agatccagta atgacctcag aactccatct ggatttggtc 2220
agaacgctcg gttgcgcgcg ggcgtttttt attggtgaga atccaagcag tagtcaaagc 2280
ttccgcaagg taccactttg ccgcggagta tttgtacatt tgaaggatcc tcaagtcggc 2340
cgcccgcttc atggatactc gtcgaccatt acgctagccg tctggagctc ggactgctta 2400

agtcgctcca tatgctcgtt cccgggacta cacaattgtc ccccggcgcc agggttgata 2460
 tctatcgccc tagggaccgt ctcgagagaa tcaatattaa tccaacgcgt ggcatcaaat 2520
 aaaacgaaag gctcagtcga aagactgggc ctttcgtttt atctgttggt tgcgggtgaa 2580
 cgctctcctg agtaggacaa atccgcgcgc ctagacttag gcgttcggct gcggcgagcg 2640
 gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga 2700
 aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg 2760
 gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag 2820
 aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc 2880
 gtgcgctctc ctgttcgcac cctgccgctt accggatacc tgtccgcctt tctcccttcg 2940
 ggaagcgtgg cgctttctca tagctcaagc tgtaggtatc tcagttcggg gtaggtcgtt 3000
 cgctccaagc tgggctgtct gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc 3060
 ggtaactatc gtcttgagtc caaccggta agacacgact tatcgccact ggcagcagcc 3120
 actggtaaca ggattagcag agcgaggtat gtaggcgggtg ctacagagtt cttgaagtgg 3180
 tggcctaact acggctacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca 3240

 gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 3300
 ggtgggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 3360
 cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggatt 3420
 ttggtcatgg ctagtgcctg gattctcacc aataaaaaac gcccggcggc aaccgagcgt 3480
 tctgaacaaa tccagatgga gttctgaggt cactactgga tctatcaaca ggagtccaag 3540
 ccaattctcg aaccccagag tcccgcctcag aagaactcgt caagaaggcg atagaaggcg 3600
 atgcgctgcg aatcgggagc ggcgataccg taaagcacga ggaagcggtc agccatttcg 3660
 ccgccaagct cttcagcaat atcacgggta gccaaacgta tgtcctgata gcggtccgcc 3720
 acaccagacc ggccacagtc gatgaatcca gaaaagcggc cattttccac catgatattc 3780
 ggcaagcagg catcgccgtg ggtcacgacg agatcctcgc cgtcgggcat acgcgccttg 3840
 agcctggcga acagttcggc tggcgcgagc ccctgatgct cttcgtccag atcatcctga 3900
 tcgacaagac cggcttccat ccgagtacgt gctcgcctga tgcgatgttt cgcttggtgg 3960
 tcgaatgggc aggtagccgg atcaagcgtg tgcagccgcc gcattgcac agccatgatg 4020
 gatactttct cggcaggagc aaggtgagat gacaggagat cctgccccgg cacttcgccc 4080
 aatagcagcc agtcccttcc cgcttcagtg acaacgtcga gcacagccgc gcaaggaaacg 4140
 cccgtcgtgg ccagccacga tagccgcgct gcctcgtctt gcagttcatt cagggcacccg 4200
 gacaggtcgg tcttgacaaa aagaaccggg cgaccctgcg ctgacagccg gaacacggcg 4260
 gcatcagagc agccgattgt ctggtgtgcc cagtcatagc cgaatagcct ctccacccaa 4320
 gccgcgggag aacctgcgtg caatccatct tgttcaatca tgcgaaacga tcctcatcct 4380
 gtctcttgat cagatcttga tcccctgcgc catcagatcc ttggcggcaa gaaagccatc 4440
 cagtttactt tgcagggcct cccaacctta ccagagggcg gcccaactgg caattcc 4497

<210> 4

<211> 4285

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 4

gacgtctgtg caagtacttc cctatcagtg atagagattg acatccctat cagtgataga	60
gatactgagc acatcagcag gacgcactga cccagctgaa ggattaagga ggtagcatgc	120
atgaaaaagc gtatcgggtat tgttggtgca ggcactgccg gcctccatct tggcctcttc	180
ctccgccagc atgacgtcga cgtcactgtg tacactgata gtaagcccga tgagtacagt	240
ggactgcggc tcctgaatac cgttgctcac aacgcgggtga cgggtgcagcg ggaggttgcc	300
ctcgacgtca atgagtggcc gtctgaggag tttggctatt tcggccacta ctactacgta	360
ggtagggccg agcccatgcg tttctacggt gatctcaagg ctcccagccg tgcagtggac	420
taccgtctct acctgccgat gctgatgcgt gcactggaag ccaggggccc caagttctgc	480
tacgacgccg tgtctgccga agatctggaa gggctgtcgg agcagtatga tctgctggtt	540
gtgtgcaact gtaaatacgc cctcggcaag gtgttcgaga agcagtccga aaactcgccc	600
ttcgagaagc cgcaacgggc actgtgcgtt ggtctcttca agggcatcaa ggaagcaccg	660
attcgcgcgg tgactatgtc cttctcgcca gggcatggcg agctgattga gattccaacc	720
ctgtcgttca atggcatgag cacagcgcgt gtgctcgaaa accatattgg tagcgatctg	780
gaagtcctcg cccacaccaa gtatgacgat gaccgcgcgt cgttcctcga tctgatgctg	840
gagaagctgc gtaagcatca tccttcggtt gccgagcgca tcgatccggc tgagttcgac	900
ctggccaaca gttctctgga catcctccag ggcgggtgtt tgccagtatt ccgcgacggt	960
catgcgaccc tcaataacgg caaaaccatc atcgggctgg gcgacatcca ggcaactgtc	1020
gatccggtct tgggccaggc cgccaacatg gcgtcctatg cggcatggat tctgggcgag	1080
gaaatccttg cgcactctgt ctacgacctg cgcttcagcg aacacctgga gcgtcgccgc	1140
caggatcgcg tgctgtgcgc caccgcgtgg accaacttca ctctgagcgc cttcacggaa	1200
cttcgcgcgg aattcctcac cttccttcag atcctgagcc agagccgtga aatggctgat	1260
gagttcacgg acaacttcaa ctatccggaa cttcagtggg atcgcttctc cagcccggaa	1320
cgtatcggtc agtgggtgcag ccagtacgca cccactattg cggcctgacg ctattgctcc	1380
gctggtaag gccagcggag ccctaactcc tgggtgattc aatgacgtt aaaaaagat	1440
gtgggtgggg atatcgactc caccagcttc cgccaggcgg ttgcactgtt cgcgacggga	1500
attgcggttc tcagcgcgga gactgacgag ggccaagtgc atggcatgac ggtgaacagc	1560
ttcacctcca tcagtctgga cccgccgact gtgatgggtg ccctgaagtc gggccgtatg	1620
catgagctgc tgactcaagg cggacgcttc ggcgtcagcc tcctgggtga aagtcagaag	1680
atgttatcgg cattcttcag caagcgtgtg atcgatggca ctccctctcc tgctttcaca	1740
gttcaggccg gcctccccac tctgcgggac gccatggcct ggttcgaatg cgaggtggag	1800
agcacggttg aagtacacga ccacacgctc ttcattgcgc gcgttagcgc ctgtggagtg	1860
ccggaggcga atgccccca gccgctgctg ttctttgcca gccgttatca cggcaacccg	1920
ttgccgctga attgaaacgt tcgagaattg gcttggactc ctgttgatag atccagtaat	1980

gacctcagaa ctccatctgg atttgttcag aacgctcggg tgccgcggg cgttttttat	2040
tggtgagaat ccaagcagta gtcaaagctt ccgcaaggta ccactttgcc gcggagtatt	2100
tgtacatttg aaggatcctc aagtcggccg cccgttccat ggatactcgt cgaccattac	2160
gctagccgtc tggagctcgg actgcttaag tcgctccata tgctcgttcc cgggactaca	2220
caattgtccc ccggcgccag ggttgatatc tatcgcccta gggaccgtct cgagagaatc	2280
aatattaatc caacgcgtgg catcaaataa aacgaaaggc tcagtcgaaa gactgggcct	2340
ttcgttttat ctgttgtttg tcggtgaacg ctctcctgag taggacaaat ccgcgcctc	2400
agacttaggc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg taatacggtt	2460
atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc	2520
caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc cccctgacga	2580
gcatacaaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac tataaagata	2640
ccaggcgttt cccctggaa gctccctcgt gcgctctcct gttccgacct tgccgcttac	2700
cggatacctg tccgccttcc tcccttcggg aagcgtggcg ctttctcata gctcacgctg	2760
taggtatctc agttcgggtg aggtcgttcg ctccaagctg ggctgtctgc acgaaccccc	2820
cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggttaag	2880
acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag cgaggatatgt	2940
aggcgggtgt acagagttct tgaagtgggt gcctaactac ggctacacta gaaggacagt	3000
atttggatat tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg	3060
atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac	3120
gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggg ctgacgctca	3180
gtggaacgaa aactcacgtt aagggtttt ggtcatggct agtgcttgga ttctcaccaa	3240
taaaaaacgc ccggcggcaa ccgagcgttc tgaacaaatc cagatggagt tctgaggtca	3300
ttactggatc tatcaacagg agtccaagcc aattctcgaa cccagagtc ccgctcagaa	3360
gaactcgtca agaaggcgat agaaggcgat gcgctgcgaa tcgggagcgg cgataccgta	3420
aagcacgagg aagcggtcag cccattcgcc gccaaagctct tcagcaatat cacgggtagc	3480
caacgctatg tcttgatagc ggtccgccac acccagccgg ccacagtoga tgaatccaga	3540
aaagcggcca ttttccacca tgatattcgg caagcaggca tcgccgtggg tcacgacgag	3600
atcctcgccg tcgggcatac gcgccttgag cctggcgaa agttcggctg gcgcgagccc	3660
ctgatgctct tcgtccagat catcctgatc gacaagaccg gcttccatcc gagtacgtgc	3720
tcgctcgatg cgatgtttcg cttgggtggtc gaatgggcag gtagccggat caagcgtatg	3780
cagccgccgc attgcatcag ccatgatgga tactttctcg gcaggagcaa ggtgagatga	3840
caggagatcc tgccccggca cttcgcccaa tagcagccag tcccttcccg cttcagtgac	3900
aacgtcgagc acagccgcgc aaggaaacgc cgtcgtggcc agccacgata gccgcgctgc	3960
ctcgtcttgc agttcattca gggcacccga caggtcggtc ttgacaaaaa gaaccgggcg	4020
accctgcgct gacagccgga acacggcggc atcagagcag ccgattgtct gttgtgccca	4080
gtcatagccg aatagcctct ccaccaagc cgccggagaa cctgcgtgca atccatcttg	4140
ttcaatcatg cgaaacgatc ctcatcctgt ctcttgatca gatcttgatc cctgcgcca	4200

tcagatcctt ggccggcaaga aagccatcca gtttactttg cagggcttcc caaccttacc 4260
agagggcggc ccaactggca attcc 4285

<210> 5

<211> 9507

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 5

aatgctacta ctattagtag aattgatgcc accttttcag ctccgcgccc aaatgaaaat 60
atagctaaac aggttattga ccatttgcga aatgtatcta atggtcaaac taaatctact 120
cgttcgcaga attgggaatc aactgttata tggaatgaaa cttccagaca ccgtacttta 180
gttgcataatt taaaacatgt tgagctacag cattatatcc agcaattaag ctctaagcca 240
tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcctgacctg 300
ttggagtttg cttccggtct ggttcgcttt gaagctcgaa ttaaaacgcg atatttgaag 360
tctttcgggc ttccctctta tctttttgat gcaatccgct ttgcttctga ctataatagt 420
cagggtaaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca 480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct 540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt 600
ggttttttatc gtcgtctggg aaacgagggt tatgatagtg ttgctcttac tatgcctcgt 660
aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg 720
atgaatcttt ctacctgtaa taatgttggt ccgttagttc gttttattaa cgtagatttt 780
tcttcccaac gtccctgactg gtataatgag ccagttctta aaatcgcata aggtaattca 840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctgggtgttt 900
ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg 960
aatatccggg tcttgtcaag attactcttg atgaaggcca gccagcctat gcgcctgggc 1020
tgtacaccgt tcatctgtcc tctttcaaag ttgggtcagtt cggttccctt atgattgacc 1080
gtctgcgcct cgttccgggt aagtaacatg gagcaggtcg cggatttcga cacaatttat 1140
caggcgatga tacaatctc cgttgtactt tgtttcgcgc ttgggtataat cgctgggggt 1200
caaagatgag tgtttttagtg tattcttttg cctctttcgt tttaggttgg tgccttcgta 1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct 1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgtg ctgaggggtga 1380
cgatcccgca aaagcggcct ttaactccct gcaagcctca gcgaccgaat atatcggtta 1440
tgcgtggggc atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa 1500
attcacctcg aaagcaagct gataaacgga tacaattaaa ggctcctttt ggagcctttt 1560
ttttggagat tttcaacgtg aaaaaattat tattcgcaat tccttttagtt gttcctttct 1620

attctcactc cgctgaaact gttgaaagtt gtttagcaaa atcccataca gaaaattcat	1680
ttactaacgt ctggaaagac gacaaaactt tagatcgta cgctaactat gagggctgtc	1740
tgtggaatgc tacaggcggt gtagtttgta ctggtgacga aactcagtgt tacggtacat	1800
gggttcctat tgggcttgct atccctgaaa atgagggtgg tggctctgag ggtggcggtt	1860
ctgagggtgg cggttctgag ggtggcggtg ctaaacctcc tgagtacggt gatacaccta	1920
ttccgggcta tacttatatc aaccctctcg acggcactta tccgcctggt actgagcaaa	1980
accccgctaa tctaatacct tctcttgagg agtctcagcc tcttaatact ttcattgttc	2040
agaataatag gttccgaaat aggcaggggg cattaactgt ttatacgggc actgttactc	2100
aaggcactga ccccggttaa acttattacc agtacactcc tgtatcatca aaagccatgt	2160
atgacgctta ctggaacggt aaattcagag actgcgcttt ccattctggc tttaatgagg	2220
atttatttgt ttgtgaatat caaggccaat cgtctgacct gcctcaacct cctgtcaatg	2280
ctggcgggcg ctctggtggt ggttctggtg gcggctctga ggggtggtggc tctgagggtg	2340
gcggttctga ggggtggcggc tctgaggag gcggttccgg tgggtggtctt ggttccggtg	2400
attttgatta tgaaaagatg gcaaacgcta ataagggggc tatgaccgaa aatgccgatg	2460
aaaacgcgct acagtctgac gctaaaggca aacttgattc tgtcgctact gattacggtg	2520
ctgctatcga tggtttcatt ggtgacgttt ccggccttgc taatggtaat ggtgctactg	2580
gtgattttgc tggctctaata tcccaaattg ctcaagtcgg tgacgggtgat aattcacctt	2640
taatgaataa tttccgtcaa tatttacctt ccctccctca atcggttgaa tgcgcctt	2700
ttgtctttgg cgctggtaaa ccatatgaat tttctattga ttgtgacaaa ataaacttat	2760
tccgtggtgt ctttgcggtt cttttatatg ttgccacctt tatgtatgta ttttctacgt	2820
ttgctaacat actgcgtaat aaggagtctt aatcatgcca gttcttttgg gtattccgtt	2880
attattgcgt ttccctcggtt tccttctggt aactttgttc ggctatctgc ttacttttct	2940
taaaaagggc ttcggtaaga tagctattgc tatttcattg tttcttgctc ttattattgg	3000
gcttaactca attcttgtgg gttatctctc tgatattagc gctcaattac cctctgactt	3060
tgttcagggt gttcagttaa ttctcccgtc taatgcgctt ccctgttttt atgttattct	3120
ctctgtaaag gctgctattt tcatttttga cgttaaacaa aaaatcgttt cttatttgga	3180
ttgggataaa taatatggct gtttattttg taactggcaa attaggctct ggaaagacgc	3240
tcgtagcgt tggtaagatt caggataaaa ttgtagctgg gtgcaaaata gcaactaatc	3300
ttgatttaag gcttcaaac ctcccgaag tcgggaggtt cgctaaaacg cctcgcgttc	3360
ttagaatacc ggataagcct tctatatctg atttgcttgc tattgggcgc ggtaatgatt	3420
cctacgatga aaataaaaac ggcttgcttg ttctcgatga gtgcggtact tggtttaata	3480
cccgttcttg gaatgataag gaaagacagc cgattattga ttggttttcta catgctcgta	3540
aattaggatg ggatattatt tttcttggtc aggacttatc tattgttgat aaacaggcgc	3600
gttctgcatt agctgaacat gttgtttatt gtcgtcgtct ggacagaatt actttacctt	3660
ttgtcggtac tttatattct cttattactg gctcgaaaat gcctctgcct aaattacatg	3720
ttggcggttg taaatatggc gattctcaat taagccctac tgttgagcgt tggctttata	3780
ctggtaagaa tttgtataac gcatatgata ctaaacaggc tttttctagt aattatgatt	3840
ccggtgttta ttcttattta acgccttatt tatcacacgg tcggtatttc aaaccattaa	3900

```

atttaggtca gaagatgaaa ttaactaaaa tatatttgaa aaagttttct cgcgttcttt 3960
gtcttgcgat tggatttgca tcagcattta catatagtta tataacccaa cctaagccgg 4020
aggttaaaaa ggtagtctct cagacctatg attttgataa attcactatt gactcttctc 4080
agcgtcttaa tctaagctat cgctatgttt tcaaggattc taagggaata ttaattaata 4140
gcgacgattt acagaagcaa ggttattcac tcacatatat tgatttatgt actgtttcca 4200
ttaaaaaagg taattcaaat gaaattgtta aatgtaatta attttgtttt cttgatgttt 4260
gtttcatcat cttcttttgc tcaggtaatt gaaatgaata attcgctctc gcgcgatttt 4320
gtaacttggg attcaaagca atcaggcgaa tccgttattg tttctccga tgtaaaagg 4380
actgttactg tatattcatc tgacgttaaa cctgaaaatc tacgcaattt ctttatttct 4440
gttttacgtg caaataattt tgatatggta ggttctaacc cttccattat tcagaagtat 4500
aatccaaaca atcaggatta tattgatgaa ttgccatcat ctgataatca ggaatatgat 4560
gataattccg ctcttctggg tggtttcttt gttccgcaa atgataatgt tactcaaact 4620
tttaaaatta ataacgttcg ggcaaaggat ttaatacgag ttgtcgaatt gtttgtaaag 4680
tctaatactt ctaaactctc aaatgtatta tctattgacg gctctaactc attagttgtt 4740
agtgcctcta aagatatttt agataacott cctcaattcc tttcaactgt tgatttgcca 4800
actgaccaga tattgattga gggtttgata ttgaggttc agcaaggatga tgctttagat 4860
ttttcatttg ctgctggctc tcagcgtggc actgttgacg gcggtgttaa tactgaccgc 4920
ctcacctctg ttttatcttc tgctgggtgg tcgttcggta tttttaatgg cgatgtttta 4980
gggctatcag ttcgcgcatt aaagactaat agccattcaa aaatattgtc tgtgccacgt 5040
attcttacgc tttcagggtca gaagggttct atctctgttg gccagaatgt cccttttatt 5100
actggtcgtg tgactgggtga atctgccaat gtaaataatc catttcagac gattgagcgt 5160

caaaatgtag gtatttccat gacggttttt cctgttgcaa tggctggcgg taatattgtt 5220
ctggatatta ccagcaaggc cgatagtttg agttcttcta ctcaggcaag tgatgttatt 5280
actaatcaaa gaagtattgc tacaacggtt aatttgctg atggacagac tcttttactc 5340
gggtggcctca ctgattataa aaacacttct caggattctg gcgtaccgtt cctgtctaaa 5400
atccctttta tgggcctcct gtttagctcc cgctctgatt ctaacgagga aagcacgtta 5460
tacgtgctcg tcaaagcaac catagtacgc gccctgtagc ggcgcattaa gcgcggcggg 5520
tgtgggtggt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgtctcttt 5580
cgctttcttc ctttcttttc tcgccacgtt cgcgggcttt ccccgtaag ctctaaatcg 5640
ggggtccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 5700
tttgggtgat ggttcacgta gtgggccatc gccctgatag acggtttttc gccctttgac 5760
gttgaggtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 5820
tatctcgggc tattcttttg atttataagg gattttgccg atttcggaac caccatcaaa 5880
caggattttc gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc 5940
caggcgggtga agggcaatca gctgttgccc gtctcactgg tgaaaagaaa aaccaccctg 6000
gcgccaata cgcaaaccgc ctctcccgcc gcgttggccg attcattaat gcagctggca 6060
cgacagggtt cccgactgga aagcgggcag tgagcgcaac gcaattaatg tgagttagct 6120

```

cactcattag gcaccccagg ctttacactt tatgcttccg gctcgtatgt tgtgtggaat	6180
tgtgagcgga taacaatttc acacaggaaa cagctatgac catgattacg aattcgagct	6240
ctgactactg cttggattct caccaataaa aaacgcccgg cggcaaccga gcgttctgaa	6300
caaatccaga tggagtcttg aggtcattac tggatctatc aacaggagtc caagccaatt	6360
ctcgaacggt tcaattcagc ggcaacgggt tgccgtgata acggctggca aagaacagca	6420
gcggctgggg ggcattcgcc tccggcactc cacaggcgct aacgcgcgca atgaagagcg	6480
tgtggctcgt tacttcaacc gtgctctcca cctcgcattc gaaccaggcc atggcgctcc	6540
gcagagtggg gaggccggcc tgaactgtga aagcaggagg aggagtgcc aatgatcacac	6600
gcttgctgaa gaatgccgat aacatcttct gactttcacc caggaggctg acgccgaagc	6660
gtccgccttg agtcagcagc tcatgcatac ggcccgaact cagggaacacc atcacagtcg	6720
gcgggtccag actgatggag gtgaagctgt tcaccgtcat gccatgcact tcgccctcgt	6780
cagtctccgc gctgagaacc gcaattcccg tcgcgaacag tgcaaccgcc tggcgggaagc	6840
tgggtggagtc gatatccacc accacatctt tttttaacgt catttgaatc acccaggagt	6900
tagggctccg ctggccttga ccagcggagc aatagcgtca ggccgcaata gtgggtgcgt	6960
actggctgca ccaactgaccg atacgttccg ggctggagaa gcgatccac tgaagttccg	7020
gatagttgaa gttgtccgtg aactcatcag ccatttcacg gctctggctc aggatctgaa	7080
ggaaggtgag gaattccggc ggaagttccg tgaaggcgct cagagtgaag ttgggtccagc	7140
gggtggcgca cagcacgga tcctggcggc gacgctccag gtgttcgctg aagcgcaggt	7200
cgtagacaga gtgcgcaagg atttcctcgc ccagaatcca tgccgcatac gacgccatgt	7260
tcgcgccctg gcccaagacc ggatcgacag ttgcctggat gtcgccacgc ccgatgatgg	7320
ttttgccgtt attgagggtc gcatgaccgt cgcggaatac tggcacaaca ccgccctgga	7380
ggatgtccag agaactgttg gccaggtoga actcagccgg atcgatgcgc tcggcaacgg	7440
aaggatgatg cttacgcagc ttctccagca tcagatcgag gaacgcacgc gggtcacgt	7500
catacttggg gtgggcgagg acttccagat cgctaccaat atggttttcg agcaccagcg	7560
ctgtgctcat gccattgaac gacagggttg gaatctcaat cagctcgcca tgccctggcg	7620
agaaggacat agtcacgcgc cgaatcgggtg cttccttgat gcccttgaag agaccaacgc	7680
acagtgcgcg ttgcggcttc tcgaagggcg agttttcgga ctgcttctcg aacaccttgc	7740
cgagggcgta ttaccagtg cacacaacca gcagatcata ctgctccgac agcccttcca	7800
gatcttcggc agacacggcg tcgtagcaga acttgccgcc cctggcttcc agtgcacgca	7860
tcagcatcgg caggtagaga cggtagtcca ctgcacggct gggagccttg agatcacctg	7920
agaaacgcat gggctgcggc ccacctacgt agtagtagtg gccgaaatag ccaaactcct	7980
cagacggcca ctcatcgac tcgagggcaa cctcccgtg caccgtcacc gcgttgtgag	8040
caacgggtatt caggagccgc agtccactgt actcatcggg cttacgatca gtgtacacag	8100
tgacgtcgac gtcattgctg cggaggaaga ggccaagatg gaggccggca gtgcctgcac	8160
caacaatacc gatacgcttt ttcattgatg ctacctcctt aatccttcag ctgtatggag	8220
aaacagtaga gagttgcgat aaaaagcgtc aggtatgatc cgctaactct atggataaaa	8280
atgctatggc atagcaaagt gtgacgcctg gcaataatc aatgtggact tttctgcctg	8340
gattatagac acttttggtt cgcgcttttg tcatggcttt ggtcccgtt tgttacagaa	8400

tgcttttaaat aagcgggggtt accggttttg ttagcgagaa gagccagtaa aagacgcagt	8460
gacggcaatg tctgatgcaa tatggactat tggtttcttg gtaccggggg atcctctaga	8520
gtcgacctgc aggcattgcaa gcttggcact ggccgtcgtt ttacaacgtc gtgactggga	8580
aaaccctggc gttacccaac ttaatcgctt tgcagcacat ccccttttcg ccagctggcg	8640
taatagcgaa gagggccgca ccgattcgcc ttcccaacag ttgcgcagcc tgaatggcga	8700
atggcgcttt gcctggtttc cggcaccaga agcggtgccg gaaagctggc tggagtgcga	8760
tcttcctgag gccgatactg tcgtcgtccc ctcaaactgg cagatgcacg gttacgatgc	8820
gccatctac accaactgta cctatcccat tacggccaat ccgccgtttg ttcccacgga	8880
gaatccgacg ggttggtact cgctcacatt taatgttgat gaaagctggc tacaggaagg	8940
ccagacgcga attatTTTTG atggcgttcc tattggtaa aaaatgagct gatttaacaa	9000
aaatttaatg cgaattttta caaaatatta acgtttacaa tttaaataatt tgcttataca	9060
atcttcctgt ttttggggct tttctgatta tcaaccgggg tacatatgat tgacatgcta	9120
gttttacgat taccgttcat cgattctctt gtttgctcca gactctcagg caatgacctg	9180
atagcctttg tagatctctc aaaaatagct accctctccg gcattaattt atcagctaga	9240
acggttgaat atcatattga tggtgatttg actgtctccg gcctttctca cccttttgaa	9300
tctttacctc cacattactc aggcattgca tttaaaatat atgagggttc taaaaatttt	9360
tatccttgcg ttgaaataaa ggcttctccc gcaaaagtat tacagggtca taatgttttt	9420
ggtacaaccg atttagcttt atgctctgag gctttattgc ttaattttgc taattctttg	9480
ccttgctgt atgatttatt ggatgtt	9507

<210> 6

<211> 9295

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 6

aatgctacta ctattagtag aattgatgcc accttttcag ctgcgcgccc aaatgaaaat	60
atagctaaac aggttattga ccatttgcca aatgtatcta atgggtcaaac taaatctact	120
cgttcgcaga attgggaatc aactgttata tggaatgaaa cttccagaca ccgtacttta	180
gttgcataatt taaaacatgt tgagctacag cattatatct agcaattaag ctctaagcca	240
tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcctgacctg	300
ttggagtttg cttccggtct gggtcgcttt gaagctcgaa ttaaaacgcg atatttgaag	360
tctttcgggc ttctcttaa tctttttgat gcaatccgct ttgcttctga ctataatagt	420
cagggtaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca	480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct	540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt	600
ggtttttatc gtcgtctggt aaacgagggt tatgatagtg ttgctcttac tatgcctcgt	660

aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg	720
atgaatcttt ctacctgtaa taatgttggt ccgtagttc gttttattaa cgtagatttt	780
tcttcccaac gtcctgactg gtataatgag ccagttctta aaatcgcata aggtaattca	840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctggtgttt	900
ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg	960
aatatccggt tcttgtcaag attactcttg atgaagggtca gccagcctat gcgcctggtc	1020
tgtacaccgt tcatctgtcc tctttcaaag ttgggtcagtt cggttccctt atgattgacc	1080
gtctgcgcct cgttccggct aagtaacatg gagcagggtcg cggatttcga cacaatttat	1140
caggcgatga taaaaatctc cgttgtactt tgtttcgcgc ttggtataat cgtgggggt	1200
caaagatgag tgttttagtg tattcttttg cctctttcgt ttaggttg tgccttcgta	1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct	1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgcgt ctgagggtga	1380
cgatcccgca aaagcggcct ttaactccct gcaagcctca gcgaccgaat atatcggtta	1440
tgcgtgggag atggttggtg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa	1500
attcacctcg aaagcaagct gataaacgca tacaattaaa ggctcctttt ggagcctttt	1560
ttttggagat tttcaacgtg aaaaaattat tattcgcaat tccttttagtt gttcctttct	1620
attctcactc cgtgaaact gttgaaagt gtttagcaaa atcccataca gaaaattcat	1680
ttactaacgt ctggaaagac gacaaaactt tagatcgtta cgctaactat gagggctgtc	1740
tgtggaatgc tacaggcgtt gtagtttgta ctgggtgacga aactcagtgt tacggtacat	1800
gggttcctat tgggcttgct atccctgaaa atgagggtgg tggctctgag ggtggcgggt	1860
ctgagggtgg cggttctgag ggtggcggta ctaaaccctc tgagtaagggt gatacaccta	1920
ttccgggcta tacttatatc aaccctctcg acggcactta tccgcctggt actgagcaaa	1980
accccgctaa tcctaactct tctcttgagg agtctcagcc tcttaatact tcatgtttc	2040
agaataatag gttccgaaat aggcaggggg cattaactgt ttatacgggc actgttactc	2100
aaggcaactga ccccgtaaaa acttattacc agtacactcc tgtatcatca aaagccatgt	2160
atgacgctta ctggaacggt aaattcagag actgcgcttt ccattctggc tttaatgagg	2220
atttatttgt ttgtgaatat caaggccaat cgtctgacct gcctcaacct cctgtcaatg	2280
ctggcggcgg ctctggtggt ggttctggtg gcggtctga ggggtggtgg tctgagggtg	2340
gcggttctga ggggtggcggc tctgaggggag gcggttccgg tgggtggtct ggttccgggtg	2400
attttgatta tgaaaagatg gcaaacgcta ataagggggc tatgaccgaa aatgccgatg	2460
aaaacgcgct acagtctgac gctaaaggca aacttgattc tgtcgtact gattaagggtg	2520
ctgctatoga tggtttcatt ggtgacgttt ccggccttgc taatggtaat ggtgctactg	2580
gtgattttgc tggctctaata tcccaaatgg ctcaagtcgg tgacgggtgat aattcacctt	2640
taatgaataa tttccgtcaa tatttacctt ccctccctca atcggttgaa tgtcgcctt	2700
ttgtctttgg cgtggtaaaa ccatatgaat tttctattga ttgtgacaaa ataaacttat	2760
tccgtggtgt ctttgcgttt cttttatatg ttgccacctt tatgtatgta tttctacgt	2820
ttgctaacat actgcgtaat aaggagtctt aatcatgcca gttcttttgg gtattccgtt	2880
attattgcgt ttccctcggt tccttctggt aactttgttc ggctatctgc ttacttttct	2940

taaaaagggc ttcggtaaga tagctattgc tatttcattg tttcttgctc ttattattgg	3000
gcttaactca attcttgtgg gttatctctc tgatattagc gctcaattac cctctgactt	3060
tgttcagggg gttcagttaa ttctcccgtc taatgcgctt ccctgttttt atgttattct	3120
ctctgtaaag gctgctattt tcatttttga cgtaaaca aaatcgttt cttatttga	3180
ttgggataaa taatatggct gtttattttg taactggcaa attaggctct ggaaagacgc	3240
tcgttagcgt tggtaagatt caggataaaa ttgtagctgg gtgcaaaata gcaactaatc	3300
ttgatttaag gcttcaaaac ctcccgcaag tcgggaggtt cgctaaaacg cctcgcgttc	3360
ttagaatacc ggataagcct tctatatctg atttgcttgc tattgggcgc ggtaatgatt	3420
cctacgatga aaataaaaac ggcttgcttg ttctcgatga gtgcggtact tggtttaata	3480
cccgttcttg gaatgataag gaaagacagc cgattattga ttggtttcta catgctcgta	3540
aattaggatg ggatattatt tttcttgctc aggacttctc tattgttgat aaacaggcgc	3600
gttctgcatt agctgaacat gttgtttatt gtcgtcgtct ggacagaatt actttacctt	3660
ttgtcggtagc tttatattct cttattactg gctcgaaaat gcctctgcct aaattacatg	3720
ttggcggttg taaatatggc gattctcaat taagccctac tgttgagcgt tggctttata	3780
ctggtaagaa tttgtataac gcatatgata ctaaacaggc tttttctagt aattatgatt	3840
ccggtgttta ttcttattta acgccttatt tatcacacgg tcggtatttc aaaccattaa	3900
atttaggtca gaagatgaaa ttaactaaaa tatatttgaa aaagttttct cgcgttcttt	3960
gtcttgcgat tggatttgca tcagcattta catatagtta tataacccaa cctaagccgg	4020
aggttaaaaa ggtagtctct cagacctatg attttgataa attcactatt gactcttctc	4080
agcgtcttaa tctaagctat cgctatgttt tcaaggattc taagggaata ttaattaata	4140
gcgacgattt acagaagcaa ggattttcac tcacatatat tgatttatgt actgtttcca	4200
ttaaaaaagg taattcaa at gaaattgtta aatgtaatta attttgtttt cttgatgttt	4260
gtttcatcat cttcttttgc tcaggtaatt gaaatgaata attcgcctct gcgcgatttt	4320
gtaacttggg attcaaagca atcaggcgaa tccgttattg tttctccoga tgtaaaagg	4380
actgttactg tatattcatc tgacgttaaa cctgaaaatc tacgcaattt ctttatttct	4440
gttttacgtg caaataattt tgatatggta gggtctaacc cttccattat tcagaagtat	4500
aatccaaaca atcaggatta tattgatgaa ttgccatcat ctgataatca ggaatatgat	4560
gataattccg ctcttcttgg tggtttcttt gttccgcaaa atgataatgt tactcaaact	4620
tttaaaatta ataacgttcg ggcaaaggat ttaatacgag ttgtcgaatt gtttgtaaag	4680
tctaatactt ctaaatectc aatgtatta tctattgacg gctctaactc attagttgtt	4740
agtgtccta aagatatttt agataacctt cctcaattcc tttcaactgt tgatttgcca	4800
actgaccaga tattgattga gggtttgata tttgaggttc agcaaggatga tgcttttagat	4860
ttttcatttg ctgctggctc tcagcgtggc actgttgacg gcgggtgttaa tactgaccgc	4920
ctcacctctg ttttatcttc tgctgggtgg tcgttcggta tttttaatgg cgatgtttta	4980
gggctatcag ttcgcgcatt aaagactaat agccattcaa aaatattgtc tgtgccacgt	5040
attcttacgc tttcaggtea gaagggttct atctctgttg gccagaatgt cctttttatt	5100
actggtcgtg tgactggatg atctgccaat gtaataatc catttcagac gattgagcgt	5160

caaaatgtag gtatttccat gagcgttttt cctgttgcaa tggctggcgg taatattgtt	5220
ctggatatta ccagcaaggc cgatagtttg agttcttcta ctcaggcaag tgatgttatt	5280
actaatcaaa gaagtattgc tacaacgggt aatttgcggt atggacagac tcttttactc	5340
ggtggcctca ctgattataa aaacacttct caggattctg gcgtaccgtt cctgtctaaa	5400
atccctttta tcggcctcct gtttagctcc cgctctgatt ctaacgagga aagcacgtta	5460
tacgtgctcg tcaaagcaac catagtacgc gccctgtagc ggcgcattaa gcgcggcggg	5520
tgtggtggtt acgcgcagcg tgaccgtac acttgccagc gccctagcgc ccgctccttt	5580
cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtaag ctctaaatcg	5640
ggggctccct ttagggttcc gatttagtgc ttacggcac ctcgacccca aaaaacttga	5700
tttgggtgat ggttcacgta gtggggccat gccctgatag acggtttttt gccctttgac	5760
gttgaggtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc	5820
tatctcgggc tattcttttg atttataagg gattttgccg atttcggaac caccatcaaa	5880
caggattttc gcctgctggg gcaaaccagc gtggaccgct tgctgcaact ctctcagggc	5940
caggcgtgta agggcaatca gctgttgccc gtctcactgg tgaaaagaaa aaccaccctg	6000
gcgcccaata cgcaaaccgc ctctccccgc gcgttgggcg attcattaat gcagctggca	6060
cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaatg tgagttagct	6120
cactcattag gcaccccagg ctttacactt tatgcttcgc gctcgtatgt tgtgtggaat	6180
tgtgagcggg taacaatttc acacaggaaa cagctatgac catgattacg aattcgagct	6240
ctgactactg cttggattct caccaataaa aaacgcccgg cggcaaccga gcgttctgaa	6300
caaatccaga tggagttctg aggtcattac tggatctatc aacaggagtc caagccaatt	6360
ctcgaacgtt tcaattcagc ggcaacgggt tgccgtgata acggctggca aagaacagca	6420
gcggctgggg ggcattcgcc tccggcactc cacaggcgct aacgcgcgca atgaagagcg	6480
tgtggtcgtg tacttcaacc gtgctctcca cctcgcattc gaaccaggcc atggcgtccc	6540
gcagagtggg gaggccggcc tgaactgtga aagcaggagg aggagtgcc tcatcacac	6600
gcttgctgaa gaatgccgat aacatcttct gactttcacc caggaggctg acgccgaagc	6660
gtccgccttg agtcagcagc tcatgcatac ggcccgactt cagggaacacc atcacagtcg	6720
gcgggtccag actgatggag gtgaagctgt tcaccgtcat gccatgcact tcgccctcgt	6780
cagtctccgc gctgagaacc gcaattcccg tcgcgaacag tgcaaccgcc tggcgggaagc	6840
tgggtggagtc gatatccacc accacatctt tttttaacgt catttgaatc acccaggagt	6900
tagggctccg ctggccttga ccagcggagc aatagcgtca ggccgcaata gtgggtgcgt	6960
actggctgca ccaactgaccg atacgttcgc ggctggagaa gcgatccac tgaagttccg	7020
gatagttgaa gttgtccgtg aactcatcag ccatttcacg gctctggctc aggatctgaa	7080
ggaaggtgag gaattccggc ggaagttccg tgaaggcgct cagagtgaag ttggtccagc	7140
gggtggcgca cagcacgca tcctggcggc gacgctccag gtgttcgctg aagcgcaggt	7200
cgtagacaga gtgcgcaagg atttcctcgc ccagaatcca tgccgcatag gacgccatgt	7260
tcgcgccctg gcccaagacc ggatcgacag ttgcctggat gtcgcccagc ccgatgatgg	7320
ttttgccgtt attgagggtc gcatgaccgt cgcggaatac tggcacaaca ccgccctgga	7380
ggatgtccag agaactgttg gccaggtcga actcagccgg atcgatgcgc tcggcaacgg	7440

```

aaggatgatg cttacgcagc ttctccagca tcagatcgag gaacgcacgc gggtcacgt      7500
catacttggg gtgggcgagg acttccagat cgctaccaat atggttttcg agcaccagcg      7560
ctgtgctcat gccattgaac gacaggggtg gaatctcaat cagctcgcca tgccctggcg      7620
agaaggacat agtcaccgcg cgaatcgggtg cttccttgat gcccttgaag agaccaacgc      7680
acagtgcctg ttgcggttgc tcgaagggcg agttttcgga ctgcttctcg aacaccttgc      7740
cgagggcgta tttaccagtg cacacaacca gcagatcata ctgctccgac agcccttcca      7800
gatcttcggc agacacggcg tcgtagcaga acttgccgcc cctggcttcc agtgcacgca      7860
tcagcatcgg caggtagaga cggtagtcca ctgcacggct gggagccttg agatcacctg      7920
agaaacgcat gggctgcggc ccacctacgt agtagtagtg gccgaaatag ccaaactcct      7980
cagacggcca ctcatcgagc tcgagggcaa cctcccgctg caccgtcacc gcgttgtgag      8040
caacgggtatt caggagccgc agtccactgt actcatcggg cttacgatca gtgtacacag      8100
tgacgtcgac gtcattgctg cgaggaaga ggccaagatg gaggccggca gtgcctgcac      8160
caacaatacc gatacgcttt ttcatgcatg ctacctcctt aatccttcag ctgggtcagt      8220
gcgtcctgct gatgtgctca gtatctctat cactgatagg gatgtcaatc tctatcactg      8280
atagggaggt acccggggat cctctagagt cgacctgcag gcatgcaagc ttggcactgg      8340
ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt taccctaactt aatcgccctg      8400
cagcacatcc ccctttcgcc agctggcgta atagcgaaga ggcccgccacc gatcgccctt      8460
cccaacagtt gcgcagcctg aatggcgaat ggcgctttgc ctggtttccg gcaccagaag      8520

cggtgccgga aagctggctg gagtgcgac ttcttgaggg cgatactgtc gtctgccct      8580
caaactggca gatgcacggg tacgatgcgc ccatctacac caacgtgacc tatcccatta      8640
cggccaatcc gccgtttggt cccacggaga atccgacggg ttgttactcg ctacattta      8700
atgttgatga aagctggcta caggaaggcc agacgcgaat tatttttgat ggcgttccta      8760
ttggttaaaa aatgagctga ttttaacaaa atttaatgcg aattttaaca aaatattaac      8820
gtttacaatt taaatatttg cttatacaat cttcctgttt ttggggcttt tctgattatc      8880
aaccggggta catatgattg acatgctagt tttacgatta ccgttcacgc attctcttgt      8940
ttgctccaga ctctcaggca atgacctgat agcctttgta gatctctcaa aaatagctac      9000
cctctccggc attaatattat cagctagaac ggttgaatat catattgatg gtgatttgac      9060
tgtctccggc ctttctcacc cttttgaatc tttacctaca cattactcag gcattgcatt      9120
taaaatatat gagggttcta aaaattttta tccttgcggt gaaataaagg cttctccgc      9180
aaaagtatta cagggtcata atgttttttg tacaaccgat ttagctttat gctctgaggc      9240
tttattgctt aattttgcta attctttgcc ttgcctgtat gatttattgg atgtt      9295

```

<210> 7

<211> 3101

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 7

gacgtctgtg caagtactac tgttctgcag tcacttgaat tcgataccca gctgggtgga	60
gtgcaccaag gagcatgcga aggaaacgtt tcgcagaagc ttccgcaagg taccactttg	120
ccgcggagta tttgtacatt tgaaggatcc tcaagtcggc cgcctgttcc atggatactc	180
gtcgaccatt acgctagccg tctggagctc ggactgctta agtcgctcca tatgctgaaa	240
tgagctgttg acaattaatc atccggctcg tataatgtgt ggaattgtga gcggataaca	300
atttcacacc ccgggataag gaggacaatt gatgcgtaaa ggagaagaac ttttcactgg	360
agttgtccca attcttgttg aattagatgg tgatgttaat gggcacaaat tttctgtcag	420
tggagagggg gaaggtgatg caacatacgg aaaacttacc cttaaattta tttgcactac	480
tggaaaacta cctgttccgt ggccaacact tgtcactact ttccggttatg gtgttcaatg	540
ctttgcgaga taccagatc acatgaaaca gcatgacttt ttcaagagtg ccatgcccga	600
aggttacgta caggaaagaa ctatatTTTTT caaagatgac gggaactaca agacacgtgc	660
tgaagtcaag tttgaagggtg atacccttgt taatagaatc gagttaaag gtattgattt	720
taaagaagat ggaaacattc ttggacacaa attggaatac aactataact cacacaatgt	780
atacatcatg gcagacaaac aaaagaatgg aatcaaagtt aacttcaaaa ttagacacaa	840
cattgaagat ggaagcgttc aactagcaga ccattatcaa caaaatactc cgattggcga	900
tggccctgtc cttttaccag acaaccatta cctgtccaca caatctgcc tttcgaaaga	960
tcccaacgaa aagagagacc acatggctct tcttgagttt gtaaccgctg ctgggattac	1020
acatggcatg gatgaactat acaaataagg cgcacagggt gatatctatc gccctaggga	1080
ccgtctcgag agaatcaata ttaatccaac gcgtggcatc aaataaaacg aaaggctcag	1140
tcgaaagact gggcctttcg ttttatctgt tgtttgtcgg tgaacgctct cctgagtagg	1200
acaaatccgc cgccttagac ttaggcgttc ggctgcggcg agcggtatca gctcactcaa	1260
aggcggtaat acggttatcc acagaatcag gggataacgc aggaagaac atgtgagcaa	1320
aaggccagca aaaggccagg aaccgtaaaa aggcgcgtt gctggcgttt ttccataggc	1380
tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaaccgga	1440
caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgogc tctcctgttc	1500
cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttccgggaagc gtggcgcttt	1560
ctcatagctc acgctgtagg tatctcagtt cgggtgtaggt cgttcgctcc aagctgggct	1620
gtctgcacga accccccgtt cagcccagac gctgcgcctt atccggtaac tatcgtcttg	1680
agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggg aacaggatta	1740
gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtgggtggcct aactacggct	1800
acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttccgaaaaa	1860
gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcgggtgg ttttttgttt	1920
gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta	1980
cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttgggc atggctagtg	2040
cttggtattc caccaataaa aaacgcccgg cggcaaccga gcgttctgaa caaatccaga	2100
tgaattctc aactcattac tgaatctatc aacaagaatc caaaccaatt ctcaaacccc	2160

```

-----
agagtcccg c tcagaagaac tcgtcaagaa ggcgatagaa ggcgatgcgc tgcgaatcgg 2220
gagcggcgat accgtaaagc acgaggaagc ggtcagccca ttcgccgcca agctcttcag 2280
caatatcacg ggtagccaac gctatgtcct gatagcggtc cgccacaccc agccggccac 2340
agtcgatgaa tccagaaaag cggccatttt ccaccatgat attcggcaag caggcatcgc 2400
cgtgggtcac gaagagatcc tcgccgtcgg gcatacgcgc cttgagcctg gcgaacagtt 2460
cggctggcgc gagccctga tgctcttcgt ccagatcatc ctgatcgaca agaccggctt 2520
ccatccgagt acgtgctcgc tcgatgcgat gtttcgcttg gtggtcgaat gggcaggtag 2580
ccggatcaag cgtatgcagc cgcgcattg catcagccat gatggatact ttctcggcag 2640
gagcaagggtg agatgacagg agatcctgcc ccggcacttc gcccaatagc agccagtccc 2700

ttcccgttc agtgacaacg tcgagcacag ccgcgcaagg aacgcccgtc gtggccagcc 2760
acgatagccg cgctgcctcg tcttgagtt cattcagggc accggacagg tcggtcttga 2820
caaaaagaac cgggcgaccc tgcgctgaca gccggaacac ggcggcatca gagcagccga 2880
ttgtctgttg tgcccagtca tagccgaata gcctctccac ccaagccgcc ggagaacctg 2940
cgtgcaatcc atcttgttca atcatgcgaa acgatcctca tcctgtctct tgatcagatc 3000
ttgatccct gcgcatcag atccttggcg gcaagaaagc catccagttt actttgcagg 3060
gcttcccaac cttaccagag ggcggcccaa ctggcaattc c 3101

```

<210> 8

<211> 3524

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 8

```

gacgtctgtg caagtactac tgttctgcag tcacttgaat tcgataccca gctgggtgga 60
gtgcaccaag gagcatgcga aggaaacgtt tcgcagaagc ttccgcaagg taccactttg 120
ccgcggagta tttgtacatt tgaaggatcc tcaagtcggc cgcgcgttcc atggatactc 180
gtcgaccatt acgctagccg tctggagctc ggactgctta agtcgctcca tatgctgaaa 240
tgagctgttg acaattaatc atccggctcg tataatgtgt ggaattgtga gcggataaca 300
atttcacacc ccgggataag gaggacaatt gatgcgtaaa ggagaagaac ttttcactgg 360
agttgtccca attcttggtg aattagatgg tgatgttaat gggcacaaat tttctgtcag 420
tgagagaggt gaaggtgatg caacatacgg aaaacttacc cttaaattta tttgcactac 480
tggaanaacta cctgttccgt ggccaacact tgtcactact ttccggttatg gtgttcaatg 540
ctttgcgaga taccagatc acatgaaca gcatgacttt ttcaagagtg ccatgcccca 600
aggttacgta caggaaagaa ctatattttt caaagatgac gggaactaca agacacgtgc 660
tgaagtcaag tttgaagggtg atacccttgt taatagaatc gagttaaag gtattgattt 720
taaagaagat ggaaacattc ttggacacaa attggaatac aactataact cacacaatgt 780

```

atacatcatg gcagacaaac aaaagaatgg aatcaaagtt aacttcaaaa ttagacacaa	840
cattgaagat ggaagcgttc aactagcaga ccattatcaa caaaatactc cgattggcga	900
tggccctgtc cttttaccag acaaccatta cctgtccaca caatctgccc tttcgaaaga	960
tcccaacgaa aagagagacc acatggtcct tcttgagttt gtaaccgctg ctgggattac	1020
acatggcatg gatgaactat acaaataagg cgccagggtt gatatctatc gccctaggga	1080
ccgtctcgag agcgccctgt agcggcgcgt taagcgcggc ggggtgtggtg gttacgcgca	1140
gcgtgaccgc tacacttgcc agcgccctag cgcccgcctc tttcgctttc ttcccttcc	1200
ttctcgccac gttcgccggc tttccccgtc aagctctaaa tcgggggctc cctttagggt	1260
tccgatttag tgctttacgg cacctcgacc ccaaaaaact tgattagggt gatggttcac	1320
gtagtgggcc atcgccctga tagacggttt ttcgcccttt gacgttgag tccacgttct	1380
ttaatagtgg actcttgttc caaactggaa caacactcaa ccctatctcg gtctattctt	1440
ttgatttata agggattttg ccgatttcgg cctattgggt aaaaaatgag ctgatttaac	1500
aaaaatttaa cgogaattaa atattaatcc aacgcgtggc atcaaataaa acgaaaggct	1560
cagtcgaaag actgggcctt tcgttttatc tggtgtttgt cggcgaacgc tctcctgagt	1620
aggacaaatc cgccgccta gacttaggcg ttccgctgcg gcgagcggta tcagctcact	1680
caaaggcggc aatacggta tccacagaat caggggataa cgcaggaaag aacatgtgag	1740
caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata	1800
ggctccgccc cctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc	1860
cgacaggact ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg	1920
ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc	1980
tttctcatag ctacgctgt aggtatctca gttcgggtga ggtcgttcgc tccaagctgg	2040
gctgtctgca cgaaccccc gttcagccc accgctgcgc cttatccggc aactatcgtc	2100
ttgagtcgaa cccggtaaga cagacttat cgccactggc agcagccact ggtaacagga	2160
ttagcagagc gaggtatgta ggcgggtgcta cagagttctt gaagtgggtg cctaactacg	2220
gctacactag aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa	2280
aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggc ggtttttttg	2340
tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt	2400
ctacgggggtc tgacgctcag tggaaacgaaa actcacgtta agggattttg gtcattggcta	2460
gtgcttggat tctcaccaat aaaaaacgcc cggcgggcaac cgagcgttct gaacaaatcc	2520
agatggagtt ctgaggtcat tactggatct atcaacagga gtccaagcca attctcgaac	2580
cccagagtcc cgctcagaag aactcgtcaa gaaggcgata gaaggcgatg cgctgcgaat	2640
cgggagcggc gataccgtaa agcacgagga agcggtcagc ccattcgccg ccaagctctt	2700
cagcaatatc acgggtagcc aacgctatgt cctgatagcg gtccgccaca ccagccggc	2760
cacagtcat gaatccagaa aagcggccat tttccaccat gatattcggc aagcaggcat	2820
cgccgtgggt cagcagaga tcctcgccgt cgggcatacg cgccttgagc ctggcgaaca	2880
gttcggctgg cgcgagcccc tgatgctctt cgtccagatc atcctgatcg acaagaccgg	2940
cttccatccg agtacgtgct cgctcgatgc gatgtttcgc ttggtggctc aatgggcagg	3000

tagccggatc aagcgtatgc agccgcgcga ttgcatcagc catgatggat actttctcgg	3060
caggagcaag gtgagatgac aggagatcct gcccgcgcac ttgcgccaat agcagccagt	3120
cccttcccgc ttcagtgaca acgtcgagca cagccgcgca aggaacgccc gtcggtggcca	3180
gccacgatag ccgcgctgcc tcgtcttgca gttcattcag ggcaccggac aggtcggtct	3240
tgacaaaaag aaccgggcga ccctgcgctg acagccggaa cacggcggca tcagagcagc	3300
cgattgtctg ttgtgcccag tcatagccga atagcctctc caccgaagcc gccggagaac	3360
ctgcgtgcaa tccatcttgt tcaatcatgc gaaacgatcc tcatcctgtc tcttgatcag	3420
atcttgatcc cctgcgccat cagatccttg gcggcaagaa agccatccag tttactttgc	3480
agggcttccc aaccttacca gagggcggcc caactggcaa ttcc	3524

<210> 9

<211> 7413

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Polynucleotide

<400> 9

aatgctacta ctattagtag aattgatgcc accttttcag ctgcgcgccc aaatgaaaat	60
atagctaaac aggttattga ccatttgcca aatgtatcta atggtcaaac taaatctact	120
cgttcgcaga attgggaatc aactgttata tggaatgaaa cttccagaca ccgtacttta	180
gttgcataatt taaaacatgt tgagctacag cattatatcc agcaattaag ctctaagcca	240
tccgcaaaaa tgacctctta tcaaaaggag caattaaagg tactctctaa tcctgacctg	300
ttggagtttg cttccggtct ggttcgcttt gaagctcgaa ttaaaacgcg atatttgaag	360
tctttcgggc ttctctctaa tctttttgat gcaatccgct ttgcttctga ctataatagt	420
cagggtaaaag acctgatttt tgatttatgg tcattctcgt tttctgaact gtttaaagca	480
tttgaggggg attcaatgaa tatttatgac gattccgcag tattggacgc tatccagtct	540
aaacatttta ctattacccc ctctggcaaa acttcttttg caaaagcctc tcgctatttt	600
ggttttttatc gtcgtctggt aaacgagggt tatgatagtg ttgctcttac tatgcctcgt	660
aattcctttt ggcgttatgt atctgcatta gttgaatgtg gtattcctaa atctcaactg	720
atgaatcttt ctacctgtaa taatgttggt ccgttagttc gttttattaa cgtagatttt	780
tcttcccaac gtctgactg gtataatgag ccagttctta aaatcgcata aggtaattca	840
caatgattaa agttgaaatt aaaccatctc aagcccaatt tactactcgt tctggtgttt	900
ctcgtcaggg caagccttat tcaactgaatg agcagctttg ttacgttgat ttgggtaatg	960
aatatccggt tcttgtcaag attactcttg atgaaggcca gccagcctat gcgcctgggc	1020
tgtacaccgt tcatctgtcc tctttcaaag ttggtcagtt cggttccctt atgattgacc	1080
gtctgcgcct cgttccggct aagtaacatg gagcaggtcg cggatttcga cacaatttat	1140
caggcgatga tacaaatctc cgttgtaactt tgtttcgcgc ttggtataat cgctgggggt	1200

caaagatgag tgttttagtg tattcttttg cctctttcgt tttaggttgg tgccttcgta	1260
gtggcattac gtattttacc cgtttaatgg aaacttcctc atgaaaaagt ctttagtcct	1320
caaagcctct gtagccgttg ctaccctcgt tccgatgctg tctttcgtg ctgaggggtga	1380
cgatcccgcg aaagcggcct ttaactccct gcaagcctca ggcaccgaat atatcggtta	1440
tgcgtgggcg atgggtgttg tcattgtcgg cgcaactatc ggtatcaagc tgtttaagaa	1500
attcacctcg aaagcaagct gataaacgca tacaattaaa ggctcctttt ggagcctttt	1560
ttttggagat tttcaacgtg aaaaaattat tattcgcaat tccttttagtt gttcctttct	1620
attctcactc cgctgaaact gttgaaagtt gtttagcaaa atcccataca gaaaattcat	1680
ttactaacgt ctggaaagac gacaaaactt tagatcgta cgctaactat gagggctgtc	1740
tgtggaatgc tacaggcggt gtagtttgta ctgggtgacga aactcagtgt tacggtacat	1800
gggttcctat tgggcttgct atccctgaaa atgaggggtgg tggctctgag ggtggcggtt	1860
ctgaggggtg cggttctgag ggtggcggtg ctaaacctcc tgagtacggt gatacaccta	1920
ttccgggcta tacttatatc aacctctcgt acggcactta tccgcctggt actgagcaaa	1980
accccgctaa tcctaatacct tctcttgagg agtctcagcc tcttaatact ttcattgttc	2040
agaataatag gttccgaaat aggcaggggg cattaaactgt ttatacgggc actgttactc	2100
aaggcactga ccccgtaaaa acttattacc agtacactcc tgtatcatca aaagccatgt	2160
atgacgctta ctggaacggt aaattcagag actgcgcttt ccattctggc tttaatgagg	2220
atttatttgt ttgtgaatat caaggccaat cgtctgacct gcctcaacct cctgtcaatg	2280
ctggcggcgg ctctggtggt ggttctggtg gcggtctctga ggggtggtggc tctgagggtg	2340
gcggttctga ggggtggcggc tctgagggag gcggttccgg tgggtggtct ggttccggtg	2400
attttgatta tgaaaagatg gcaaacgcta ataagggggc tatgaccgaa aatgccgatg	2460
aaaacgcgct acagtctgac gctaaaggca aacttgattc tgtcgctact gattacggtg	2520
ctgctatcga tggtttcatt ggtgacgttt ccggccttgc taatggtaat ggtgctactg	2580
gtgattttgc tggctctaata tcccaaattg ctcaagtcgg tgacgggtgat aattcacctt	2640
taatgaataa tttccgtcaa tatttacctt ccctccctca atcggttgaa tgtcggcctt	2700
ttgtctttgg cgctggtaaa ccatatgaat tttctattga ttgtgacaaa ataaacttat	2760
tccgtggtgt ctttgcggtt cttttatatg ttgccacctt tatgtatgta ttttctacgt	2820
ttgctaacat actgcgtaat aaggagtctt aatcatgccg gttcttttgg gtattccgtt	2880
attattgcgt ttccctcggtt tccttctggt aactttgttc ggctatctgc ttacttttct	2940
taaaaagggc ttcggtaaga tagctattgc tatttcattg tttcttgctc ttattattgg	3000
gcttaactca attcttgtgg gttatctctc tgatattagc gctcaattac cctctgactt	3060
tgttcagggg gttcagttaa ttctcccgtc taatgcgctt ccctgttttt atgttattct	3120
ctctgtaaag gctgctattt tcatttttga cgtaaacaa aaaatcggtt cttatttgga	3180
ttgggataaa taatatggct gtttattttg taactggcaa attaggtctt ggaaagacgc	3240
tcgttagcgt tggtaagatt caggataaaa ttgtagctgg gtgcaaaata gcaactaatc	3300
ttgatttaag gcttcaaaac ctcccgaag tcgggaggtt cgctaaaacg cctcgcgttc	3360
ttagaatacc ggataagcct tctatatctg atttgcttgc tattgggcgc ggtaatgatt	3420
cctacgataa aaataaaaaa gacttaacta ttctcagata ctacgactact tcaatttaata	3480

```

-----
cccgttcttg gaatgataag gaaagacagc cgattattga ttggtttcta catgctcgta 3540
aattaggatg ggatattatt tttcttgttc aggacttata tattgttgat aaacaggcgc 3600
gttctgcatt agctgaacat gttgtttatt gtcgtcgtct ggacagaatt actttacdt 3660
ttgtcggtao tttatattct cttattactg gtcgaaaaat gcctctgct aaattacatg 3720
ttggcgttgt taaatatggc gattctcaat taagccctac tggtgagcgt tggctttata 3780
ctggtaagaa tttgtataac gcatatgata ctaaacaggc ttttctagt aattatgatt 3840
ccgggtgttta ttcttattta acgccttatt tatcacacgg tcgggtatttc aaaccattaa 3900
atttaggtca gaagatgaaa ttaactaaaa tatatttgaa aaagttttct cgcgttcttt 3960
gtcttgcgat tggatttgca tcagcattta catatagtta tataacccaa cctaagccgg 4020
aggttaaaaa ggtagtctct cagacctatg attttgataa attcactatt gactcttctc 4080
agcgtcttaa tctaagctat cgctatgttt tcaaggattc taagggaaaa ttaattaata 4140
gcgacgattt acagaagcaa ggttattcac tcacatatat tgatttatgt actgtttcca 4200
ttaaaaaagg taattcaaat gaaattgtta aatgtaatta attttgtttt cttgatgttt 4260
gtttcatcat cttcttttgc tcaggtaatt gaaatgaata attcgcctct gcgcgatttt 4320
gtaacttggg attcaaagca atcaggcgaa tccgttattg tttctccga tgtaaaagg 4380
actgttactg tatattcact tgacgttaaa cctgaaaatc tacgcaattt ctttatttct 4440
gttttacgtg caaataattt tgatatggta ggttctaacc cttccattat tcagaagtat 4500
aatccaaaca atcaggatta tattgatgaa ttgccatcat ctgataatca ggaatatgat 4560
gataattcgg ctcttcttgg tggtttcttt gtccgcgaaa atgataatgt tactcaaact 4620
tttaaaatta ataacgttgc ggcaaaggat ttaatacagag ttgtcgaatt gtttgtaaag 4680
tctaatactt ctaaactctc aaatgtatta tctattgacg gctctaactt attagttgtt 4740
agtgcctcta aagatatttt agataacct cctcaattcc tttcaactgt tgatttgcca 4800
actgaccaga tattgattga gggtttgata ttgaggttc agcaaggaga tgcttttagat 4860
ttttcatttg ctgctggctc tcagcgtggc actgttgacg gcgggtgtta tactgaccgc 4920

ctcacctctg ttttatcttc tgctgggtgg tcgttcggta tttttaatgg cgatgtttta 4980
gggctatcag ttgcgcgatt aaagactaat agccattcaa aaatattgtc tgtgccacgt 5040
attcttaacg tttcaggtea gaagggttct atctctgttg gccagaatgt cccttttatt 5100
actggtcgtg tgactggaga atctgccaat gtaaataatc catttcagac gattgagcgt 5160
caaaatgtag gtatttccat gagcgttttt cctgttgcaa tggctggcgg taatattgtt 5220
ctggatatta ccagcaaggc cgatagtttg agttcttcta ctcaggcaag tgatgttatt 5280
actaatcaaa gaagtattgc tacaacggtt aatttgctg atggacagac tcttttactc 5340
ggtggcctca ctgattataa aaacacttct caggattctg gcgtaccgtt cctgtctaaa 5400
atccctttaa tcggcctcct gtttagctcc cgctctgatt ctaacgagga aagcacgtta 5460
tacgtgctcg tcaaagcaac catagtacgc gccctgtagc ggcgcatata gcgcggcggg 5520
tgtggtgggt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt 5580
cgctttcttc ccttccttcc tcgccacgtt cgccggcttt ccccgtaag ctctaaatcg 5640
ggggctccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 5700
tttgcctcat gatttagctc ctggcctcga ggcctctctc ggccttttca ggccttttca 5760

```

```

cttgggtgat ggttcacgta gtggggccatc gcccctgatag acggctctctc gcccctctgac 5760
gttggagtc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 5820
tatctcgggc tattcttttg attataagc gattttgccg atttcgggac tgcttaagtc 5880
gctccatatg ctgaaatgag ctgttgacaa ttaatcatcc ggctcgtata atgtgtggaa 5940
ttgtgagcgg ataacaattt cacaccccg gataaggagg acaattgatg cgtaaaggag 6000
aagaactttt cactggagtt gtcccaattc ttgttgaatt agatggatg gttaatgggc 6060
acaaattttc tgtcagtga gaggggtgaag gtgatgcaac atacggaaaa cttaccctta 6120
aatttatctg cactactgga aaactacctg ttccgtggcc aacacttgct actactttcg 6180
gttatgggtg tcaatgcttt gcgagatacc cagatcacat gaaacagcat gactttttca 6240
agagtgccat gccgaaggt tacgtacagg aaagaactat atttttcaaa gatgacggga 6300
actacaagac acgtgctgaa gtcaagtttg aaggtgatac ccttgtaaat agaactcagt 6360
taaaagggtat tgattttaaa gaagatggaa acattcttgg acacaaattg gaatacaact 6420
ataactcaca caatgtatac atcatggcag acaaacaaaa gaatggaatc aaagttaact 6480
tcaaaattag acacaacatt gaagatggaa gcgttcaact agcagaccat tatcaacaaa 6540
atactccgat tggcgatggc cctgtccttt taccagacaa ccattacctg tccacacaat 6600
ctgccctttc gaaagatccc aacgaaaaga gagaccacat ggtccttctt gagtttgtaa 6660
ccgctgctgg gattacacat ggcattgatg aactatacaa ataaggcgcc agggttgata 6720
tctatcgccc tagggaccgt ctcgagagaa tcaatattaa tccaacgcgt ggcatacaat 6780

aaaacgaaag gctcagtcga aagactgggc ctttcgtttt atctgttggt tgtcggtgaa 6840
cgctctcctg agtaggacaa atccgccgcc ctagactatt ggttaaaaaa tgagctgatt 6900
taacaaaaat ttaatgcgaa ttttaacaaa atattaacgt ttacaattta aatatttgct 6960
tatacaatct tcctgttttt ggggcttttc tgattatcaa ccgggggtaca tatgattgac 7020
atgctagttt tacgattacc gttcatcgat tctcttggtt gctccagact ctcaggcaat 7080
gacctgatag cctttgtaga tctctcaaaa atagctaccc tctccggcat taatttatca 7140
gctagaacgg ttgaatatca tattgatggg gatttgactg tctccggcct ttctcaccct 7200
tttgaatctt tacctacaca ttactcaggc attgcattta aaatatatga gggttctaaa 7260
aatttttatc cttgcgttga aataaaggct tctcccgcaa aagtattaca gggtcataat 7320
gtttttggta caaccgattt agctttatgc tctgaggctt tattgcttaa ttttgcta 7380
tctttgcctt gcctgtatga ttattggat gtt 7413

```

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all

liability in this regard.

Patent documents cited in the description

- WO2004007695A2 [0003]
- US4683202A [0040]
- US5928906A [0040]
- US20120003630A [0079] [0082] [0083] [0084]
- US61841904B [0136]

Non-patent literature cited in the description

- **HOOGENBOOM et al.** nucleic acids research, 1991, vol. 19, 154133-4137 [0003]
- **FROYEN et al.** Eur. J. Biochem., 1997, vol. 243, 3762-769 [0003]
- **BERG et al.** Trends in Microbiology, 1996, vol. 4, 11430-435 [0003]
- **HAMADY et al.** Annals of the Royal College of Surgeons of England, 2013, vol. 95, 4235-240 [0003]
- **REYES et al.** Nature Reviews Microbiology, 2012, vol. 10, 9607-617 [0003]
- **WESTWATER CA et al.** Microbiology, 2002, vol. 148, 943-50 [0027]
- **KITTLESON JT et al.** ACS Synthetic Biology, 2012, vol. 1, 583-89 [0027]
- **MEAD DA et al.** Biotechnology, 1988, vol. 10, 85-102 [0027]
- **OWAUSUBELJ.** Bacteriol., 1983, vol. 155, 704-713 [0058]
- **LORBACH et al.** J. Mol. Biol., 2000, vol. 296, 1175-81 [0058]
- **LOESSNER et al.** Mol. Micro., 2000, vol. 35, 324-340 [0058]
- **MATSUURA et al.** J Bacteriol., 1996, vol. 178, 3374-3376 [0058]
- **GROTH, A. C. CALOS, M. P.** J Mol Biol, 2004, vol. 335, 667-678 [0061]
- **GORDLEY, R. M. et al.** Proc Natl Acad Sci USA, 2009, vol. 106, 5053-5058 [0061]
- recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes **WEBB, EDWIN C** Enzyme nomenclature 1992 International Union of Biochemistry and Molecular Biology by Academic Press 1992 20000 [0070]
- **AUSUBEL, F.M. et al.** Current Protocols in Molecular Biology John Wiley & Sons 2006 0000 [0086]
- **GIBSON, D.G. et al.** Nature Methods, 2009, vol. 6, 5343-345 [0086]
- **WOO et al.** Journal of Microbiological Methods, 2000, vol. 40, 181-191 [0096]
- **O'CONNOR et al.** Applied and Environmental Microbiology, 1997, vol. 63, 4287-4291 [0096]
- **PINERO-FERNANDEZ et al.** Journal of Bacteriology, 2011, vol. 193, 1793-1798 [0096]

- **LITCOFSKY et al.** Nat Meth, 2012, vol. 9, 111077-1080 [\[0098\]](#)
- **PIZARRO et al.** Trends in Mol Med., 2003, [\[0114\]](#)
- **WIRTZ et al.** Nature Protocols, 2007, [\[0114\]](#)

Patentkrav

- 1.** Rekombinant ikke-lytisk bakteriofag til anvendelse i behandlingen af gastrointestinal sygdom, hvor det rekombinante bakteriofag er manipuleret til at levere til ikke-patogene endogene bakterieceller mindst ét genetisk kredsløb, hvor
- 5 det mindst ene genetiske kredsløb omfatter en nukleotidsekvens der koder for et terapeutisk molekyle der ikke er et antimikrobielt protein, og hvor de endogene bakterieceller forbliver levedygtige og i stand til stabilt at opretholde ekspression af det genetiske kredsløb.
- 10 **2.** Det rekombinante bakteriofag ifølge krav 1 til anvendelsen ifølge krav 1, hvor det ikke-lytiske bakteriofag er af en familie valgt fra *Myoviridae*, *Siphoviridae*, *Podoviridae*, *Tectiviridae*, *Corticoviridae*, *Lipothrixviridae*, *Plasmaviridae*, *Rudiviridae*, *Fuselloviridae*, *Inoviridae*, *Microviridae*, *Leviviridae* og *Cystoviridae*.
- 15 **3.** Det rekombinante bakteriofag ifølge krav 1 eller krav 2 til anvendelsen ifølge krav 1 eller krav 2, hvor det ikke-lytiske rekombinante *Inoviridae*-bakteriofag er et M13-bakteriofag eller M13-lignende bakteriofag.
- 4.** Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-3 til
- 20 anvendelsen ifølge et hvilket som helst af kravene 1-3, hvor de endogene bakterieceller er *Escherichia coli*.
- 5.** Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-4 til anvendelsen ifølge et hvilket som helst af kravene 1-4, hvor det genetiske
- 25 kredsløb indeholder en rekombinant eller syntetisk nukleinsyre med en konstitutiv eller inducerbar promoter virksomt forbundet til en nukleotidsekvens der koder for et genprodukt.
- 6.** Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-5 til
- 30 anvendelsen ifølge et hvilket som helst af kravene 1-5, hvor det genetiske kredsløb er et rekombinase-baseret genetisk kredsløb.

7. Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-6 til anvendelsen ifølge et hvilket som helst af kravene 1-6, hvor det genetiske kredsløb omfatter en nukleinsyre med en promoter virksomt forbundet til en nukleotidsekvens der koder for det terapeutiske molekyle.

5

8. Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-7 til anvendelsen ifølge et hvilket som helst af kravene 1-7, hvor det terapeutiske molekyle er et antistof, antistof-baseret stof, Fc-fusionsprotein, antikoagulationsmiddel, blodfaktor, knoglemorfogent protein, manipuleret
10 proteinskabelon, enzym, vækstfaktor, hormon, interferon, interleukin eller thrombolytisk.

9. Det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-8 til anvendelsen ifølge et hvilket som helst af kravene 1-8, hvor det genetiske
15 kredsløb er indeholdt på et phagemid.

10. Det rekombinante bakteriofag ifølge krav 9 til anvendelsen ifølge krav 9, hvor det rekombinante phagemid er et M13-afledt phagemid.

20 **11.** Sammensætning omfattende det rekombinante bakteriofag ifølge et hvilket som helst af kravene 1-10 til anvendelsen i behandlingen af gastrointestinal sygdom.

25

DRAWINGS




FIG. 1

StyAB Network




FIG. 2





FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B






FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16